NZ737412B2 - 5-ht2c receptor agonists and compositions and methods of use - Google Patents
5-ht2c receptor agonists and compositions and methods of use Download PDFInfo
- Publication number
- NZ737412B2 NZ737412B2 NZ737412A NZ73741216A NZ737412B2 NZ 737412 B2 NZ737412 B2 NZ 737412B2 NZ 737412 A NZ737412 A NZ 737412A NZ 73741216 A NZ73741216 A NZ 73741216A NZ 737412 B2 NZ737412 B2 NZ 737412B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- individual
- compound
- smoking
- tobacco
- nicotine
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 161
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 title claims description 8
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 title claims description 7
- 239000000018 receptor agonist Substances 0.000 title description 30
- 150000001875 compounds Chemical class 0.000 claims abstract description 600
- SNICXCGAKADSCV-JTQLQIEISA-N Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims abstract description 162
- 229960002715 Nicotine Drugs 0.000 claims abstract description 158
- 229930015196 nicotine Natural products 0.000 claims abstract description 158
- 241000208125 Nicotiana Species 0.000 claims abstract description 140
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims abstract description 139
- 230000000391 smoking Effects 0.000 claims abstract description 132
- 230000004584 weight gain Effects 0.000 claims abstract description 130
- 235000019786 weight gain Nutrition 0.000 claims abstract description 130
- 230000005586 smoking cessation Effects 0.000 claims abstract description 96
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 claims abstract description 77
- 206010012335 Dependence Diseases 0.000 claims abstract description 75
- 208000008589 Obesity Diseases 0.000 claims abstract description 74
- 235000020824 obesity Nutrition 0.000 claims abstract description 73
- 235000019505 tobacco product Nutrition 0.000 claims abstract description 60
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 58
- 230000000153 supplemental Effects 0.000 claims abstract description 50
- 230000003405 preventing Effects 0.000 claims abstract description 42
- 230000001276 controlling effect Effects 0.000 claims abstract description 40
- 206010015037 Epilepsy Diseases 0.000 claims abstract description 26
- 230000037406 food intake Effects 0.000 claims abstract description 22
- 235000012631 food intake Nutrition 0.000 claims abstract description 22
- 230000036186 satiety Effects 0.000 claims abstract description 21
- 235000019627 satiety Nutrition 0.000 claims abstract description 21
- 208000007848 Alcoholism Diseases 0.000 claims abstract description 19
- 206010013663 Drug dependence Diseases 0.000 claims abstract description 17
- 206010046543 Urinary incontinence Diseases 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims description 225
- 239000011780 sodium chloride Substances 0.000 claims description 132
- 150000003839 salts Chemical class 0.000 claims description 129
- 239000012453 solvate Substances 0.000 claims description 118
- 150000004677 hydrates Chemical class 0.000 claims description 111
- 238000004519 manufacturing process Methods 0.000 claims description 79
- 230000037396 body weight Effects 0.000 claims description 53
- -1 N-(2,2-difluoroethyl) methyl-1,2,3,4,6,7- hexahydro- [1,4]diazepino[6,7,1- hi]indolecarboxamide (S)-N-(2,2-difluoroethyl)- 7-methyl-1,2,3,4,6,7- hexahydro- [1,4]diazepino[6,7,1- hi]indolecarboxamide (R)-N-(2,2-difluoroethyl)- 7-methyl-1,2,3,4,6,7- hexahydro- [1,4]diazepino[6,7,1- hi]indolecarboxamide Compound Chemical class 0.000 claims description 50
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 239000000126 substance Substances 0.000 claims description 18
- 241000282414 Homo sapiens Species 0.000 claims description 17
- 239000003937 drug carrier Substances 0.000 claims description 10
- 230000000051 modifying Effects 0.000 claims description 9
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 claims description 8
- 201000007547 Dravet syndrome Diseases 0.000 claims description 6
- 230000001603 reducing Effects 0.000 abstract description 113
- 201000010099 disease Diseases 0.000 abstract description 67
- 230000037221 weight management Effects 0.000 abstract description 63
- 230000003247 decreasing Effects 0.000 abstract description 58
- 206010020772 Hypertension Diseases 0.000 abstract description 29
- 206010058108 Dyslipidaemia Diseases 0.000 abstract description 24
- 206010061227 Lipid metabolism disease Diseases 0.000 abstract description 24
- 206010057342 Onychophagia Diseases 0.000 abstract description 21
- 230000001939 inductive effect Effects 0.000 abstract description 19
- 206010001897 Alzheimer's disease Diseases 0.000 abstract description 18
- 206010057852 Nicotine dependence Diseases 0.000 abstract description 18
- 230000000561 anti-psychotic Effects 0.000 abstract description 18
- 201000009457 movement disease Diseases 0.000 abstract description 18
- 206010034158 Pathological gambling Diseases 0.000 abstract description 16
- 206010037175 Psychiatric disease Diseases 0.000 abstract description 16
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract description 15
- 201000001881 impotence Diseases 0.000 abstract description 15
- 208000000927 Sleep Apnea Syndrome Diseases 0.000 abstract description 13
- 206010040979 Sleep apnoea syndrome Diseases 0.000 abstract description 13
- 201000002859 sleep apnea Diseases 0.000 abstract description 13
- 201000000980 schizophrenia Diseases 0.000 abstract description 12
- 201000010874 syndrome Diseases 0.000 abstract description 12
- 201000010769 Prader-Willi syndrome Diseases 0.000 abstract description 11
- 201000001880 sexual dysfunction Diseases 0.000 abstract description 11
- 231100000872 sexual dysfunction Toxicity 0.000 abstract description 11
- 230000007958 sleep Effects 0.000 abstract description 11
- 206010022437 Insomnia Diseases 0.000 abstract description 10
- 206010029151 Nephropathy Diseases 0.000 abstract description 10
- 230000037322 slow-wave sleep Effects 0.000 abstract description 10
- 238000001228 spectrum Methods 0.000 abstract description 10
- 208000000103 Anorexia Nervosa Diseases 0.000 abstract description 9
- 206010061215 Impulse-control disease Diseases 0.000 abstract description 9
- 108009000135 Nonalcoholic fatty liver disease Proteins 0.000 abstract description 9
- 206010038428 Renal disease Diseases 0.000 abstract description 9
- 206010006550 Bulimia nervosa Diseases 0.000 abstract description 8
- 208000008338 Non-alcoholic Fatty Liver Disease Diseases 0.000 abstract description 8
- 208000003715 Parkinsonian Disorders Diseases 0.000 abstract description 7
- 206010034010 Parkinsonism Diseases 0.000 abstract description 7
- 206010040984 Sleep disease Diseases 0.000 abstract description 7
- 208000010309 Disruptive, Impulse Control, and Conduct Disorders Diseases 0.000 abstract description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 188
- 229940079593 drugs Drugs 0.000 description 123
- 230000035492 administration Effects 0.000 description 93
- 230000004580 weight loss Effects 0.000 description 71
- 102000005962 receptors Human genes 0.000 description 60
- 108020003175 receptors Proteins 0.000 description 60
- 238000006722 reduction reaction Methods 0.000 description 46
- 230000000694 effects Effects 0.000 description 38
- 210000000577 Adipose Tissue Anatomy 0.000 description 36
- 239000002552 dosage form Substances 0.000 description 36
- 239000000047 product Substances 0.000 description 35
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 34
- 210000001624 Hip Anatomy 0.000 description 33
- 230000002265 prevention Effects 0.000 description 33
- 229960005060 lorcaserin Drugs 0.000 description 32
- 238000000034 method Methods 0.000 description 31
- 206010033307 Overweight Diseases 0.000 description 29
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 29
- 235000020825 overweight Nutrition 0.000 description 29
- 230000002401 inhibitory effect Effects 0.000 description 23
- 238000002560 therapeutic procedure Methods 0.000 description 23
- 230000001965 increased Effects 0.000 description 21
- 239000004480 active ingredient Substances 0.000 description 20
- 230000036541 health Effects 0.000 description 20
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 19
- SNPPWIUOZRMYNY-UHFFFAOYSA-N Bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 19
- BHHGXPLMPWCGHP-UHFFFAOYSA-N 2-Phenethylamine Chemical class NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 18
- 239000000556 agonist Substances 0.000 description 18
- WRZCAWKMTLRWPR-VSODYHHCSA-N lorcaserin hydrochloride hemihydrate Chemical compound O.Cl.Cl.C[C@H]1CNCCC2=CC=C(Cl)C=C12.C[C@H]1CNCCC2=CC=C(Cl)C=C12 WRZCAWKMTLRWPR-VSODYHHCSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 229940025084 Amphetamine Drugs 0.000 description 17
- 229940107161 Cholesterol Drugs 0.000 description 17
- 206010010904 Convulsion Diseases 0.000 description 17
- 206010012601 Diabetes mellitus Diseases 0.000 description 17
- 206010039911 Seizure Diseases 0.000 description 17
- 229960002734 amfetamine Drugs 0.000 description 17
- 239000000883 anti-obesity agent Substances 0.000 description 17
- 230000006399 behavior Effects 0.000 description 17
- 239000003112 inhibitor Substances 0.000 description 17
- 239000000843 powder Substances 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 17
- 229940120049 Belviq Drugs 0.000 description 16
- XTTZERNUQAFMOF-QMMMGPOBSA-N Lorcaserin Chemical compound C[C@H]1CNCCC2=CC=C(Cl)C=C12 XTTZERNUQAFMOF-QMMMGPOBSA-N 0.000 description 16
- 239000000902 placebo Substances 0.000 description 16
- 229940068196 placebo Drugs 0.000 description 16
- 239000003826 tablet Substances 0.000 description 16
- 235000019504 cigarettes Nutrition 0.000 description 15
- 235000005911 diet Nutrition 0.000 description 15
- 229960003638 dopamine Drugs 0.000 description 15
- 239000007788 liquid Substances 0.000 description 15
- MKXZASYAUGDDCJ-NJAFHUGGSA-N Dextromethorphan Chemical compound C([C@@H]12)CCC[C@]11CCN(C)[C@H]2CC2=CC=C(OC)C=C21 MKXZASYAUGDDCJ-NJAFHUGGSA-N 0.000 description 14
- 230000027455 binding Effects 0.000 description 14
- 230000037213 diet Effects 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 210000004556 Brain Anatomy 0.000 description 13
- 229940076279 Serotonin Drugs 0.000 description 13
- JQSHBVHOMNKWFT-DTORHVGOSA-N Varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 13
- 230000001058 adult Effects 0.000 description 13
- 239000002775 capsule Substances 0.000 description 13
- 239000000969 carrier Substances 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 229960004751 varenicline Drugs 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- IWBJJCOKGLUQIZ-HQKKAZOISA-N Hyperforin Chemical compound OC1=C(CC=C(C)C)C(=O)[C@@]2(CC=C(C)C)C[C@H](CC=C(C)C)[C@](CCC=C(C)C)(C)[C@]1(C(=O)C(C)C)C2=O IWBJJCOKGLUQIZ-HQKKAZOISA-N 0.000 description 12
- 206010056997 Impaired fasting glucose Diseases 0.000 description 12
- 230000001684 chronic Effects 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 12
- 229960001058 Bupropion Drugs 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 239000000935 antidepressant agent Substances 0.000 description 11
- 229960003920 cocaine Drugs 0.000 description 11
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 11
- 230000002354 daily Effects 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- 240000000218 Cannabis sativa Species 0.000 description 10
- 229960001985 Dextromethorphan Drugs 0.000 description 10
- 230000001430 anti-depressive Effects 0.000 description 10
- ZPUCINDJVBIVPJ-BARDWOONSA-N cocaine Natural products O([C@@H]1C[C@H]2CC[C@H](N2C)[C@@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-BARDWOONSA-N 0.000 description 10
- 235000012765 hemp Nutrition 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 235000012766 marijuana Nutrition 0.000 description 10
- 230000000407 monoamine reuptake Effects 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 208000008787 Cardiovascular Disease Diseases 0.000 description 9
- 229960001158 Nortriptyline Drugs 0.000 description 9
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 9
- 229940117803 Phenethylamine Drugs 0.000 description 9
- 230000034994 death Effects 0.000 description 9
- 231100000517 death Toxicity 0.000 description 9
- 230000001976 improved Effects 0.000 description 9
- 239000007937 lozenge Substances 0.000 description 9
- 239000007921 spray Substances 0.000 description 9
- YQEZLKZALYSWHR-UHFFFAOYSA-N Calypsol Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 8
- 238000008214 LDL Cholesterol Methods 0.000 description 8
- VAYOSLLFUXYJDT-RDTXWAMCSA-N LSD Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 8
- 229950002454 Lysergide Drugs 0.000 description 8
- DHHVAGZRUROJKS-UHFFFAOYSA-N Phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 8
- 239000008186 active pharmaceutical agent Substances 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 210000002569 neurons Anatomy 0.000 description 8
- SJZRECIVHVDYJC-UHFFFAOYSA-N γ-Hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 8
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1H-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 7
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Adhd patch Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 7
- 229960003562 Phentermine Drugs 0.000 description 7
- QKTAAWLCLHMUTJ-UHFFFAOYSA-N Psilocybin Chemical compound C1C=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CN=C21 QKTAAWLCLHMUTJ-UHFFFAOYSA-N 0.000 description 7
- 231100000494 adverse effect Toxicity 0.000 description 7
- 201000007930 alcohol dependence Diseases 0.000 description 7
- 239000003263 anabolic agent Substances 0.000 description 7
- 230000000271 cardiovascular Effects 0.000 description 7
- 229940000425 combination drugs Drugs 0.000 description 7
- 229910052805 deuterium Inorganic materials 0.000 description 7
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 7
- 230000004634 feeding behavior Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 229960003299 ketamine Drugs 0.000 description 7
- 238000002372 labelling Methods 0.000 description 7
- 238000002670 nicotine replacement therapy Methods 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 230000002829 reduced Effects 0.000 description 7
- 238000009256 replacement therapy Methods 0.000 description 7
- 230000000862 serotonergic Effects 0.000 description 7
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 6
- DHPDSOCOUJHGHE-VSTIYMNMSA-N Adhyperforin Natural products O=C([C@H](CC)C)[C@@]12[C@@](CC/C=C(\C)/C)(C)[C@@H](C/C=C(\C)/C)C[C@@](C/C=C(\C)/C)(C1=O)C(=O)C(C/C=C(\C)/C)=C2O DHPDSOCOUJHGHE-VSTIYMNMSA-N 0.000 description 6
- 229950010365 Bicifadine Drugs 0.000 description 6
- OFYVIGTWSQPCLF-NWDGAFQWSA-N Bicifadine Chemical compound C1=CC(C)=CC=C1[C@@]1(CNC2)[C@H]2C1 OFYVIGTWSQPCLF-NWDGAFQWSA-N 0.000 description 6
- AHOUBRCZNHFOSL-YOEHRIQHSA-N Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 6
- 229940059344 Chantix Drugs 0.000 description 6
- WSEQXVZVJXJVFP-UHFFFAOYSA-N Citalopram Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 6
- XLMALTXPSGQGBX-GCJKJVERSA-N Dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 6
- KWGRBVOPPLSCSI-WPRPVWTQSA-N Ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 6
- CBQGYUDMJHNJBX-OALUTQOASA-N Esreboxetine Chemical compound CCOC1=CC=CC=C1O[C@@H](C=1C=CC=CC=1)[C@H]1OCCNC1 CBQGYUDMJHNJBX-OALUTQOASA-N 0.000 description 6
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 description 6
- YECBIJXISLIIDS-UHFFFAOYSA-N Mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 6
- 229960001344 Methylphenidate Drugs 0.000 description 6
- 206010053219 Non-alcoholic steatohepatitis Diseases 0.000 description 6
- 229960002748 Norepinephrine Drugs 0.000 description 6
- 125000004429 atoms Chemical group 0.000 description 6
- 230000003542 behavioural Effects 0.000 description 6
- 229960001653 citalopram Drugs 0.000 description 6
- 238000009223 counseling Methods 0.000 description 6
- 229960004193 dextropropoxyphene Drugs 0.000 description 6
- 235000014632 disordered eating Nutrition 0.000 description 6
- 201000006180 eating disease Diseases 0.000 description 6
- 239000003571 electronic cigarette Substances 0.000 description 6
- 235000020828 fasting Nutrition 0.000 description 6
- 229920000591 gum Polymers 0.000 description 6
- 229960000582 mepyramine Drugs 0.000 description 6
- 229960001252 methamphetamine Drugs 0.000 description 6
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 6
- 229960002296 paroxetine Drugs 0.000 description 6
- 229940002612 prodrugs Drugs 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 6
- 231100000486 side effect Toxicity 0.000 description 6
- 239000000375 suspending agent Substances 0.000 description 6
- 238000010189 synthetic method Methods 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 108091019276 5-hydroxytryptamine receptor family Proteins 0.000 description 5
- 102000037085 5-hydroxytryptamine receptor family Human genes 0.000 description 5
- 229940005513 ANTIDEPRESSANTS Drugs 0.000 description 5
- GBBSUAFBMRNDJC-INIZCTEOSA-N Eszopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-INIZCTEOSA-N 0.000 description 5
- 229960002464 Fluoxetine Drugs 0.000 description 5
- 208000002705 Glucose Intolerance Diseases 0.000 description 5
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- SFLSHLFXELFNJZ-MRVPVSSYSA-N L-Noradrenaline Natural products NC[C@@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-MRVPVSSYSA-N 0.000 description 5
- USSIQXCVUWKGNF-UHFFFAOYSA-N Methadone Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 5
- SYHGEUNFJIGTRX-UHFFFAOYSA-N Methylenedioxypyrovalerone Chemical compound C=1C=C2OCOC2=CC=1C(=O)C(CCC)N1CCCC1 SYHGEUNFJIGTRX-UHFFFAOYSA-N 0.000 description 5
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 5
- 108010078762 Protein Precursors Proteins 0.000 description 5
- 102000014961 Protein Precursors Human genes 0.000 description 5
- 229960002073 Sertraline Drugs 0.000 description 5
- VGKDLMBJGBXTGI-SJCJKPOMSA-N Sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 5
- 208000005809 Status Epilepticus Diseases 0.000 description 5
- KWTWDQCKEHXFFR-SMDDNHRTSA-N Tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 description 5
- 229940018503 Zyban Drugs 0.000 description 5
- 230000035507 absorption Effects 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 235000019788 craving Nutrition 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 239000002270 dispersing agent Substances 0.000 description 5
- 230000004064 dysfunction Effects 0.000 description 5
- 235000005686 eating Nutrition 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 229960001797 methadone Drugs 0.000 description 5
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 229960005126 tapentadol Drugs 0.000 description 5
- 230000001225 therapeutic Effects 0.000 description 5
- 229910052722 tritium Inorganic materials 0.000 description 5
- YZCKVEUIGOORGS-NJFSPNSNSA-N tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 5
- DLNKOYKMWOXYQA-VXNVDRBHSA-N (+)-Norephedrine Chemical compound C[C@@H](N)[C@@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-VXNVDRBHSA-N 0.000 description 4
- OYPPVKRFBIWMSX-SXGWCWSVSA-N (Z)-3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-3-ylprop-2-en-1-amine Chemical compound C=1C=CN=CC=1C(=C/CN(C)C)\C1=CC=C(Br)C=C1 OYPPVKRFBIWMSX-SXGWCWSVSA-N 0.000 description 4
- GJSURZIOUXUGAL-UHFFFAOYSA-N 2-((2,6-Dichlorophenyl)imino)imidazolidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 4
- 210000004227 Basal Ganglia Anatomy 0.000 description 4
- OROGSEYTTFOCAN-DNJOTXNNSA-N Codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 4
- DUGOZIWVEXMGBE-CHWSQXEVSA-N Dexmethylphenidate Chemical compound C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 DUGOZIWVEXMGBE-CHWSQXEVSA-N 0.000 description 4
- ZEUITGRIYCTCEM-KRWDZBQOSA-N Duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 4
- WSEQXVZVJXJVFP-FQEVSTJZSA-N Escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 4
- 229960001578 Eszopiclone Drugs 0.000 description 4
- 229960004038 Fluvoxamine Drugs 0.000 description 4
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 4
- 208000001083 Kidney Disease Diseases 0.000 description 4
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 4
- 229960003406 Levorphanol Drugs 0.000 description 4
- QSLMDECMDJKHMQ-GSXCWMCISA-N Maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 4
- ZKLXUUYLEHCAMF-UUWFMWQGSA-N Oripavine Chemical compound C([C@@H](N(CC1)C)C2=CC=C3OC)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 ZKLXUUYLEHCAMF-UUWFMWQGSA-N 0.000 description 4
- AHLBNYSZXLDEJQ-FWEHEUNISA-N Orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 4
- 229940069956 Propoxyphene Drugs 0.000 description 4
- 102100016749 SLC5A2 Human genes 0.000 description 4
- 101710040674 SLC5A2 Proteins 0.000 description 4
- 238000010928 TGA analysis Methods 0.000 description 4
- PHLBKPHSAVXXEF-UHFFFAOYSA-N Trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 4
- 229960003991 Trazodone Drugs 0.000 description 4
- 208000002271 Trichotillomania Diseases 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229960002896 clonidine Drugs 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 230000001419 dependent Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 229960001042 dexmethylphenidate Drugs 0.000 description 4
- 229960002069 diamorphine Drugs 0.000 description 4
- 229960002866 duloxetine Drugs 0.000 description 4
- 229960004341 escitalopram Drugs 0.000 description 4
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 230000002068 genetic Effects 0.000 description 4
- 230000002641 glycemic Effects 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- OCZDCIYGECBNKL-UHFFFAOYSA-N lithium;alumanuide Chemical compound [Li+].[AlH4-] OCZDCIYGECBNKL-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229960004090 maprotiline Drugs 0.000 description 4
- 239000002547 new drug Substances 0.000 description 4
- 230000003000 nontoxic Effects 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 229960001243 orlistat Drugs 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 239000002831 pharmacologic agent Substances 0.000 description 4
- 230000037081 physical activity Effects 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 238000000634 powder X-ray diffraction Methods 0.000 description 4
- 230000002335 preservative Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000000069 prophylaxis Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 238000002411 thermogravimetry Methods 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- 229960004688 venlafaxine Drugs 0.000 description 4
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 229960002791 zimeldine Drugs 0.000 description 4
- PTJADDMMFYXMMG-LJQANCHMSA-N (1R)-1-(4-fluorophenyl)-1-[3-(methylamino)propyl]-3H-2-benzofuran-5-carbonitrile Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCNC)=CC=C(F)C=C1 PTJADDMMFYXMMG-LJQANCHMSA-N 0.000 description 3
- BSMNRYCSBFHEMQ-KCJUWKMLSA-N (1R,5S)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane Chemical compound C1=C(Cl)C(Cl)=CC=C1[C@]1(CNC2)[C@@H]2C1 BSMNRYCSBFHEMQ-KCJUWKMLSA-N 0.000 description 3
- WIQRCHMSJFFONW-HNNXBMFYSA-N (3S)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound O([C@@H](CCN)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 WIQRCHMSJFFONW-HNNXBMFYSA-N 0.000 description 3
- RGPDEAGGEXEMMM-UHFFFAOYSA-N 3,4,5,6-tetrahydro-5-methyl-1-phenyl-1H-2,5-Benzoxazocine Chemical compound C12=CC=CC=C2CN(C)CCOC1C1=CC=CC=C1 RGPDEAGGEXEMMM-UHFFFAOYSA-N 0.000 description 3
- SNICXCGAKADSCV-UHFFFAOYSA-N 3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 3
- SADQVAVFGNTEOD-UHFFFAOYSA-N 3-(2-piperidin-4-ylethyl)-1H-indole Chemical compound C=1NC2=CC=CC=C2C=1CCC1CCNCC1 SADQVAVFGNTEOD-UHFFFAOYSA-N 0.000 description 3
- FKHYYOUFMJBLAF-UHFFFAOYSA-N 3-(3,3-dimethyl-1-phenyl-2-benzothiophen-1-yl)-N-methylpropan-1-amine Chemical compound S1C(C)(C)C2=CC=CC=C2C1(CCCNC)C1=CC=CC=C1 FKHYYOUFMJBLAF-UHFFFAOYSA-N 0.000 description 3
- FZSPJBYOKQPKCD-UHFFFAOYSA-N Alaproclate Chemical compound CC(N)C(=O)OC(C)(C)CC1=CC=C(Cl)C=C1 FZSPJBYOKQPKCD-UHFFFAOYSA-N 0.000 description 3
- 229960003225 Alaproclate Drugs 0.000 description 3
- GTQLIPQFXVKRKJ-UNSMHXHVSA-N Altropane Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C\C=C\I)[C@H]2C(=O)OC)=CC=C(F)C=C1 GTQLIPQFXVKRKJ-UNSMHXHVSA-N 0.000 description 3
- HBGWAZBZXJBYQD-UHFFFAOYSA-N Amedalin Chemical compound C12=CC=CC=C2C(CCCNC)(C)C(=O)N1C1=CC=CC=C1 HBGWAZBZXJBYQD-UHFFFAOYSA-N 0.000 description 3
- 229950000203 Amedalin Drugs 0.000 description 3
- ONNOFKFOZAJDHT-UHFFFAOYSA-N Amineptine Chemical compound C1CC2=CC=CC=C2C(NCCCCCCC(=O)O)C2=CC=CC=C21 ONNOFKFOZAJDHT-UHFFFAOYSA-N 0.000 description 3
- 229950003533 Amitifadine Drugs 0.000 description 3
- VHGCDTVCOLNTBX-QGZVFWFLSA-N Atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 3
- 210000001772 Blood Platelets Anatomy 0.000 description 3
- NRLIFEGHTNUYFL-QJDHNRDASA-N Brasofensine Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C)[C@@H]2/C=N/OC)=CC=C(Cl)C(Cl)=C1 NRLIFEGHTNUYFL-QJDHNRDASA-N 0.000 description 3
- 229950006941 Brasofensine Drugs 0.000 description 3
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 3
- 206010007554 Cardiac failure Diseases 0.000 description 3
- 210000003169 Central Nervous System Anatomy 0.000 description 3
- 240000000425 Chaenomeles speciosa Species 0.000 description 3
- 235000005078 Chaenomeles speciosa Nutrition 0.000 description 3
- LQXYCDLHSKICDY-UHFFFAOYSA-N Cianopramine Chemical compound C1CC2=CC=C(C#N)C=C2N(CCCN(C)C)C2=CC=CC=C21 LQXYCDLHSKICDY-UHFFFAOYSA-N 0.000 description 3
- 229950001408 Cianopramine Drugs 0.000 description 3
- VKQDZNZTPGLGFD-UHFFFAOYSA-N Ciclazindol Chemical compound C12=NCCCN2C2=CC=CC=C2C1(O)C1=CC=CC(Cl)=C1 VKQDZNZTPGLGFD-UHFFFAOYSA-N 0.000 description 3
- 229950009468 Ciclazindol Drugs 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 208000004981 Coronary Disease Diseases 0.000 description 3
- YFAIJBZEDDOCAN-UHFFFAOYSA-N Daledalin Chemical compound C12=CC=CC=C2C(CCCNC)(C)CN1C1=CC=CC=C1 YFAIJBZEDDOCAN-UHFFFAOYSA-N 0.000 description 3
- 229950009245 Daledalin Drugs 0.000 description 3
- USRHYDPUVLEVMC-FQEVSTJZSA-N Dapoxetine Chemical compound C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-FQEVSTJZSA-N 0.000 description 3
- 206010061428 Decreased appetite Diseases 0.000 description 3
- 206010012374 Depressed mood Diseases 0.000 description 3
- SRPXSILJHWNFMK-ZBEGNZNMSA-N Desmethylsertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)N)=CC=C(Cl)C(Cl)=C1 SRPXSILJHWNFMK-ZBEGNZNMSA-N 0.000 description 3
- RWTNXJXZVGHMGI-UHFFFAOYSA-N Desoxypipradrol Chemical compound N1CCCCC1C(C=1C=CC=CC=1)C1=CC=CC=C1 RWTNXJXZVGHMGI-UHFFFAOYSA-N 0.000 description 3
- KYYIDSXMWOZKMP-UHFFFAOYSA-N Desvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 description 3
- ZJDCGVDEEHWEIG-UHFFFAOYSA-N Diclofensine Chemical compound C1N(C)CC2=CC(OC)=CC=C2C1C1=CC=C(Cl)C(Cl)=C1 ZJDCGVDEEHWEIG-UHFFFAOYSA-N 0.000 description 3
- 229950007329 Diclofensine Drugs 0.000 description 3
- RKUKMUWCRLRPEJ-SFHVURJKSA-N Didesmethylcitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN)=CC=C(F)C=C1 RKUKMUWCRLRPEJ-SFHVURJKSA-N 0.000 description 3
- UHZJPVXMMCFPNR-UHFFFAOYSA-N Difemetorex Chemical compound OCCN1CCCCC1C(C=1C=CC=CC=1)C1=CC=CC=C1 UHZJPVXMMCFPNR-UHFFFAOYSA-N 0.000 description 3
- XSYGBVSQKPLETJ-ANULTFPQSA-N Difluoropine Chemical compound O([C@H]1C[C@H]2CC[C@H](N2C)[C@@H]1C(=O)OC)C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 XSYGBVSQKPLETJ-ANULTFPQSA-N 0.000 description 3
- 229960004993 Dimenhydrinate Drugs 0.000 description 3
- MZDOIJOUFRQXHC-UHFFFAOYSA-N Dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 3
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N Diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 3
- OGCGXUGBDJGFFY-UHFFFAOYSA-N Diphenylprolinol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)C1CCCN1 OGCGXUGBDJGFFY-UHFFFAOYSA-N 0.000 description 3
- CPBHSHYQQLFAPW-ZWKOTPCHSA-N Edivoxetine Chemical compound COC1=CC=C(F)C=C1C[C@](O)([C@H]1OCCNC1)C1CCOCC1 CPBHSHYQQLFAPW-ZWKOTPCHSA-N 0.000 description 3
- 229950003015 Edivoxetine Drugs 0.000 description 3
- 229950008247 Esreboxetine Drugs 0.000 description 3
- AIVSIRYZIBXTMM-UHFFFAOYSA-N Ethylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OCC)C1CCCCN1 AIVSIRYZIBXTMM-UHFFFAOYSA-N 0.000 description 3
- OJSFTALXCYKKFQ-YLJYHZDGSA-N Femoxetine Chemical compound C1=CC(OC)=CC=C1OC[C@@H]1[C@@H](C=2C=CC=CC=2)CCN(C)C1 OJSFTALXCYKKFQ-YLJYHZDGSA-N 0.000 description 3
- IKFBPFGUINLYQI-UHFFFAOYSA-N Fencamfamine Chemical compound CCNC1C(C2)CCC2C1C1=CC=CC=C1 IKFBPFGUINLYQI-UHFFFAOYSA-N 0.000 description 3
- PDTADBTVZXKSJM-UHFFFAOYSA-N Fencamine Chemical compound N=1C=2N(C)C(=O)N(C)C(=O)C=2N(C)C=1NCCN(C)C(C)CC1=CC=CC=C1 PDTADBTVZXKSJM-UHFFFAOYSA-N 0.000 description 3
- 229960001582 Fenfluramine Drugs 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N GABA Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 240000002883 Ginkgo biloba Species 0.000 description 3
- 235000008100 Ginkgo biloba Nutrition 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 206010019233 Headache Diseases 0.000 description 3
- 229940120060 Heroin Drugs 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 229940088597 Hormone Drugs 0.000 description 3
- 210000003016 Hypothalamus Anatomy 0.000 description 3
- ZHFIAFNZGWCLHU-YPMHNXCESA-N Ifoxetine Chemical compound CC1=CC=CC(O[C@@H]2[C@@H](CNCC2)O)=C1C ZHFIAFNZGWCLHU-YPMHNXCESA-N 0.000 description 3
- 229950006314 Ifoxetine Drugs 0.000 description 3
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 3
- YEJZJVJJPVZXGX-MRXNPFEDSA-N Lefetamine Chemical compound C([C@@H](N(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 YEJZJVJJPVZXGX-MRXNPFEDSA-N 0.000 description 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N Leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 3
- 102000016267 Leptin Human genes 0.000 description 3
- 108010092277 Leptin Proteins 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- GJJFMKBJSRMPLA-DZGCQCFKSA-N Levomilnacipran Chemical compound C=1C=CC=CC=1[C@]1(C(=O)N(CC)CC)C[C@H]1CN GJJFMKBJSRMPLA-DZGCQCFKSA-N 0.000 description 3
- 229960000685 Levomilnacipran Drugs 0.000 description 3
- MJJDYOLPMGIWND-UHFFFAOYSA-N Litoxetine Chemical compound C=1C=C2C=CC=CC2=CC=1COC1CCNCC1 MJJDYOLPMGIWND-UHFFFAOYSA-N 0.000 description 3
- 229950004138 Litoxetine Drugs 0.000 description 3
- 229950004863 Lortalamine Drugs 0.000 description 3
- MJRPHRMGEKCADU-JVLSTEMRSA-N Lortalamine Chemical compound C12=CC(Cl)=CC=C2O[C@]23CCN(C)C[C@@H]2[C@H]1CC(=O)N3 MJRPHRMGEKCADU-JVLSTEMRSA-N 0.000 description 3
- HTODIQZHVCHVGM-JTQLQIEISA-N Lubazodone Chemical compound C1=2CCCC=2C(F)=CC=C1OC[C@@H]1CNCCO1 HTODIQZHVCHVGM-JTQLQIEISA-N 0.000 description 3
- 229950004415 Lubazodone Drugs 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 229950006048 Manifaxine Drugs 0.000 description 3
- OZGPVYJHWWPEFT-RGNHYFCHSA-N Manifaxine Chemical compound C[C@@H]1N[C@H](C)CO[C@@]1(O)C1=CC(F)=CC(F)=C1 OZGPVYJHWWPEFT-RGNHYFCHSA-N 0.000 description 3
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 3
- QNMGHBMGNRQPNL-UHFFFAOYSA-N Medifoxamine Chemical compound C=1C=CC=CC=1OC(CN(C)C)OC1=CC=CC=C1 QNMGHBMGNRQPNL-UHFFFAOYSA-N 0.000 description 3
- DAHIQPJTGIHDGO-IAGOWNOFSA-N Mesembrine Chemical compound C1=C(OC)C(OC)=CC=C1[C@]1(CCC(=O)C2)[C@@H]2N(C)CC1 DAHIQPJTGIHDGO-IAGOWNOFSA-N 0.000 description 3
- DMHQLXUFCQSQQQ-LVZFUZTISA-N Mesocarb Chemical compound C=1\C(=N/C(=O)NC=2C=CC=CC=2)O[N-][N+]=1C(C)CC1=CC=CC=C1 DMHQLXUFCQSQQQ-LVZFUZTISA-N 0.000 description 3
- 229950010421 Mesocarb Drugs 0.000 description 3
- 229960000600 Milnacipran Drugs 0.000 description 3
- GJJFMKBJSRMPLA-HIFRSBDPSA-N Milnacipran Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 3
- RONZAEMNMFQXRA-UHFFFAOYSA-N Mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 3
- 229960001785 Mirtazapine Drugs 0.000 description 3
- DTNUPBSOODGRKW-UHFFFAOYSA-N Naphyrone Chemical compound C=1C=C2C=CC=CC2=CC=1C(=O)C(CCC)N1CCCC1 DTNUPBSOODGRKW-UHFFFAOYSA-N 0.000 description 3
- 229960000751 Nefopam Drugs 0.000 description 3
- KYGZCKSPAKDVKC-UHFFFAOYSA-N Nidantin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 KYGZCKSPAKDVKC-UHFFFAOYSA-N 0.000 description 3
- ITJNARMNRKSWTA-UHFFFAOYSA-N Nisoxetine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=CC=C1OC ITJNARMNRKSWTA-UHFFFAOYSA-N 0.000 description 3
- 229950004211 Nisoxetine Drugs 0.000 description 3
- 229960001073 Nomifensine Drugs 0.000 description 3
- XXPANQJNYNUNES-UHFFFAOYSA-N Nomifensine Chemical compound C12=CC=CC(N)=C2CN(C)CC1C1=CC=CC=C1 XXPANQJNYNUNES-UHFFFAOYSA-N 0.000 description 3
- DBGIVFWFUFKIQN-UHFFFAOYSA-N Obedrex Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 3
- KVWDHTXUZHCGIO-UHFFFAOYSA-N Olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 3
- FAHGZANUNVVDFL-HYBUGGRVSA-N Omiloxetine Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](COC=2C=C3OCOC3=CC=2)CN(CC(=O)C=2C=CC(F)=CC=2)CC1 FAHGZANUNVVDFL-HYBUGGRVSA-N 0.000 description 3
- 229950005637 Omiloxetine Drugs 0.000 description 3
- AQFFJGJVFJCQQL-UHFFFAOYSA-N Panuramine Chemical compound C1CN(CC=2C=C3C=CC=CC3=CC=2)CCC1NC(=O)NC(=O)C1=CC=CC=C1 AQFFJGJVFJCQQL-UHFFFAOYSA-N 0.000 description 3
- 229950010577 Panuramine Drugs 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- XSWHNYGMWWVAIE-UHFFFAOYSA-N Pipradrol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)C1CCCCN1 XSWHNYGMWWVAIE-UHFFFAOYSA-N 0.000 description 3
- AMJPIGOYWBNJLP-UHFFFAOYSA-N Pirandamine Chemical compound C1C2=CC=CC=C2C2=C1C(CCN(C)C)(C)OCC2 AMJPIGOYWBNJLP-UHFFFAOYSA-N 0.000 description 3
- 229950007239 Pirandamine Drugs 0.000 description 3
- 210000002381 Plasma Anatomy 0.000 description 3
- 229960003089 Pramipexole Drugs 0.000 description 3
- FASDKYOPVNHBLU-ZETCQYMHSA-N Pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 3
- OJCPSBCUMRIPFL-UHFFFAOYSA-N Prolintane Chemical compound C1CCCN1C(CCC)CC1=CC=CC=C1 OJCPSBCUMRIPFL-UHFFFAOYSA-N 0.000 description 3
- 229940079863 Pyrilamine Drugs 0.000 description 3
- SWUVZKWCOBGPTH-UHFFFAOYSA-N Pyrovalerone Chemical compound C=1C=C(C)C=CC=1C(=O)C(CCC)N1CCCC1 SWUVZKWCOBGPTH-UHFFFAOYSA-N 0.000 description 3
- 229950010600 Pyrovalerone Drugs 0.000 description 3
- SIIICDNNMDMWCI-YJNKXOJESA-N RTI-55 Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C)[C@H]2C(=O)OC)=CC=C(I)C=C1 SIIICDNNMDMWCI-YJNKXOJESA-N 0.000 description 3
- RCOBKSKAZMVBHT-TVQRCGJNSA-N Radafaxine Chemical compound C[C@@H]1NC(C)(C)CO[C@@]1(O)C1=CC=CC(Cl)=C1 RCOBKSKAZMVBHT-TVQRCGJNSA-N 0.000 description 3
- 229950010561 Radafaxine Drugs 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 206010038683 Respiratory disease Diseases 0.000 description 3
- 229950000366 Roxindole Drugs 0.000 description 3
- BKTTWZADZNUOBW-UHFFFAOYSA-N Roxindole Chemical compound C=12[CH]C(O)=CC=C2N=CC=1CCCCN(CC=1)CCC=1C1=CC=CC=C1 BKTTWZADZNUOBW-UHFFFAOYSA-N 0.000 description 3
- 229950000319 Seproxetine Drugs 0.000 description 3
- 206010042458 Suicidal ideation Diseases 0.000 description 3
- 229950007352 TALOPRAM Drugs 0.000 description 3
- LJBBMCNHIUJBDU-UHFFFAOYSA-N Talopram Chemical compound O1C(C)(C)C2=CC=CC=C2C1(CCCNC)C1=CC=CC=C1 LJBBMCNHIUJBDU-UHFFFAOYSA-N 0.000 description 3
- 229950002139 Talsupram Drugs 0.000 description 3
- 229950001671 Tametraline Drugs 0.000 description 3
- BRPOADLGOFPKKJ-UHFFFAOYSA-N Tandamine Chemical compound C12=CC=CC=C2N(CC)C2=C1CCSC2(C)CCN(C)C BRPOADLGOFPKKJ-UHFFFAOYSA-N 0.000 description 3
- 229950006964 Tandamine Drugs 0.000 description 3
- CVASBKDYSQKLSO-UHFFFAOYSA-N Tedatioxetine Chemical compound C1=CC(C)=CC=C1SC1=CC=CC=C1C1CCNCC1 CVASBKDYSQKLSO-UHFFFAOYSA-N 0.000 description 3
- 229950005877 Tedatioxetine Drugs 0.000 description 3
- OILWWIVKIDXCIB-UHFFFAOYSA-N Teniloxazine Chemical compound C1NCCOC1COC1=CC=CC=C1CC1=CC=CS1 OILWWIVKIDXCIB-UHFFFAOYSA-N 0.000 description 3
- 229950003014 Teniloxazine Drugs 0.000 description 3
- VCVWXKKWDOJNIT-ZOMKSWQUSA-N Tesofensine Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C)[C@@H]2COCC)=CC=C(Cl)C(Cl)=C1 VCVWXKKWDOJNIT-ZOMKSWQUSA-N 0.000 description 3
- 229950009970 Tesofensine Drugs 0.000 description 3
- 206010048828 Underweight Diseases 0.000 description 3
- 210000003932 Urinary Bladder Anatomy 0.000 description 3
- NPTIPEQJIDTVKR-STQMWFEESA-N Vabicaserin Chemical compound C1CNCC2=CC=CC3=C2N1C[C@@H]1CCC[C@@H]13 NPTIPEQJIDTVKR-STQMWFEESA-N 0.000 description 3
- 229950009968 Vabicaserin Drugs 0.000 description 3
- 229950007136 Vanoxerine Drugs 0.000 description 3
- NAUWTFJOPJWYOT-UHFFFAOYSA-N Vanoxerine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)OCCN1CCN(CCCC=2C=CC=CC=2)CC1 NAUWTFJOPJWYOT-UHFFFAOYSA-N 0.000 description 3
- UXDQRXUZPXSLJK-UHFFFAOYSA-N Vilazodone Chemical compound C1=CC(C#N)=C[C]2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CN=C21 UXDQRXUZPXSLJK-UHFFFAOYSA-N 0.000 description 3
- 229960001255 Viloxazine Drugs 0.000 description 3
- YWPHCCPCQOJSGZ-UHFFFAOYSA-N Viloxazine Chemical compound CCOC1=CC=CC=C1OCC1OCCNC1 YWPHCCPCQOJSGZ-UHFFFAOYSA-N 0.000 description 3
- YQNWZWMKLDQSAC-UHFFFAOYSA-N Vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 description 3
- 229960002263 Vortioxetine Drugs 0.000 description 3
- ZAFYATHCZYHLPB-UHFFFAOYSA-N Zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000001154 acute Effects 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000002730 additional Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 229950004560 altropane Drugs 0.000 description 3
- 229960000959 amineptine Drugs 0.000 description 3
- 229960003692 aminobutyric acid Drugs 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000001773 anti-convulsant Effects 0.000 description 3
- 239000001961 anticonvulsive agent Substances 0.000 description 3
- 125000005418 aryl aryl group Chemical group 0.000 description 3
- 229960002430 atomoxetine Drugs 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960004596 cabergoline Drugs 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 230000002490 cerebral Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001713 cholinergic Effects 0.000 description 3
- 230000001149 cognitive Effects 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000001186 cumulative Effects 0.000 description 3
- 229960005217 dapoxetine Drugs 0.000 description 3
- 229960001623 desvenlafaxine Drugs 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 229950011229 difemetorex Drugs 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229960000520 diphenhydramine Drugs 0.000 description 3
- 229960002179 ephedrine Drugs 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 229950003930 femoxetine Drugs 0.000 description 3
- 229960001938 fencamfamin Drugs 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000000381 ginkgo Nutrition 0.000 description 3
- 108091005979 glycated hemoglobin Proteins 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 235000003642 hunger Nutrition 0.000 description 3
- 229950002473 indalpine Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 229950008279 lefetamine Drugs 0.000 description 3
- 229940039781 leptin Drugs 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960000299 mazindol Drugs 0.000 description 3
- 239000002609 media Substances 0.000 description 3
- 229960003123 medifoxamine Drugs 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000001537 neural Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 201000008430 obsessive-compulsive disease Diseases 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 229960005017 olanzapine Drugs 0.000 description 3
- 229960000321 oxolinic acid Drugs 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000000275 pharmacokinetic Effects 0.000 description 3
- 229960000753 pipradrol Drugs 0.000 description 3
- 229960004654 prolintane Drugs 0.000 description 3
- 229960003770 reboxetine Drugs 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 239000000779 smoke Substances 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 201000009032 substance abuse Diseases 0.000 description 3
- 230000002459 sustained Effects 0.000 description 3
- 230000002194 synthesizing Effects 0.000 description 3
- 230000000699 topical Effects 0.000 description 3
- 229960003740 vilazodone Drugs 0.000 description 3
- 229960001475 zolpidem Drugs 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- AHFWIQIYAXSLBA-RQXATKFSSA-N (2S,3R,4R,5S,6R)-2-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(F)C(CC=2SC3=CC=CC=C3C=2)=C1 AHFWIQIYAXSLBA-RQXATKFSSA-N 0.000 description 2
- VWVKUNOPTJGDOB-BDHVOXNPSA-N (3S,3'R,4'S,5'S,6'R)-5-[(4-ethylphenyl)methyl]-6'-(hydroxymethyl)spiro[1H-2-benzofuran-3,2'-oxane]-3',4',5'-triol Chemical compound C1=CC(CC)=CC=C1CC1=CC=C(CO[C@@]23[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C2=C1 VWVKUNOPTJGDOB-BDHVOXNPSA-N 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N 107444-51-9 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- VIHAEDVKXSOUAT-UHFFFAOYSA-N 2-Furanone Chemical compound O=C1OCC=C1 VIHAEDVKXSOUAT-UHFFFAOYSA-N 0.000 description 2
- VTKWFWXOVZIATL-NPPUSCPJSA-N 2-[[(2S)-3-(4H-imidazol-4-yl)-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]acetic acid Chemical compound C([C@@H](C(=O)NCC(=O)O)NC(=O)[C@H]1NC(=O)CC1)C1C=NC=N1 VTKWFWXOVZIATL-NPPUSCPJSA-N 0.000 description 2
- BQDUNOMMYOKHEP-GQALSZNTSA-N 3-(2,5-difluorophenyl)-7-[1,1,1,3,3,3-hexadeuterio-2-(trideuteriomethyl)propan-2-yl]-6-[(2-methyl-1,2,4-triazol-3-yl)methoxy]-[1,2,4]triazolo[4,3-b]pyridazine Chemical compound N12N=C(OCC=3N(N=CN=3)C)C(C(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])=CC2=NN=C1C1=CC(F)=CC=C1F BQDUNOMMYOKHEP-GQALSZNTSA-N 0.000 description 2
- GICMHQJTKXNMGB-UHFFFAOYSA-N 4-(5-methoxy-1-benzofuran-2-yl)aniline Chemical compound C=1C2=CC(OC)=CC=C2OC=1C1=CC=C(N)C=C1 GICMHQJTKXNMGB-UHFFFAOYSA-N 0.000 description 2
- 229960001391 Alfentanil Drugs 0.000 description 2
- 229960001349 Alphaprodine Drugs 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N Alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- XXEPPPIWZFICOJ-UHFFFAOYSA-N Amfepramone Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 description 2
- LKYQLAWMNBFNJT-UHFFFAOYSA-N Anileridine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC1=CC=C(N)C=C1 LKYQLAWMNBFNJT-UHFFFAOYSA-N 0.000 description 2
- 229960002512 Anileridine Drugs 0.000 description 2
- 206010002820 Antisocial behaviour Diseases 0.000 description 2
- 206010002855 Anxiety Diseases 0.000 description 2
- 206010057666 Anxiety disease Diseases 0.000 description 2
- 208000006673 Asthma Diseases 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 206010003736 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 206010003805 Autism Diseases 0.000 description 2
- CJAVTWRYCDNHSM-UHFFFAOYSA-N Benfluorex Chemical compound C=1C=CC=CC=1C(=O)OCCNC(C)CC1=CC=CC(C(F)(F)F)=C1 CJAVTWRYCDNHSM-UHFFFAOYSA-N 0.000 description 2
- YXKTVDFXDRQTKV-HNNXBMFYSA-N Benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 description 2
- FLKWNFFCSSJANB-UHFFFAOYSA-N Bezitramide Chemical compound O=C1N(C(=O)CC)C2=CC=CC=C2N1C(CC1)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 FLKWNFFCSSJANB-UHFFFAOYSA-N 0.000 description 2
- 206010004938 Bipolar disease Diseases 0.000 description 2
- OZVBMTJYIDMWIL-AYFBDAFISA-N Bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 2
- 229960002802 Bromocriptine Drugs 0.000 description 2
- 229960004367 Bupropion Hydrochloride Drugs 0.000 description 2
- YDSDEBIZUNNPOB-UHFFFAOYSA-N Carfentanil Chemical compound C1CN(CCC=2C=CC=CC=2)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 YDSDEBIZUNNPOB-UHFFFAOYSA-N 0.000 description 2
- 229950004689 Carfentanil Drugs 0.000 description 2
- MVCQKIKWYUURMU-UHFFFAOYSA-N Cetilistat Chemical compound C1=C(C)C=C2C(=O)OC(OCCCCCCCCCCCCCCCC)=NC2=C1 MVCQKIKWYUURMU-UHFFFAOYSA-N 0.000 description 2
- 229950002397 Cetilistat Drugs 0.000 description 2
- ZCKAMNXUHHNZLN-UHFFFAOYSA-N Chlorphentermine Chemical compound CC(C)(N)CC1=CC=C(Cl)C=C1 ZCKAMNXUHHNZLN-UHFFFAOYSA-N 0.000 description 2
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 2
- DGBIGWXXNGSACT-UHFFFAOYSA-N Clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 2
- HYPPXZBJBPSRLK-UHFFFAOYSA-N Co-phenotrope Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010052895 Coronary artery insufficiency Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 101700040453 DRD2 Proteins 0.000 description 2
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 2
- 229960004597 Dexfenfluramine Drugs 0.000 description 2
- 229940119750 Dextroamphetamine Drugs 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N Diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- RBOXVHNMENFORY-DNJOTXNNSA-N Dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 2
- BRTSNYPDACNMIP-FAWZKKEFSA-N Dihydroetorphine Chemical compound O([C@H]1[C@@]2(OC)CC[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O BRTSNYPDACNMIP-FAWZKKEFSA-N 0.000 description 2
- 208000002173 Dizziness Diseases 0.000 description 2
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 2
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 2
- 206010013781 Dry mouth Diseases 0.000 description 2
- 206010049119 Emotional distress Diseases 0.000 description 2
- OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 description 2
- 229960004578 Ethylmorphine Drugs 0.000 description 2
- 229950004155 Etorphine Drugs 0.000 description 2
- 206010049796 Excoriation Diseases 0.000 description 2
- 108010011459 Exenatide Proteins 0.000 description 2
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exendin-4 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 2
- 206010016256 Fatigue Diseases 0.000 description 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N Fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 2
- 229960002428 Fentanyl Drugs 0.000 description 2
- 208000001836 Firesetting Behavior Diseases 0.000 description 2
- 206010056465 Food craving Diseases 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 229960004666 Glucagon Drugs 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N Glucagonum Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- LLPOLZWFYMWNKH-CMKMFDCUSA-N Hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 2
- WVLOADHCBXTIJK-YNHQPCIGSA-N Hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 2
- 206010021750 Infantile spasms Diseases 0.000 description 2
- 206010022489 Insulin resistance Diseases 0.000 description 2
- 206010022568 Intermittent explosive disease Diseases 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 108010041872 Islet amyloid polypeptide Proteins 0.000 description 2
- 102000036849 Islet amyloid polypeptide Human genes 0.000 description 2
- IFKPLJWIEQBPGG-UHFFFAOYSA-N Isomethadone Chemical compound C=1C=CC=CC=1C(C(C)CN(C)C)(C(=O)CC)C1=CC=CC=C1 IFKPLJWIEQBPGG-UHFFFAOYSA-N 0.000 description 2
- 210000003734 Kidney Anatomy 0.000 description 2
- 206010023461 Kleptomania Diseases 0.000 description 2
- XBMIVRRWGCYBTQ-AVRDEDQJSA-N Levacetylmethadol Chemical compound C=1C=CC=CC=1C(C[C@H](C)N(C)C)([C@@H](OC(C)=O)CC)C1=CC=CC=C1 XBMIVRRWGCYBTQ-AVRDEDQJSA-N 0.000 description 2
- 229950004990 Levomethorphan Drugs 0.000 description 2
- 229940040461 Lipase Drugs 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 108010019598 Liraglutide Proteins 0.000 description 2
- VOBHXZCDAVEXEY-JSGCOSHPSA-N Lisdexamfetamine Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)CC1=CC=CC=C1 VOBHXZCDAVEXEY-JSGCOSHPSA-N 0.000 description 2
- DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 description 2
- 229950009131 METAZOCINE Drugs 0.000 description 2
- VHFVKMTVMIZMIK-UHFFFAOYSA-N Meta-Chlorophenylpiperazine Chemical compound ClC1=CC=CC(N2CCNCC2)=C1 VHFVKMTVMIZMIK-UHFFFAOYSA-N 0.000 description 2
- YGSVZRIZCHZUHB-COLVAYQJSA-N Metazocine Chemical compound C1C2=CC=C(O)C=C2[C@]2(C)CCN(C)[C@@]1([H])[C@@H]2C YGSVZRIZCHZUHB-COLVAYQJSA-N 0.000 description 2
- 229960003105 Metformin Drugs 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- NPZXCTIHHUUEEJ-CMKMFDCUSA-N Metopon Chemical compound O([C@@]1(C)C(=O)CC[C@@H]23)C4=C5[C@@]13CCN(C)[C@@H]2CC5=CC=C4O NPZXCTIHHUUEEJ-CMKMFDCUSA-N 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N Morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 2
- UZHSEJADLWPNLE-GRGSLBFTSA-N Naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 2
- 229960004127 Naloxone Drugs 0.000 description 2
- 229960003086 Naltrexone Drugs 0.000 description 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N Naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 2
- 210000003928 Nasal Cavity Anatomy 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 229940087730 Nicorette Drugs 0.000 description 2
- 229940078420 Nicotine Transdermal System Drugs 0.000 description 2
- 210000001009 Nucleus accumbens Anatomy 0.000 description 2
- LDUARVOCMXITCM-ILMFCTMOSA-N Obinepitide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 LDUARVOCMXITCM-ILMFCTMOSA-N 0.000 description 2
- 229950003861 Obinepitide Drugs 0.000 description 2
- 206010029897 Obsessive thoughts Diseases 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 102000003840 Opioid Receptors Human genes 0.000 description 2
- 108090000137 Opioid Receptors Proteins 0.000 description 2
- 239000008896 Opium Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycontin Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 2
- WYWIFABBXFUGLM-UHFFFAOYSA-N Oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 2
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 2
- 229950006445 PIMINODINE Drugs 0.000 description 2
- 102100002332 PYY Human genes 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 240000001090 Papaver somniferum Species 0.000 description 2
- 235000008753 Papaver somniferum Nutrition 0.000 description 2
- 108010088847 Peptide YY Proteins 0.000 description 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Petidina Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
- ZQHYKVKNPWDQSL-KNXBSLHKSA-N Phenazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CCC1=CC=CC=C1 ZQHYKVKNPWDQSL-KNXBSLHKSA-N 0.000 description 2
- 229960000897 Phenazocine Drugs 0.000 description 2
- 229960000436 Phendimetrazine Drugs 0.000 description 2
- MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical compound O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 description 2
- OOBHFESNSZDWIU-UHFFFAOYSA-N Phenmetrazine Chemical compound CC1NCCOC1C1=CC=CC=C1 OOBHFESNSZDWIU-UHFFFAOYSA-N 0.000 description 2
- 229960003209 Phenmetrazine Drugs 0.000 description 2
- 229960000395 Phenylpropanolamine Drugs 0.000 description 2
- PXXKIYPSXYFATG-UHFFFAOYSA-N Piminodine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCCNC1=CC=CC=C1 PXXKIYPSXYFATG-UHFFFAOYSA-N 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N Pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 229960005095 Pioglitazone Drugs 0.000 description 2
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N Pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- UVAZQQHAVMNMHE-CJNGLKHVSA-N Prodine Chemical compound C=1C=CC=CC=1[C@]1(OC(=O)CC)CCN(C)C[C@H]1C UVAZQQHAVMNMHE-CJNGLKHVSA-N 0.000 description 2
- 229960003908 Pseudoephedrine Drugs 0.000 description 2
- KWGRBVOPPLSCSI-WCBMZHEXSA-N Pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 2
- SSJGXNSABQPEKM-SBUIBGKBSA-N Pyy peptide Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 SSJGXNSABQPEKM-SBUIBGKBSA-N 0.000 description 2
- 238000010357 RNA editing Methods 0.000 description 2
- 230000026279 RNA modification Effects 0.000 description 2
- 229950011009 Racemorphan Drugs 0.000 description 2
- ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 description 2
- 229960003394 Remifentanil Drugs 0.000 description 2
- 206010038444 Renal failure chronic Diseases 0.000 description 2
- JZCPYUJPEARBJL-UHFFFAOYSA-N Rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 2
- 229960003015 Rimonabant Drugs 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 108060007763 SLC6A4 Proteins 0.000 description 2
- 102100001823 SLC6A4 Human genes 0.000 description 2
- UNAANXDKBXWMLN-UHFFFAOYSA-N Sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 210000003523 Substantia Nigra Anatomy 0.000 description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
- 229960004739 Sufentanil Drugs 0.000 description 2
- HMXDWDSNPRNUKI-UHFFFAOYSA-N Surinabant Chemical compound CCC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Br)C=C1 HMXDWDSNPRNUKI-UHFFFAOYSA-N 0.000 description 2
- 229950003174 Surinabant Drugs 0.000 description 2
- WRGVLTAWMNZWGT-VQSPYGJZSA-N Taspoglutide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 WRGVLTAWMNZWGT-VQSPYGJZSA-N 0.000 description 2
- 229950007151 Taspoglutide Drugs 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- FQXXSQDCDRQNQE-VMDGZTHMSA-N Thebaine Chemical compound C([C@@H](N(CC1)C)C2=CC=C3OC)C4=CC=C(OC)C5=C4[C@@]21[C@H]3O5 FQXXSQDCDRQNQE-VMDGZTHMSA-N 0.000 description 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 2
- 208000000323 Tourette Syndrome Diseases 0.000 description 2
- 206010044126 Tourette's disease Diseases 0.000 description 2
- 229940116362 Tragacanth Drugs 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- GXPHKUHSUJUWKP-UHFFFAOYSA-N Troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- UBQNRHZMVUUOMG-UHFFFAOYSA-N Zonegran Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001299 aldehydes Chemical group 0.000 description 2
- 229960004538 alprazolam Drugs 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000001539 anorectic Effects 0.000 description 2
- 230000003042 antagnostic Effects 0.000 description 2
- 230000003276 anti-hypertensive Effects 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000002830 appetite depressant Substances 0.000 description 2
- 201000006287 attention deficit hyperactivity disease Diseases 0.000 description 2
- 201000002055 autistic disease Diseases 0.000 description 2
- 229960001264 benfluorex Drugs 0.000 description 2
- 229960002837 benzphetamine Drugs 0.000 description 2
- 229960004611 bezitramide Drugs 0.000 description 2
- 201000008176 body dysmorphic disease Diseases 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- 229960001713 canagliflozin Drugs 0.000 description 2
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229960003609 cathine Drugs 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 201000001084 cerebrovascular disease Diseases 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 201000000522 chronic kidney disease Diseases 0.000 description 2
- 229960004606 clomipramine Drugs 0.000 description 2
- 229960003120 clonazepam Drugs 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 229960004126 codeine Drugs 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 201000009929 conduct disease Diseases 0.000 description 2
- 230000037020 contractile activity Effects 0.000 description 2
- 201000008739 coronary artery disease Diseases 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000005712 crystallization Effects 0.000 description 2
- 229960003834 dapagliflozin Drugs 0.000 description 2
- 230000003111 delayed Effects 0.000 description 2
- 230000000994 depressed Effects 0.000 description 2
- 229960000632 dexamfetamine Drugs 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229960004890 diethylpropion Drugs 0.000 description 2
- 229960000920 dihydrocodeine Drugs 0.000 description 2
- 229960004192 diphenoxylate Drugs 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000035510 distribution Effects 0.000 description 2
- 229940000406 drug candidates Drugs 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 229960003345 empagliflozin Drugs 0.000 description 2
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000002148 esters Chemical group 0.000 description 2
- UAOCLDQAQNNEAX-ABMICEGHSA-N ethyl [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[5-methyl-1-propan-2-yl-4-[(4-propan-2-yloxyphenyl)methyl]pyrazol-3-yl]oxyoxan-2-yl]methyl carbonate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)OCC)O[C@H]1OC1=NN(C(C)C)C(C)=C1CC1=CC=C(OC(C)C)C=C1 UAOCLDQAQNNEAX-ABMICEGHSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N ethyl amine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- DBGIVFWFUFKIQN-VIFPVBQESA-N ethyl[(2S)-1-[3-(trifluoromethyl)phenyl]propan-2-yl]amine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 2
- QRHQPCRIZNMZIZ-MASJHSKDSA-N etorphine Chemical compound O([C@H]1[C@@]2(OC)C=C[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=CC=CC5=C2[C@]41CCN(C)[C@@H]3C5 QRHQPCRIZNMZIZ-MASJHSKDSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960001519 exenatide Drugs 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 201000003010 gallbladder disease Diseases 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229960000240 hydrocodone Drugs 0.000 description 2
- 229960001410 hydromorphone Drugs 0.000 description 2
- 239000000864 hyperglycemic agent Substances 0.000 description 2
- 201000001916 hypochondriasis Diseases 0.000 description 2
- 230000003059 hypodopaminergic Effects 0.000 description 2
- 239000000859 incretin Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000009114 investigational therapy Methods 0.000 description 2
- 229950000991 ipragliflozin Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229950009272 isomethadone Drugs 0.000 description 2
- 150000002576 ketones Chemical group 0.000 description 2
- 150000002596 lactones Chemical group 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 102000004882 lipase Human genes 0.000 description 2
- 108090001060 lipase Proteins 0.000 description 2
- 229960002701 liraglutide Drugs 0.000 description 2
- YSDQQAXHVYUZIW-QCIJIYAXSA-N liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 2
- 229960001451 lisdexamfetamine Drugs 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 229960004391 lorazepam Drugs 0.000 description 2
- ITIHHRMYZPNGRC-QRPNPIFTSA-N lorcaserin hydrochloride Chemical compound Cl.C[C@H]1CNCCC2=CC=C(Cl)C=C12 ITIHHRMYZPNGRC-QRPNPIFTSA-N 0.000 description 2
- 229960003283 lorcaserin hydrochloride Drugs 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic Effects 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229950006080 metopon Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 229930014694 morphine Natural products 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 2
- 229960001027 opium Drugs 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 229960002085 oxycodone Drugs 0.000 description 2
- 229960001528 oxymetazoline Drugs 0.000 description 2
- 229960005118 oxymorphone Drugs 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000006201 parenteral dosage form Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000001575 pathological Effects 0.000 description 2
- 230000002093 peripheral Effects 0.000 description 2
- 229960000482 pethidine Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 201000008839 post-traumatic stress disease Diseases 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 230000036515 potency Effects 0.000 description 2
- 229960003611 pramlintide Drugs 0.000 description 2
- 108010029667 pramlintide Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000001107 psychogenic Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 230000002685 pulmonary Effects 0.000 description 2
- 108010022711 pyroglutamyl-histidyl-glycine Proteins 0.000 description 2
- 201000004645 pyromania Diseases 0.000 description 2
- 230000000306 recurrent Effects 0.000 description 2
- 230000001105 regulatory Effects 0.000 description 2
- 229950011516 remogliflozin etabonate Drugs 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 229960004586 rosiglitazone Drugs 0.000 description 2
- 231100000489 sensitizer Toxicity 0.000 description 2
- 230000002295 serotoninergic Effects 0.000 description 2
- 229960004425 sibutramine Drugs 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000002269 spontaneous Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000010902 straw Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 108010048573 taspoglutide Proteins 0.000 description 2
- 229930003945 thebaine Natural products 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 229950006667 tofogliflozin Drugs 0.000 description 2
- 231100000730 tolerability Toxicity 0.000 description 2
- 229960004394 topiramate Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 230000001052 transient Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 229960001641 troglitazone Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 229960002911 zonisamide Drugs 0.000 description 2
- OKTJSMMVPCPJKN-BJUDXGSMSA-N (11)6C Chemical compound [11C] OKTJSMMVPCPJKN-BJUDXGSMSA-N 0.000 description 1
- AELCINSCMGFISI-DTWKUNHWSA-N (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@@H]1C[C@H]1C1=CC=CC=C1 AELCINSCMGFISI-DTWKUNHWSA-N 0.000 description 1
- XUFXOAAUWZOOIT-WVJZLWNXSA-N (2S,3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-WVJZLWNXSA-N 0.000 description 1
- RZFGPAMUAXASRE-QOUXGBQNSA-N (3R,8R,9S,10R,13S,14S,17S)-10,13-dimethyl-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-3,17-diol Chemical compound C1[C@@H](O)C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC21 RZFGPAMUAXASRE-QOUXGBQNSA-N 0.000 description 1
- ZROLHBHDLIHEMS-HUUCEWRRSA-N (6aR,10aR)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCC)=CC(O)=C3[C@@H]21 ZROLHBHDLIHEMS-HUUCEWRRSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- UMDMOUPSFIQQIK-UHFFFAOYSA-N 1,3-dihydro-1,4-diazepin-2-one Chemical compound O=C1CN=CC=CN1 UMDMOUPSFIQQIK-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- NTJQREUGJKIARY-UHFFFAOYSA-N 1-(2,5-dimethoxy-4-methylphenyl)propan-2-amine Chemical compound COC1=CC(CC(C)N)=C(OC)C=C1C NTJQREUGJKIARY-UHFFFAOYSA-N 0.000 description 1
- HSDFGSHQNADARG-UHFFFAOYSA-N 1-(2,5-dimethoxyphenyl)-N-iodopropan-2-amine Chemical compound COC1=CC=C(OC)C(CC(C)NI)=C1 HSDFGSHQNADARG-UHFFFAOYSA-N 0.000 description 1
- NJBLMIGSYNJINU-UHFFFAOYSA-N 1-(2-aminophenyl)propan-2-one Chemical compound CC(=O)CC1=CC=CC=C1N NJBLMIGSYNJINU-UHFFFAOYSA-N 0.000 description 1
- WJIQCDPCDVWDDE-WZNAKSSCSA-N 1-Androstenedione Chemical compound C1C(=O)C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 WJIQCDPCDVWDDE-WZNAKSSCSA-N 0.000 description 1
- GRUIIAQNNWQJPW-UHFFFAOYSA-N 1-[1-(3-chlorophenyl)-2-(4-methylpiperazin-1-yl)ethyl]cyclohexan-1-ol Chemical compound C1CN(C)CCN1CC(C1(O)CCCCC1)C1=CC=CC(Cl)=C1 GRUIIAQNNWQJPW-UHFFFAOYSA-N 0.000 description 1
- WLRUDCOZJXADDC-UHFFFAOYSA-N 1-[2-(methylamino)phenyl]propan-1-ol Chemical compound CCC(O)C1=CC=CC=C1NC WLRUDCOZJXADDC-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- AQFLVLHRZFLDDV-UHFFFAOYSA-N 1-phenylpropan-1-amine Chemical compound CCC(N)C1=CC=CC=C1 AQFLVLHRZFLDDV-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- JRIZOGLBRPZBLQ-QXUSFIETSA-N 19-Norandrostenedione Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JRIZOGLBRPZBLQ-QXUSFIETSA-N 0.000 description 1
- OGILRWGTRMMULL-UHFFFAOYSA-N 2-(1-benzothiophen-2-yl)-1-cyclohexylpiperidine Chemical compound C1CCCCC1N1C(C=2SC3=CC=CC=C3C=2)CCCC1 OGILRWGTRMMULL-UHFFFAOYSA-N 0.000 description 1
- SGVQMKDQDTWFEM-UHFFFAOYSA-N 2-(diethylamino)ethyl 4-(chloroamino)benzoate Chemical compound CCN(CC)CCOC(=O)C1=CC=C(NCl)C=C1 SGVQMKDQDTWFEM-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- SUXGNJVVBGJEFB-UHFFFAOYSA-N 25B-NBOMe Chemical compound COC1=CC=CC=C1CNCCC1=CC(OC)=C(Br)C=C1OC SUXGNJVVBGJEFB-UHFFFAOYSA-N 0.000 description 1
- FJFPOGCVVLUYAQ-UHFFFAOYSA-N 25C-NBOMe Chemical compound COC1=CC=CC=C1CNCCC1=CC(OC)=C(Cl)C=C1OC FJFPOGCVVLUYAQ-UHFFFAOYSA-N 0.000 description 1
- ZFUOLNAKPBFDIJ-UHFFFAOYSA-N 25I-NBOMe Chemical compound COC1=CC=CC=C1CNCCC1=CC(OC)=C(I)C=C1OC ZFUOLNAKPBFDIJ-UHFFFAOYSA-N 0.000 description 1
- YMHOBZXQZVXHBM-UHFFFAOYSA-N 2C-B Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 description 1
- LGUVDOBGXUFUAJ-UHFFFAOYSA-N 2C-T-19 Chemical compound CCCCSC1=CC(OC)=C(CCN)C=C1OC LGUVDOBGXUFUAJ-UHFFFAOYSA-N 0.000 description 1
- AHMSSHCYIDBVQB-UHFFFAOYSA-N 2C-T-8 Chemical compound C1=C(CCN)C(OC)=CC(SCC2CC2)=C1OC AHMSSHCYIDBVQB-UHFFFAOYSA-N 0.000 description 1
- MGBKJKDRMRAZKC-UHFFFAOYSA-N 3-aminobenzene-1,2-diol Chemical compound NC1=CC=CC(O)=C1O MGBKJKDRMRAZKC-UHFFFAOYSA-N 0.000 description 1
- AGUNEISBPXQOPA-XMUHMHRVSA-N 4-Chlorodehydromethyltestosterone Chemical compound C1CC2=C(Cl)C(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 AGUNEISBPXQOPA-XMUHMHRVSA-N 0.000 description 1
- QAVFEDRVOUKIPM-UHFFFAOYSA-N 4-Fluoro-2,5-dimethoxyphenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1F QAVFEDRVOUKIPM-UHFFFAOYSA-N 0.000 description 1
- BQOIJSIMMIDHMO-FBPKJDBXSA-N 4-Hydroxytestosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1O BQOIJSIMMIDHMO-FBPKJDBXSA-N 0.000 description 1
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 1
- QADHLRWLCPCEKT-LOVVWNRFSA-N 5-Androstenediol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC=C21 QADHLRWLCPCEKT-LOVVWNRFSA-N 0.000 description 1
- FQDAMYLMQQKPRX-UHFFFAOYSA-N 6-APB Chemical compound CC(N)CC1=CC=C2C=COC2=C1 FQDAMYLMQQKPRX-UHFFFAOYSA-N 0.000 description 1
- 229960004308 ACETYLCYSTEINE Drugs 0.000 description 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 1
- 229940005530 ANXIOLYTICS Drugs 0.000 description 1
- 206010000059 Abdominal discomfort Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000125 Abnormal dreams Diseases 0.000 description 1
- 229960004373 Acetylcholine Drugs 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 229950007829 Amfonelic Acid Drugs 0.000 description 1
- WHHHJDGNBVQNAU-UHFFFAOYSA-N Amfonelic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC=C1CC1=CC=CC=C1 WHHHJDGNBVQNAU-UHFFFAOYSA-N 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N Amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960000836 Amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N Amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960002519 Amoxapine Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N Amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 210000004727 Amygdala Anatomy 0.000 description 1
- AEMFNILZOJDQLW-QAGGRKNESA-N Androstenedione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
- 229960005471 Androstenedione Drugs 0.000 description 1
- 206010002650 Anorexia nervosa and bulimia Diseases 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- 206010003119 Arrhythmia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003549 Asthenia Diseases 0.000 description 1
- 229950006996 BOLANDIOL Drugs 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 244000187129 Bacopa monnieria Species 0.000 description 1
- 235000015418 Bacopa monnieria Nutrition 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N Benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- DQFQCHIDRBIESA-UHFFFAOYSA-N Benzazepine Chemical compound N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 description 1
- CYGODHVAJQTCBG-UHFFFAOYSA-N Bifeprunox Chemical compound C=12OC(=O)NC2=CC=CC=1N(CC1)CCN1CC(C=1)=CC=CC=1C1=CC=CC=C1 CYGODHVAJQTCBG-UHFFFAOYSA-N 0.000 description 1
- 229950009087 Bifeprunox Drugs 0.000 description 1
- 208000004093 Binge-Eating Disorder Diseases 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- CMXKUJNZWYTFJN-XFUVECHXSA-N Bolandiol Chemical compound O[C@H]1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 CMXKUJNZWYTFJN-XFUVECHXSA-N 0.000 description 1
- IVFYLRMMHVYGJH-VLOLGRDOSA-N Bolasterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-VLOLGRDOSA-N 0.000 description 1
- 229950008036 Bolasterone Drugs 0.000 description 1
- RSIHSRDYCUFFLA-DYKIIFRCSA-N Boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 1
- 229950007271 Boldenone Drugs 0.000 description 1
- LUJVUUWNAPIQQI-QAGGRKNESA-N Boldione Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 LUJVUUWNAPIQQI-QAGGRKNESA-N 0.000 description 1
- LWUDDYHYYNNIQI-ZDUSSCGKSA-N Bretazenil Chemical compound O=C1C2=C(Br)C=CC=C2N2C=NC(C(=O)OC(C)(C)C)=C2[C@@H]2CCCN21 LWUDDYHYYNNIQI-ZDUSSCGKSA-N 0.000 description 1
- 229950010832 Bretazenil Drugs 0.000 description 1
- VMIYHDSEFNYJSL-UHFFFAOYSA-N Bromazepam Chemical compound C12=CC(Br)=CC=C2NC(=O)CN=C1C1=CC=CC=N1 VMIYHDSEFNYJSL-UHFFFAOYSA-N 0.000 description 1
- 206010006451 Bronchitis Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- UMSGKTJDUHERQW-UHFFFAOYSA-N Brotizolam Chemical compound C1=2C=C(Br)SC=2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl UMSGKTJDUHERQW-UHFFFAOYSA-N 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N Buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960001113 Butorphanol Drugs 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N Butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- CYILBEADSHJQIB-UHFFFAOYSA-N C1NCCN2CCC=3C(=CC=C1C2=3)C(=O)N Chemical compound C1NCCN2CCC=3C(=CC=C1C2=3)C(=O)N CYILBEADSHJQIB-UHFFFAOYSA-N 0.000 description 1
- HLOCJJORRHQDKS-UHFFFAOYSA-N CP-39,332 Chemical compound C12=CC=CC=C2CC(NC)CC1C1=CC=CC=C1 HLOCJJORRHQDKS-UHFFFAOYSA-N 0.000 description 1
- 102100005543 CYP2D6 Human genes 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N Calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 229950009823 Calusterone Drugs 0.000 description 1
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N Cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 1
- 229950011318 Cannabidiol Drugs 0.000 description 1
- QHMBSVQNZZTUGM-MSOLQXFVSA-N Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@@H]1[C@@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-MSOLQXFVSA-N 0.000 description 1
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 description 1
- 229960003453 Cannabinol Drugs 0.000 description 1
- 206010007521 Cardiac arrhythmias Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 206010046973 Cardiac valve disease Diseases 0.000 description 1
- 208000005846 Cardiomyopathy Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- PUAQLLVFLMYYJJ-ZETCQYMHSA-N Cathinone Chemical compound C[C@H](N)C(=O)C1=CC=CC=C1 PUAQLLVFLMYYJJ-ZETCQYMHSA-N 0.000 description 1
- 229950002698 Cathinone Drugs 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 description 1
- 206010008479 Chest pain Diseases 0.000 description 1
- 229960004782 Chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N Chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N Chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 Chloroprocaine Drugs 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- 210000002987 Choroid Plexus Anatomy 0.000 description 1
- 210000000349 Chromosomes Anatomy 0.000 description 1
- 208000007451 Chronic Bronchitis Diseases 0.000 description 1
- 206010008874 Chronic fatigue syndrome Diseases 0.000 description 1
- XAXMYHMKTCNRRZ-UHFFFAOYSA-N Cinolazepam Chemical compound C12=CC(Cl)=CC=C2N(CCC#N)C(=O)C(O)N=C1C1=CC=CC=C1F XAXMYHMKTCNRRZ-UHFFFAOYSA-N 0.000 description 1
- CXOXHMZGEKVPMT-UHFFFAOYSA-N Clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 description 1
- KCZCIYZKSLLNNH-FBPKJDBXSA-N Clostebol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1Cl KCZCIYZKSLLNNH-FBPKJDBXSA-N 0.000 description 1
- 229960001481 Clostebol Drugs 0.000 description 1
- CHBRHODLKOZEPZ-UHFFFAOYSA-N Clotiazepam Chemical compound S1C(CC)=CC2=C1N(C)C(=O)CN=C2C1=CC=CC=C1Cl CHBRHODLKOZEPZ-UHFFFAOYSA-N 0.000 description 1
- ZIXNZOBDFKSQTC-UHFFFAOYSA-N Cloxazolam Chemical compound C12=CC(Cl)=CC=C2NC(=O)CN2CCOC21C1=CC=CC=C1Cl ZIXNZOBDFKSQTC-UHFFFAOYSA-N 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N Clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 229920001405 Coding region Polymers 0.000 description 1
- 206010057668 Cognitive disease Diseases 0.000 description 1
- 206010011652 Cushing's syndrome Diseases 0.000 description 1
- JURKNVYFZMSNLP-UHFFFAOYSA-N Cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 description 1
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- 101700066096 DAD2 Proteins 0.000 description 1
- BSMNRYCSBFHEMQ-UHFFFAOYSA-N DOV-216,303 Chemical compound C1=C(Cl)C(Cl)=CC=C1C1(CNC2)C2C1 BSMNRYCSBFHEMQ-UHFFFAOYSA-N 0.000 description 1
- POZRVZJJTULAOH-LHZXLZLDSA-N Danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
- SRPXSILJHWNFMK-MEDUHNTESA-N Dasotraline Chemical compound C1([C@@H]2CC[C@H](C3=CC=CC=C32)N)=CC=C(Cl)C(Cl)=C1 SRPXSILJHWNFMK-MEDUHNTESA-N 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N Dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- CHIFCDOIPRCHCF-UHFFFAOYSA-N Delorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl CHIFCDOIPRCHCF-UHFFFAOYSA-N 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- FRVHJVATKMIOPQ-PAPWGAKMSA-N Desoxymethyltestosterone Chemical compound C([C@@H]1CC2)C=CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 FRVHJVATKMIOPQ-PAPWGAKMSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 229960003701 Dextromoramide Drugs 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N Dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 229940087091 Dichlorotetrafluoroethane Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 210000002108 Dorsomedial Hypothalamic Nucleus Anatomy 0.000 description 1
- 229960005426 Doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N Doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 229950005101 Drostanolone Drugs 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 206010013754 Drug withdrawal syndrome Diseases 0.000 description 1
- 229940112141 Dry Powder Inhaler Drugs 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- JXMVQBDHMBOHDH-UHFFFAOYSA-N EXP-561 Chemical compound C1CC(N)(CC2)CCC12C1=CC=CC=C1 JXMVQBDHMBOHDH-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Enkephalin L Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 210000002615 Epidermis Anatomy 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N Epinephrine Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229960002336 Estazolam Drugs 0.000 description 1
- CDCHDCWJMGXXRH-UHFFFAOYSA-N Estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 description 1
- 229940012017 Ethylenediamine Drugs 0.000 description 1
- AOXRBFRFYPMWLR-XGXHKTLJSA-N Ethylestrenol Chemical compound C1CC2=CCCC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](CC)(O)[C@@]1(C)CC2 AOXRBFRFYPMWLR-XGXHKTLJSA-N 0.000 description 1
- VMZUTJCNQWMAGF-UHFFFAOYSA-N Etizolam Chemical compound S1C(CC)=CC2=C1N1C(C)=NN=C1CN=C2C1=CC=CC=C1Cl VMZUTJCNQWMAGF-UHFFFAOYSA-N 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 230000036826 Excretion Effects 0.000 description 1
- 206010015832 Extrapyramidal disease Diseases 0.000 description 1
- 210000003414 Extremities Anatomy 0.000 description 1
- 208000009745 Eye Disease Diseases 0.000 description 1
- 206010016165 Failure to thrive Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- OFBIFZUFASYYRE-UHFFFAOYSA-N Flumazenil Chemical compound C1N(C)C(=O)C2=CC(F)=CC=C2N2C=NC(C(=O)OCC)=C21 OFBIFZUFASYYRE-UHFFFAOYSA-N 0.000 description 1
- 229960004381 Flumazenil Drugs 0.000 description 1
- 229960002200 Flunitrazepam Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N Fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229960001751 Fluoxymesterone Drugs 0.000 description 1
- SAADBVWGJQAEFS-UHFFFAOYSA-N Flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 description 1
- 229960003528 Flurazepam Drugs 0.000 description 1
- OFVXPDXXVSGEPX-UHFFFAOYSA-N Flutoprazepam Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C11)=NCC(=O)N1CC1CC1 OFVXPDXXVSGEPX-UHFFFAOYSA-N 0.000 description 1
- AMVODTGMYSRMNP-GNIMZFFESA-N Formebolone Chemical compound C1CC2=CC(=O)C(C=O)=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@H]2O AMVODTGMYSRMNP-GNIMZFFESA-N 0.000 description 1
- RGLLOUBXMOGLDQ-IVEVATEUSA-N Furazabol Chemical compound C([C@@H]1CC2)C3=NON=C3C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 RGLLOUBXMOGLDQ-IVEVATEUSA-N 0.000 description 1
- 229950010710 Furazabol Drugs 0.000 description 1
- 108060003412 GRP Proteins 0.000 description 1
- 208000001613 Gambling Diseases 0.000 description 1
- 206010017918 Gastroenteritis viral Diseases 0.000 description 1
- 208000008665 Gastrointestinal Disease Diseases 0.000 description 1
- 206010018090 Generalised non-convulsive epilepsy Diseases 0.000 description 1
- BJJXHLWLUDYTGC-ANULTFPQSA-N Gestrinone Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](CC)([C@](CC3)(O)C#C)C=C3)C3=C21 BJJXHLWLUDYTGC-ANULTFPQSA-N 0.000 description 1
- 229960004761 Gestrinone Drugs 0.000 description 1
- 210000001905 Globus Pallidus Anatomy 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 206010018659 Grand mal convulsion Diseases 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 101710045397 HTR2C Proteins 0.000 description 1
- 229940087496 Habitrol Drugs 0.000 description 1
- WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 208000002907 Heart Valve Disease Diseases 0.000 description 1
- 210000003709 Heart Valves Anatomy 0.000 description 1
- 206010019280 Heart failure Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 210000001320 Hippocampus Anatomy 0.000 description 1
- 206010020400 Hostility Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N Imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229940102223 Injectable Solution Drugs 0.000 description 1
- 229940102213 Injectable Suspension Drugs 0.000 description 1
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N Isocarboxazid Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
- 229960004423 KETAZOLAM Drugs 0.000 description 1
- PWAJCNITSBZRBL-UHFFFAOYSA-N Ketazolam Chemical compound O1C(C)=CC(=O)N2CC(=O)N(C)C3=CC=C(Cl)C=C3C21C1=CC=CC=C1 PWAJCNITSBZRBL-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 229960003019 LOPRAZOLAM Drugs 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- INUNXTSAACVKJS-NRFANRHFSA-N Levomoramide Chemical compound C([C@H](C)C(C(=O)N1CCCC1)(C=1C=CC=CC=1)C=1C=CC=CC=1)N1CCOCC1 INUNXTSAACVKJS-NRFANRHFSA-N 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- UTEFBSAVJNEPTR-RGEXLXHISA-N Loprazolam Chemical compound C1CN(C)CCN1\C=C/1C(=O)N2C3=CC=C([N+]([O-])=O)C=C3C(C=3C(=CC=CC=3)Cl)=NCC2=N\1 UTEFBSAVJNEPTR-RGEXLXHISA-N 0.000 description 1
- FJIKWRGCXUCUIG-UHFFFAOYSA-N Lormetazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1Cl FJIKWRGCXUCUIG-UHFFFAOYSA-N 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- SHXWCVYOXRDMCX-UHFFFAOYSA-N MDMA Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 1
- 229950006489 MIBOLERONE Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L Magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- YLCXGBZIZBEVPZ-UHFFFAOYSA-N Medazepam Chemical compound C12=CC(Cl)=CC=C2N(C)CCN=C1C1=CC=CC=C1 YLCXGBZIZBEVPZ-UHFFFAOYSA-N 0.000 description 1
- 229960003194 Meglumine Drugs 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 102000001796 Melanocortin 4 receptor Human genes 0.000 description 1
- 206010027175 Memory impairment Diseases 0.000 description 1
- 206010061284 Mental disease Diseases 0.000 description 1
- RHCSKNNOAZULRK-UHFFFAOYSA-N Mescaline Chemical compound COC1=CC(CCN)=CC(OC)=C1OC RHCSKNNOAZULRK-UHFFFAOYSA-N 0.000 description 1
- WYZDXEKUWRCKOB-YDSAWKJFSA-N Mestanolone Chemical compound C([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 WYZDXEKUWRCKOB-YDSAWKJFSA-N 0.000 description 1
- UXYRZJKIQKRJCF-TZPFWLJSSA-N Mesterolone Chemical compound C1C[C@@H]2[C@@]3(C)[C@@H](C)CC(=O)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H](O)[C@]21C UXYRZJKIQKRJCF-TZPFWLJSSA-N 0.000 description 1
- 229960005272 Mesterolone Drugs 0.000 description 1
- GHFGJTVYMNRGBY-UHFFFAOYSA-N Meta-Tyramine Chemical compound NCCC1=CC=CC(O)=C1 GHFGJTVYMNRGBY-UHFFFAOYSA-N 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 230000036650 Metabolic stability Effects 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 229960003377 Metandienone Drugs 0.000 description 1
- ANJQEDFWRSLVBR-VHUDCFPWSA-N Metenolone Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H](O)[C@]21C ANJQEDFWRSLVBR-VHUDCFPWSA-N 0.000 description 1
- WRWBCPJQPDHXTJ-DTMQFJJTSA-N Methandriol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 WRWBCPJQPDHXTJ-DTMQFJJTSA-N 0.000 description 1
- XWALNWXLMVGSFR-HLXURNFRSA-N Methandrostenolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 XWALNWXLMVGSFR-HLXURNFRSA-N 0.000 description 1
- QCWCXSMWLJFBNM-FOVYBZIDSA-N Methasterone Chemical compound C1C[C@@H]2[C@@]3(C)C[C@@H](C)C(=O)C[C@@H]3CC[C@H]2[C@@H]2CC[C@](C)(O)[C@]21C QCWCXSMWLJFBNM-FOVYBZIDSA-N 0.000 description 1
- 229960001116 Methenolone Drugs 0.000 description 1
- RDJBOAMEIJEKEY-XWSJACJDSA-N Methyldienolone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 RDJBOAMEIJEKEY-XWSJACJDSA-N 0.000 description 1
- ZXSWTMLNIIZPET-ZOFHRBRSSA-N Methylestrenolone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 ZXSWTMLNIIZPET-ZOFHRBRSSA-N 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- CCCIJQPRIXGQOE-XWSJACJDSA-N Metribolone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C=C2 CCCIJQPRIXGQOE-XWSJACJDSA-N 0.000 description 1
- 229950003695 Metribolone Drugs 0.000 description 1
- PTQMMNYJKCSPET-OMHQDGTGSA-N Mibolerone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@H](C)CC3=CC(=O)CC[C@@H]3[C@H]21 PTQMMNYJKCSPET-OMHQDGTGSA-N 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N Midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 Midazolam Drugs 0.000 description 1
- 206010027599 Migraine Diseases 0.000 description 1
- 208000008085 Migraine Disorders Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000840267 Moma Species 0.000 description 1
- 208000001022 Morbid Obesity Diseases 0.000 description 1
- 229940066491 Mucolytics Drugs 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- 210000004413 Myocytes, Cardiac Anatomy 0.000 description 1
- 210000000329 Myocytes, Smooth Muscle Anatomy 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N N',N'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- SASNBVQSOZSTPD-UHFFFAOYSA-N N-Methylphenethylamine Chemical compound CNCCC1=CC=CC=C1 SASNBVQSOZSTPD-UHFFFAOYSA-N 0.000 description 1
- YELGXBUYFOSFJM-UHFFFAOYSA-N N-methyl-1-phenylpropan-1-amine Chemical compound CCC(NC)C1=CC=CC=C1 YELGXBUYFOSFJM-UHFFFAOYSA-N 0.000 description 1
- 102100015978 NPY Human genes 0.000 description 1
- 108020001430 NPY Proteins 0.000 description 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N Nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
- 229960000805 Nalbuphine Drugs 0.000 description 1
- NPAGDVCDWIYMMC-IZPLOLCNSA-N Nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 description 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N Nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
- 210000001577 Neostriatum Anatomy 0.000 description 1
- 206010029149 Nephropathy Diseases 0.000 description 1
- 206010052639 Nerve injury Diseases 0.000 description 1
- 229940099632 Nicotrol Drugs 0.000 description 1
- GWUSZQUVEVMBPI-UHFFFAOYSA-N Nimetazepam Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1 GWUSZQUVEVMBPI-UHFFFAOYSA-N 0.000 description 1
- KJONHKAYOJNZEC-UHFFFAOYSA-N Nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
- 229960001454 Nitrazepam Drugs 0.000 description 1
- FTBJKONNNSKOLX-XUDSTZEESA-N Norboletone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](CC)(O)[C@@]1(CC)CC2 FTBJKONNNSKOLX-XUDSTZEESA-N 0.000 description 1
- 229950010948 Norboletone Drugs 0.000 description 1
- OZDDFAQVVGFDJP-YGRHGMIBSA-N Norclostebol Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1Cl OZDDFAQVVGFDJP-YGRHGMIBSA-N 0.000 description 1
- 229950001380 Norclostebol Drugs 0.000 description 1
- AKPLHCDWDRPJGD-UHFFFAOYSA-N Nordazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)CN=C1C1=CC=CC=C1 AKPLHCDWDRPJGD-UHFFFAOYSA-N 0.000 description 1
- 229960002640 Nordazepam Drugs 0.000 description 1
- ZDHCJEIGTNNEMY-XGXHKTLJSA-N Norethandrolone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](CC)(O)[C@@]1(C)CC2 ZDHCJEIGTNNEMY-XGXHKTLJSA-N 0.000 description 1
- 229960000492 Norethandrolone Drugs 0.000 description 1
- LRCXRAABFLIVAI-UHFFFAOYSA-N Norfenefrine Chemical compound NCC(O)C1=CC=CC(O)=C1 LRCXRAABFLIVAI-UHFFFAOYSA-N 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 1
- 208000001797 Obstructive Sleep Apnea Diseases 0.000 description 1
- QHGUCRYDKWKLMG-UHFFFAOYSA-N Octopamine Chemical compound NCC(O)C1=CC=C(O)C=C1 QHGUCRYDKWKLMG-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- GXHBCWCMYVTJOW-YGRHGMIBSA-N Oxabolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1O GXHBCWCMYVTJOW-YGRHGMIBSA-N 0.000 description 1
- QSLJIVKCVHQPLV-PEMPUTJUSA-N Oxandrin Chemical compound C([C@@H]1CC2)C(=O)OC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 QSLJIVKCVHQPLV-PEMPUTJUSA-N 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N Oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- DIVDFFZHCJEHGG-UHFFFAOYSA-N Oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
- RXXBBHGCAXVBES-XMUHMHRVSA-N Oxymesterone Chemical compound C1CC2=C(O)C(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 RXXBBHGCAXVBES-XMUHMHRVSA-N 0.000 description 1
- ICMWWNHDUZJFDW-DHODBPELSA-N Oxymetholone Chemical compound C([C@@H]1CC2)C(=O)\C(=C/O)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 ICMWWNHDUZJFDW-DHODBPELSA-N 0.000 description 1
- 229940116369 Pancreatic lipase Drugs 0.000 description 1
- 102000019280 Pancreatic lipase Human genes 0.000 description 1
- 108050006759 Pancreatic lipase Proteins 0.000 description 1
- 206010033775 Paraesthesia Diseases 0.000 description 1
- 210000002963 Paraventricular Hypothalamic Nucleus Anatomy 0.000 description 1
- 208000007697 Partial Epilepsy Diseases 0.000 description 1
- 206010061334 Partial seizure Diseases 0.000 description 1
- 206010034759 Petit mal epilepsy Diseases 0.000 description 1
- 206010034800 Phaeochromocytoma Diseases 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N Phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229960000964 Phenelzine Drugs 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N Phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001802 Phenylephrine Drugs 0.000 description 1
- MFZOSKPPVCIFMT-UHFFFAOYSA-N Pinazepam Chemical compound C12=CC(Cl)=CC=C2N(CC#C)C(=O)CN=C1C1=CC=CC=C1 MFZOSKPPVCIFMT-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 description 1
- 229960004856 Prazepam Drugs 0.000 description 1
- 206010036596 Premature ejaculation Diseases 0.000 description 1
- CNWSHOJSFGGNLC-UHFFFAOYSA-N Premazepam Chemical compound C=1N(C)C(C)=C2C=1NC(=O)CN=C2C1=CC=CC=C1 CNWSHOJSFGGNLC-UHFFFAOYSA-N 0.000 description 1
- 229950003432 Premazepam Drugs 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N Proprasylyt Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- AGJAMJZFPDQSEW-KOTDIDPQSA-N Prostanozol Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(CC=5C=NNC=5C[C@@H]4CC3)C)CC[C@@]21C)C1CCCCO1 AGJAMJZFPDQSEW-KOTDIDPQSA-N 0.000 description 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N Protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
- 206010037180 Psychiatric symptom Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000002815 Pulmonary Hypertension Diseases 0.000 description 1
- BGRWSFIQQPVEML-UHFFFAOYSA-N Pyrazolam Chemical compound C12=CC(Br)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=N1 BGRWSFIQQPVEML-UHFFFAOYSA-N 0.000 description 1
- IKMPWMZBZSAONZ-UHFFFAOYSA-N Quazepam Chemical compound FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=CC=C(Cl)C=C12 IKMPWMZBZSAONZ-UHFFFAOYSA-N 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N Quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N Quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 210000001609 Raphe Nuclei Anatomy 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 210000001525 Retina Anatomy 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 1
- PJSUYRBCBFPCQW-UHFFFAOYSA-N SB-649,915 Chemical compound O1CC(=O)NC2=CC(CC3CCN(CC3)CCOC=3C4=CC=C(N=C4C=CC=3)C)=CC=C21 PJSUYRBCBFPCQW-UHFFFAOYSA-N 0.000 description 1
- 102100001467 SLC18A2 Human genes 0.000 description 1
- 101710044968 SLC18A2 Proteins 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N Salbutamol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 229940053479 Selective serotonin reuptake inhibitors Drugs 0.000 description 1
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- LKAJKIOFIWVMDJ-IYRCEVNGSA-N Stanazolol Chemical compound C([C@@H]1CC[C@H]2[C@@H]3CC[C@@]([C@]3(CC[C@@H]2[C@@]1(C)C1)C)(O)C)C2=C1C=NN2 LKAJKIOFIWVMDJ-IYRCEVNGSA-N 0.000 description 1
- 229960000912 Stanozolol Drugs 0.000 description 1
- GYBGISLVORKLBN-YNZDMMAESA-N Stenbolone Chemical compound C1C[C@@H]2[C@@]3(C)C=C(C)C(=O)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H](O)[C@]21C GYBGISLVORKLBN-YNZDMMAESA-N 0.000 description 1
- 229950005638 Stenbolone Drugs 0.000 description 1
- 210000000495 Subthalamus Anatomy 0.000 description 1
- 206010065604 Suicidal behaviour Diseases 0.000 description 1
- 229940090121 Sulfonylureas for blood glucose lowering Drugs 0.000 description 1
- 210000000225 Synapses Anatomy 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- VOKSWYLNZZRQPF-UHFFFAOYSA-N Talwin Chemical compound C1C2=CC=C(O)C=C2C2(C)C(C)C1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-UHFFFAOYSA-N 0.000 description 1
- CEIJFEGBUDEYSX-FZDBZEDMSA-N Tandospirone Chemical compound O=C([C@@H]1[C@H]2CC[C@H](C2)[C@@H]1C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 CEIJFEGBUDEYSX-FZDBZEDMSA-N 0.000 description 1
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
- 229960003188 Temazepam Drugs 0.000 description 1
- 208000001189 Temporomandibular Joint Dysfunction Syndrome Diseases 0.000 description 1
- 206010043220 Temporomandibular joint syndrome Diseases 0.000 description 1
- 229960003604 Testosterone Drugs 0.000 description 1
- 229940033529 Tetrahydrocannabinol Drugs 0.000 description 1
- OXHNQTSIKGHVBH-ANULTFPQSA-N Tetrahydrogestrinone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@](CC)(O)[C@@]1(CC)C=C2 OXHNQTSIKGHVBH-ANULTFPQSA-N 0.000 description 1
- IQWYAQCHYZHJOS-UHFFFAOYSA-N Tetrazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CCCCC1 IQWYAQCHYZHJOS-UHFFFAOYSA-N 0.000 description 1
- 210000001103 Thalamus Anatomy 0.000 description 1
- 230000036335 Tissue distribution Effects 0.000 description 1
- 208000004371 Toothache Diseases 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- MEHHPFQKXOUFFV-OWSLCNJRSA-N Trenbolone Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@H](CC3)O)C=C3)C3=C21 MEHHPFQKXOUFFV-OWSLCNJRSA-N 0.000 description 1
- 229960000312 Trenbolone Drugs 0.000 description 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N Triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N Trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N Trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 1
- PGAVKCOVUIYSFO-XVFCMESISA-N Uridine triphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 201000006791 West syndrome Diseases 0.000 description 1
- 229940002552 Xenical Drugs 0.000 description 1
- HUNXMJYCHXQEGX-UHFFFAOYSA-N Zaleplon Chemical compound CCN(C(C)=O)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C#N)=C1 HUNXMJYCHXQEGX-UHFFFAOYSA-N 0.000 description 1
- 229960000820 Zopiclone Drugs 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant Effects 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated Effects 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 229950009148 androstenediol Drugs 0.000 description 1
- 230000000578 anorexic Effects 0.000 description 1
- 230000002891 anorexigenic Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000002426 anti-panic Effects 0.000 description 1
- 230000002738 anti-smoking Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 230000000949 anxiolytic Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 201000001320 atherosclerosis Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 235000021053 average weight gain Nutrition 0.000 description 1
- 150000001538 azepines Chemical class 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 229960000074 biopharmaceuticals Drugs 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940090129 blood glucose lowering drugs Thiazolidinediones Drugs 0.000 description 1
- 229960002729 bromazepam Drugs 0.000 description 1
- 230000003182 bronchodilatating Effects 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 229960003051 brotizolam Drugs 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- RMRJXGBAOAMLHD-CTAPUXPBSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-CTAPUXPBSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N butylene glycol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000002317 cardiac myocyte Anatomy 0.000 description 1
- 201000008031 cardiomyopathy Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 210000004027 cells Anatomy 0.000 description 1
- 201000003861 cerebellar disease Diseases 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 230000001055 chewing Effects 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229950007046 chlorphentermine Drugs 0.000 description 1
- CRBHXDCYXIISFC-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CC[O-] CRBHXDCYXIISFC-UHFFFAOYSA-N 0.000 description 1
- 230000000718 cholinopositive Effects 0.000 description 1
- 235000019506 cigar Nutrition 0.000 description 1
- 229960002753 cinolazepam Drugs 0.000 description 1
- 229960001403 clobazam Drugs 0.000 description 1
- 229960004362 clorazepate Drugs 0.000 description 1
- XDDJGVMJFWAHJX-UHFFFAOYSA-N clorazepic acid Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)O)N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-N 0.000 description 1
- 229960003622 clotiazepam Drugs 0.000 description 1
- 229960003932 cloxazolam Drugs 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- 230000000295 complement Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 230000001010 compromised Effects 0.000 description 1
- 231100000867 compulsive behavior Toxicity 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 229960003572 cyclobenzaprine Drugs 0.000 description 1
- 229960000766 danazol Drugs 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229950007393 delorazepam Drugs 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229960003461 dezocine Drugs 0.000 description 1
- VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 description 1
- 201000008286 diarrhea Diseases 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 230000000378 dietary Effects 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 230000037228 dieting Effects 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000003292 diminished Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 1
- 230000003291 dopaminomimetic Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
- 230000001544 dysphoric Effects 0.000 description 1
- 230000005584 early death Effects 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000002996 emotional Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 230000001037 epileptic Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000001667 episodic Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960001460 ethylestrenol Drugs 0.000 description 1
- 229960004404 etizolam Drugs 0.000 description 1
- 230000002743 euphoric Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 229950009299 flutoprazepam Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 201000007186 focal epilepsy Diseases 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229950010292 formebolone Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000019525 fullness Nutrition 0.000 description 1
- 229940013945 gamma-Aminobutyric Acid Drugs 0.000 description 1
- 230000000574 ganglionic Effects 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229960002158 halazepam Drugs 0.000 description 1
- 201000010238 heart disease Diseases 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000002017 high-resolution X-ray diffraction Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000000147 hypnotic Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003382 ingestive Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960002672 isocarboxazid Drugs 0.000 description 1
- 230000002045 lasting Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000002197 limbic Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- HPQVWDOOUQVBTO-UHFFFAOYSA-N lithium aluminium hydride Substances [Li+].[Al-] HPQVWDOOUQVBTO-UHFFFAOYSA-N 0.000 description 1
- 201000004044 liver cirrhosis Diseases 0.000 description 1
- 201000009673 liver disease Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000003137 locomotive Effects 0.000 description 1
- 229960004033 lormetazepam Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 239000011776 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 201000003895 major depressive disease Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000018984 mastication Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960002225 medazepam Drugs 0.000 description 1
- 230000003340 mental Effects 0.000 description 1
- JLICHNCFTLFZJN-HNNXBMFYSA-N meptazinol Chemical compound C=1C=CC(O)=CC=1[C@@]1(CC)CCCCN(C)C1 JLICHNCFTLFZJN-HNNXBMFYSA-N 0.000 description 1
- 229960000365 meptazinol Drugs 0.000 description 1
- 229950008604 mestanolone Drugs 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229960003578 metenolone Drugs 0.000 description 1
- 229960001833 methandriol Drugs 0.000 description 1
- IKXILDNPCZPPRV-RFMGOVQKSA-N metholone Chemical compound C1C[C@@H]2[C@@]3(C)C[C@@H](C)C(=O)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H](O)[C@]21C IKXILDNPCZPPRV-RFMGOVQKSA-N 0.000 description 1
- NEHPFNBRZYFWFN-UHFFFAOYSA-N methyl 2-cyclopentyl-2-(3,4-dichlorophenyl)acetate Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(C(=O)OC)C1CCCC1 NEHPFNBRZYFWFN-UHFFFAOYSA-N 0.000 description 1
- GADIKQPUNWAMEB-UHFFFAOYSA-N methyl 4-ethyl-6,7-dimethoxy-9H-pyrido[5,4-b]indole-3-carboxylate Chemical compound N1C2=CC(OC)=C(OC)C=C2C2=C1C=NC(C(=O)OC)=C2CC GADIKQPUNWAMEB-UHFFFAOYSA-N 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 229960000270 methylestrenolone Drugs 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 230000001730 monoaminergic Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 230000000510 mucolytic Effects 0.000 description 1
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
- 229960004719 nandrolone Drugs 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 229960001800 nefazodone Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001722 neurochemical Effects 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 230000000926 neurological Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 229950001981 nimetazepam Drugs 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 229960001856 norfenefrine Drugs 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229950010171 oxabolone Drugs 0.000 description 1
- 229960000464 oxandrolone Drugs 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 229950008280 oxymesterone Drugs 0.000 description 1
- 229960005244 oxymetholone Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 230000018052 penile erection Effects 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 230000002085 persistent Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229960002034 pinazepam Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000003234 polygenic Effects 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000001242 postsynaptic Effects 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 229960002847 prasterone Drugs 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229960002601 protriptyline Drugs 0.000 description 1
- 229940001470 psychoactive drugs Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 229960001964 quazepam Drugs 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- 229960001819 quinbolone Drugs 0.000 description 1
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000029556 regulation of feeding behavior Effects 0.000 description 1
- 230000003014 reinforcing Effects 0.000 description 1
- 230000000246 remedial Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory Effects 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 230000000698 schizophrenic Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000247 serious adverse effect Toxicity 0.000 description 1
- 231100000197 serious side effect Toxicity 0.000 description 1
- 239000003762 serotonin receptor affecting agent Substances 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 230000001568 sexual Effects 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Substances [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 description 1
- 230000001954 sterilising Effects 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000002739 subcortical Effects 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000000946 synaptic Effects 0.000 description 1
- 230000003977 synaptic function Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000002278 tabletting lubricant Substances 0.000 description 1
- 229950000505 tandospirone Drugs 0.000 description 1
- 201000008914 temporal lobe epilepsy Diseases 0.000 description 1
- ODGCEQLVLXJUCC-UHFFFAOYSA-N tetrafluoroborate Chemical class F[B-](F)(F)F ODGCEQLVLXJUCC-UHFFFAOYSA-N 0.000 description 1
- 229960005214 tetrazepam Drugs 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- 229960003386 triazolam Drugs 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- 229950010342 uridine triphosphate Drugs 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 230000002618 waking Effects 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 229960004010 zaleplon Drugs 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- Y10S514/811—
-
- Y10S514/866—
-
- Y10S514/909—
Abstract
Provided in some embodiments are compounds herein. Also provided in some embodiments are methods for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea. Also provided in some embodiments are compositions comprising a compound herein, optionally in combination with a supplemental agent, and methods for reducing the frequency of smoking tobacco in an individual attempting to reduce frequency of smoking tobacco; aiding in the cessation or lessening of use of a tobacco product in an individual attempting to cease or lessen use of a tobacco product; aiding in smoking cessation and preventing associated weight gain; controlling weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; reducing weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; treating nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine dependency, addiction and/or withdrawal; or reducing the likelihood of relapse use of nicotine by an individual attempting to cease nicotine use comprising administering a compound herein, optionally in combination with a supplemental agent. ependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea. Also provided in some embodiments are compositions comprising a compound herein, optionally in combination with a supplemental agent, and methods for reducing the frequency of smoking tobacco in an individual attempting to reduce frequency of smoking tobacco; aiding in the cessation or lessening of use of a tobacco product in an individual attempting to cease or lessen use of a tobacco product; aiding in smoking cessation and preventing associated weight gain; controlling weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; reducing weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; treating nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine dependency, addiction and/or withdrawal; or reducing the likelihood of relapse use of nicotine by an individual attempting to cease nicotine use comprising administering a compound herein, optionally in combination with a supplemental agent.
Description
-HT c RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE
Obesity is a life-threatening disorder in which there is an increased risk of morbidity and
mortality arising from concomitant diseases such as type II diabetes, hypertension, stroke, cancer, and
gallbladder disease.
Obesity is now a major healthcare issue in the Western World and increasingly in some third
world countries. The increase in numbers of obese people is due largely to the increasing preference for
high fat content foods but also the decrease in activity in most people's lives. Currently about 30% of
the population of the USA is now considered obese.
Whether someone is classified as overweight or obese is generally determined on the basis of
their body mass index (BMI) which is calculated by dividing body weight (kg) by height squared (m2).
Thus, the units of BMI are kg/m and it is possible to calculate the BMI range associated with minimum
mortality in each decade of life. Overweight is defined as a BMI in the range 25-30 kg/m , and obesity
as a BMI greater than 30 kg/m (see table below).
Classification Of Weight By Body Mass Index (BMI)
BMI CLASSIFICATION
< 18.5 Underweight
18.5-24.9 Normal
.0-29.9 Overweight
Obesity (Class I)
.0-34.9
.0-39.9 Obesity (Class II)
Extreme Obesity (Class III)
As the BMI increases there is an increased risk of death from a variety of causes that are
independent of other risk factors. The most common diseases associated with obesity are cardiovascular
disease (particularly hypertension), diabetes ( obesity aggravates the development of diabetes), gall
bladder disease (particularly cancer) and diseases of reproduction. The strength of the link between
obesity and specific conditions varies. One of the strongest is the link with type 2 diabetes. Excess body
fat underlies 64% of cases of diabetes in men and 77% of cases in women (Seidell, Semin Vase Med
:3-14 (2005)). Research has shown that even a modest reduction in body weight can correspond to a
significant reduction in the risk of developing coronary heart disease.
There are problems however with the BMI definition in that it does not take into account the
proportion of body mass that is muscle in relation to fat ( adipose tissue). To account for this, obesity
can also be defined on the basis of body fat content: greater than 25% in males and greater than 30% in
females.
Obesity considerably increases the risk of developing cardiovascular diseases as well. Coronary
insufficiency, atheromatous disease, and cardiac insufficiency are at the forefront of the cardiovascular
complications induced by obesity. It is estimated that if the entire population had an ideal weight, the
risk of coronary insufficiency would decrease by 25 % and the risk of cardiac insufficiency and of
cerebral vascular accidents would decrease by 35%. The incidence of coronary diseases is doubled in
subjects less than 50 years of age who are 30% overweight. The diabetes patient faces a 30% reduced
lifespan. After age 45, people with diabetes are about three times more likely than people without
diabetes to have significant heart disease and up to five times more likely to have a stroke. These
findings emphasize the inter-relations between risks factors for diabetes and coronary heart disease and
the potential value of an integrated approach to the prevention of these conditions based on the
prevention ofobesity (Perry, I. J., et al., BM] 310, 560-564 (1995)).
Diabetes has also been implicated in the development of kidney disease, eye diseases and
nervous system problems. Kidney disease, also called nephropathy, occurs when the kidney's "filter
mechanism" is damaged and protein leaks into urine in excessive amounts and eventually the kidney
fails. Diabetes is also a leading cause of damage to the retina at the back of the eye and increases risk of
cataracts and glaucoma. Finally, diabetes is associated with nerve damage, especially in the legs and
feet, which interferes with the ability to sense pain and contributes to serious infections. Taken together,
diabetes complications are one of the nation's leading causes of death.
The first line of treatment is to offer diet and life style advice to patients such as reducing the
fat content of their diet and increasing their physical activity. However, many patients find this difficult
and need additional help from drug therapy to maintain results from these efforts.
Most currently marketed products have been unsuccessful as treatments for obesity because of
a lack of efficacy or unacceptable side-effect profiles. The most successful drug so far was the
indirectly acting 5-hydroxytryptamine (5-HT) agonist d-fenfluramine (Redux™) but reports of cardiac
valve defects in up to one third of patients led to its withdrawal by the FDA in 1998.
In addition, two drugs have been launched in the USA and Europe: orlistat (Xenical™), a drug
that prevents absorption of fat by the inhibition of pancreatic lipase, and sibutramine (Reductil™), a 5-
HT/noradrenaline re-uptake inhibitor. However, side effects associated with these products may limit
their long-term utility. Treatment with Xenical is reported to induce gastrointestinal distress in some
patients, while sibutramine has been associated with raised blood pressure in some patients.
Serotonin (5-HT) neurotransmission plays an important role in numerous physiological
processes both in physical and in psychiatric disorders. 5-HT has been implicated in the regulation of
feeding behavior. 5-HT is believed to work by inducing a feeling of satiety, such that a subject with
enhanced 5-HT stops eating earlier and fewer calories are consumed. It has been shown that a
stimulatory action of 5-HT on the 5-HT c receptor plays an important role in the control of eating and
in the anti-obesity effect of d-fenfluramine. As the 5-HT c receptor is expressed in high density in the
brain (notably in the limbic structures, extrapyramidal pathways, thalamus and hypothalamus i.e.
paraventricular hypothalamic nucleus and dorsomedial hypothalamic nucleus, and predominantly in the
choroid plexus) and is expressed in low density or is absent in peripheral tissues, the compounds
provided herein can be a more effective and safe anti-obesity agent. Also, 5-HT c knockout mice are
overweight with cognitive impairment and susceptibility to seizure.
It is believed that the 5-HT c receptor may play a role in obsessive compulsive disorder, some
forms of depression, and epilepsy. Accordingly, agonists can have anti-panic properties, and properties
useful for the treatment of sexual dysfunction.
In sum, the 5-HT c receptor is a receptor target for the treatment of obesity and psychiatric
disorders, and it can be seen that there is a need for 5-HT c agonists which safely decrease food intake
and body weight.
The 5-HT c receptor is one of 14 distinct serotonin receptor subtypes. Two receptors that are
closely related to the 5-HT c receptor are the 5-HT A and 5-HT B receptors, which share considerable
2 2 2
sequence homology. It is believed that activation of central 5-HT A receptors is a cause for a number of
adverse central nervous system effects of nonselective serotonergic drugs including changes in
perception and hallucination. Activation of 5-HT B receptors located in the cardiovascular system is
hypothesized to result in the heart valve disease and pulmonary hypertension associated with the use of
fenfluramine and a number of other drugs that act via serotonergic mechanisms.
Lorcaserin ( disclosed in PCT patent publication W02003/086303) is an agonist of the 5-HT c
receptor and shows effectiveness at reducing obesity in animal models and humans. In December 2009,
Arena Pharmaceuticals submitted a New Drug Application, or NDA, for lorcaserin to the US Food and
Drug Administration (FDA). The NDA submission is based on an extensive data package from
lorcaserin's clinical development program that includes 18 clinical trials totaling 8,576 patients. The
pivotal phase 3 clinical trial program evaluated nearly 7,200 patients treated for up to two years, and
showed that lorcaserin consistently produced significant weight loss with excellent tolerability. About
two-thirds of patients achieved at least 5% weight loss and over one-third achieved at least 10% weight
loss. On average, patients lost 17 to 18 pounds or about 8% of their weight. Secondary endpoints,
including body composition, lipids, cardiovascular risk factors and glycemic parameters improved
compared to placebo. In addition, heart rate and blood pressure went down. Lorcaserin did not increase
the risk of cardiac valvulopathy. Lorcaserin improved quality oflife, and there was no signal for
depression or suicidal ideation. The only adverse event that exceeded the placebo rate by 5% was
generally mild or moderate, transient headache. Based on a normal BMI of 25, patients in the first
phase 3 trial lost about one-third of their excess body weight. The average weight loss was 35 pounds or
16% of body weight for the top quartile of patients in the second phase 3 trial.
As a part of the phase 3 clinical trial program, lorcaserin was evaluated in a randomized,
placebo-controlled, multi-site, double-blind trial of 604 adults with poorly controlled type 2 diabetes
mellitus treated with oral hyperglycemic agents ("BLOOM-OM"). Analysis of the overall study results
showed significant weight loss with lorcaserin, measured as proportion of patients achieving 2:: 5 % or 2::
% weight loss at 1 year, or as mean weight change (Diabetes 60, Suppl 1, 2011). Lorcaserin
significantly improved glycemic control in the overall patient population. Accordingly, in addition to
being useful for weight management, lorcaserin is also useful for the treatment of type 2 diabetes.
On June 27, 2012 the FDA provisionally approved lorcaserin (BELVIQ®), contingent upon a
final scheduling decision by the Drug Enforcement Administration (DEA), as an adjunct to a reduced-
calorie diet and increased physical activity for chronic weight management in adult patients with an
initial body mass index (BMI) of 30 kg/m or greater (obese), or 27 kg/m or greater (overweight) in the
presence of at least one weight related comorbid condition (e.g., hypertension, dyslipidemia, type 2
diabetes). On December 19, 2012 the DEA recommended that lorcaserin should be classified as a
schedule 4 drug, having a low risk for abuse. The Office of the Federal Register filed for public
inspection DEA' s final rule placing BEL VIQ into schedule 4 of the Controlled Substances Act. The
scheduling designation was effective and BELVIQ was launched in the United States on June 7, 2013,
days after publication of the DEA' s final rule in the Federal Register.
Tobacco use is the leading cause of preventable illness and early death across the globe.
According to the World Health Organization Fact Sheet (July 2013), 50% of all tobacco users die from
a tobacco-related illness - this amounts to approximately six million people each year. It is estimated
that greater than five million deaths per year result from direct tobacco use, with the remaining deaths
resulting from exposure to second-hand smoke (World Health Organization website. Fact Sheet No
339: Tobacco. www.who.int/mediacentre/factsheets/fs339/en/index.html. Updated July 2013. Accessed
September 10, 2013). According to the Centers for Disease Control and Prevention (CDC),
approximately 43.8 million adults in the United States (U.S.) are cigarette smokers. In the U.S.,
tobacco use is responsible for one in five deaths each year (World Health Organization website. Fact
Sheet No 339: Tobacco. www.who.int/mediacentre/factsheets/fs339/en/index.html. Updated July 2013.
Accessed September 10, 2013). Tobacco use is directly related to cardiovascular disease, lung and
other cancers, and chronic lower respiratory diseases (chronic bronchitis, emphysema, asthma, and
other chronic lower respiratory diseases) (Health Effects of Cigarette Smoking. Centers for Disease
Prevention website.
www.cdc.gov/tobacco!data_statistics/fact_sheets/health_effects/effects_cig_smoking/ Accessed
September 10, 2013). These have held position as the top three leading causes of death in the U.S.
since 2008, when chronic lower respiratory disease replaced cerebrovascular disease, which is also
directly associated with tobacco use (Molgaard CA, Bartok A, Peddecord KM, Rothrock J. The
association between cerebrovascular disease and smoking: a case-control study. Neuroepidemiology.
1986;5(2):88-94).
A study which surveyed the smoking behavior of 2138 US smokers over 8 years beginning in
2002 found that approximately one-third of subjects reported making a quit attempt over the previous
year, approximately 85% of the original cohort made at least one quit attempt over the survey period,
and the average quit rate was 3.8% for the retained cohort. Therefore the vast majority of smokers make
quit attempts, but continued abstinence remains difficult to achieve ( Cummings KM, Cornelius ME,
Carpenter Ml, et al. Abstract: How Many Smokers Have Tried to Quit? Society for Research on
Nicotine and Tobacco. Poster Session 2. March 2013. POS2-65).
Existing smoking cessation treatments include CHANTIX (varenicline) and ZYBAN
(bupropion SR). However, the prescribing information for both CHANTIX and ZYBAN include black
box warnings. The CHANTIX prescribing information carries a warning for serious neuropsychiatric
events, to include symptoms of agitation, hostility, depressed mood changes, behavior or thinking that
are not typical for the patient, and suicidal ideation or suicidal behavior (CHANTIX (varenicline)
(package insert), New York, NY: Pfizer Labs, Division of Pfizer, Inc.; 2012). In addition, the warning
notes that a meta-analysis found cardiovascular events were infrequent, but some were reported more
frequently in individuals treated with CHANTIX; the difference was not statistically significant
(CHANTIX (varenicline) (package insert), New York, NY: Pfizer Labs, Division of Pfizer, Inc.; 2012).
The ZYBAN prescribing information includes a similar black box warning for serious neuropsychiatric
events during treatment as well as after discontinuation of treatment (ZYBAN (bupropion
hydrochloride) (package insert), Research Triangle Park, NC: GlaxoSmithKline; 2012). Additional
warnings include monitoring of individuals using antidepressants as there is an increased risk of
suicidal thinking and behavior in children, adolescents and young adults, and other psychiatric disorders
(ZYBAN (bupropion hydrochloride) (package insert), Research Triangle Park, NC: GlaxoSmithKline;
2012).
Further, weight gain is a well-recognized side effect of quitting smoking. Smoking cessation
leads to weight gain in about 80% of smokers. The average weight gain in the first year after quitting is
4-5 kg, most of which is gained during the first 3 months. This amount of weight is typically viewed as
a modest inconvenience compared with the health benefits of smoking cessation, but 10-20% of
quitters gain more than 10 kg. Furthermore, a third of all subjects stated that they were unable to lose
the excess weight after resuming smoking, lending support to the hypothesis that multiple quit attempts
lead to cumulative weight gain (Veldheer S, Yingst l, Foulds G, Hrabovsky S, Berg A, Sciamanna C,
Foulds l. Once bitten, twice shy: concern about gaining weight after smoking cessation and its
association with seeking treatment. Intl Clin Pract. (2014) 68:388-395).
Given these statistics, it is perhaps not surprising that 50% of female smokers and 25 % of male
smokers cite fear of post-cessation weight gain (PCWG) as a major barrier to quitting, and
approximately the same proportion cite weight gain as a cause of relapse in a previous quit attempt
(Meyers AW, Klesges RC, Winders SE, Ward KD, Peterson BA, Eck LH. Are weight concerns predictive
of smoking cessation? A prospective analysis. l Consult Clin Psychol. ( 1997) 65: 448-452; Clark MM,
Decker PA, Offord KP, Patten CA, Vickers KS, Croghan IT, Hays lT, Hurt RD, Dale LC. Weight
concerns among male smokers. Addict Behav. (2004) 29:1637- 1641; Clark MM, Hurt RD, Croghan
IT, Patten CA, Novotny P, Sloan lA, Dakhil SR, Croghan GA, Was El, Rowland KM, Bernath A,
Morton RF, Thomas SP, Tschetter LK, Garneau S, Stella Pl, Ebbert LP, Wender DB, Loprinzi CL. The
prevalence of weight concerns in a smoking abstinence clinical trial. Addict Behav. (2006) 31:1144-
1152.; Pomerleau CS, Kurth CL. Willingness of female smokers to tolerate postcessation weight gain. l
Subst Abuse. (1996) 8:371-378; Pomerleau CS, Zucker AN, Stewart Al. Characterizing concerns about
post cessation weight gain: results from a national survey of women smokers. Nicotine Toh Res. (2001)
3:51-60). Women, in particular, are reluctant to gain weight while quitting; about 40% state they would
resume smoking if they gained any weight at all (Veldheer S, Yingst l, Foulds G, Hrabovsky S, Berg A,
Sciamanna C, Foulds l. Once bitten, twice shy: concern about gaining weight after smoking cessation
and its association with seeking treatment. Int J Clin Pract. (2014) 68:388-395; Pomerleau CS, Kurth
CL. Willingness of female smokers to tolerate postcessation weight gain. J Subst Abuse ( 1996) 8:371-
378; Pomerleau CS, Zucker AN, Stewart Al. Characterizing concerns about post-cessation weight
gain: results from a national survey of women smokers. Nicotine Toh Res. (2001) 3:51-60; T¢nnesen P,
Paoletti P, Gustavsson G, Russell MA, Saracci R, Gulsvik A, Rijcken B, Sawe U. Higher dosage
nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial.
Collaborative European Anti-Smoking Evaluation. European Respiratory Society. Eur Respir J. ( 1999)
13:238-246).
Light and moderate smokers are generally considered to be more motivated to quit than heavy
smokers, leaving an increasingly high proportion of 'hard-core' smokers who are less likely to stop
smoking (Hughes JR. The hardening hypothesis: is the ability to quit decreasing due to increasing
nicotine dependence? A review and commentary. Drug Alcohol Depend. (2011) 117:111-117). One of
the factors commonly associated with weight-gain concern (WGC) is high nicotine dependence; thus,
the prospect of quitting may be even more difficult for smokers who are both highly nicotine-dependent
and weight concerned. In addition, somewhat paradoxically, heavy smokers tend to have higher body
weights and a higher likelihood of obesity than lighter smokers, suggesting a more complex relationship
between body weight and smoking (Chiolero A, Jacot-Sadowski I, Faeh D, Paccaud F, Cornuz J.
Association of cigarettes smoked daily with obesity in a general adult population. Obesity (Silver
Spring) (2007) 15:1311-1318; John U, Hanke M, Rumpf HJ, Thyrian JR. Smoking status, cigarettes per
day, and their relationship to overweight and obesity among former and current smokers in a national
adult general population sample. Int J Obes (Land). (2005) 29:1289-1294). Several studies have found
that overweight and obese smokers exhibit higher levels of smoking-related weight-gain concern than
normal weight smokers (Aubin H-J, Berlin I, Smadja E, West R. Factors associated with higher body
mass index, weight concern, and weight gain in a multinational cohort study of smokers intending to
quit. Int. J. Environ. Res. Public Health. (2009). 6:943-957; Levine MD, Bush T, Magnusson B, Cheng,
Y, Chen X. Smoking-related weight concerns and obesity: differences among normal weight,
overweight, and obese smokers using a telephone tobacco quitline. Nicotine Toh Res. (2013) 15: 1136-
1140). Given the convergence of high nicotine dependence and high weight-gain concern in obese
smokers, smoking cessation interventions that address post-cessation weight gain could be especially
beneficial for this subpopulation.
Despite the existence of several therapies for smoking cessation, long-term success rates are
low and major barriers to quitting remain. There is a significant unmet need for safe and effective
therapies that address these barriers. There also remains a need for alternative compounds for the
treatment of diseases and disorders related to the 5-HT c receptor. The compounds described herein are
5-HT c receptor agonists that satisfy this need and provide related advantages as well. The present
disclosure satisfies this need and provides related advantages as well.
SUMMARY
Provided herein are compounds selected from the compounds of Table A, and pharmaceutically
acceptable salts, hydrates, and solvates thereof:
Table A
Compound
Chemical Structure Chemical Name
N-(2,2-difluoroethyl)methyl-
1,2,3,4,6,7-hexahydro
[1,4]diazepino[6, 7, 1-hi]indole-
8-carboxamide
( S )-N-(2,2-difluoroethyl)
methyl-1,2,3,4,6,7-hexahydro
[1,4]diazepino[6, 7, 1-hi]indole-
8-carboxamide
( R)-N-(2,2-difluoroethyl)
methyl-1,2,3,4,6,7-hexahydro
[1,4]diazepino[6, 7, 1-hi]indole-
8-carboxamide
( S )-N-(2,2-difluoroethyl)
ethyl-1,2,3,4,6, 7-hexahydro
[1,4]diazepino[6, 7, 1-hi]indole-
8-carboxamide
Compound
Chemical Structure Chemical Name
( R)-N-(2,2-difluoroethyl)
ethyl-1,2,3,4,6, 7-hexahydro
[1,4]diazepino[6, 7, 1-hi]indole-
8-carboxamide
N-(2,2-difluoroethyl)-7 ,7-
dimethyl-1,2,3,4,6, 7-
hexahydro-
[1,4]diazepino[6, 7, 1-hi]indole-
8-carboxamide
N-(2,2-difluoroethyl)-2,3,4,6-
tetrahydro-lH
spiro[[l,4]diazepino[6,7, 1-
hi]indole-7, 1 '-cyclobutane ]
carboxamide
(S)-N-(2,2-difluoroethyl)
(2,2,2-trifluoroethyl)-
1,2,3,4,6,7-hexahydro
[1,4]diazepino[6, 7, 1-hi]indole-
8-carboxamide
(R)-N-(2,2-difluoroethyl)
(2,2,2-trifluoroethyl)-
9 1,2,3,4,6,7-hexahydro
[1,4]diazepino[6, 7, 1-hi]indole-
8-carboxamide
Also provided are compositions comprising a compound provided herein and a
pharmaceutically acceptable carrier.
Also provided are processes for preparing compositions, comprising admixing a compound
provided herein and a pharmaceutically acceptable carrier.
Also provided are pharmaceutical compositions comprising a compound provided herein and a
pharmaceutically acceptable carrier.
Also provided are processes for preparing pharmaceutical compositions, comprising admixing a
compound provided herein a pharmaceutically acceptable carrier.
Also provided are methods for decreasing food intake in an individual in need thereof,
comprising administering to said individual a therapeutically effective amount of a compound provided
herein.
Also provided are methods for inducing satiety in an individual in need thereof, comprising
administering to said individual a therapeutically effective amount of a compound provided herein.
Also provided are methods for the treatment of obesity in an individual in need thereof,
comprising administering to said individual a therapeutically effective amount of a compound provided
herein.
Also provided are methods for the prevention of obesity in an individual in need thereof,
comprising administering to said individual a therapeutically effective amount of a compound provided
herein.
Also provided are methods for weight management in an individual in need thereof, comprising
administering to said individual a therapeutically effective amount of a compound provided herein.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
decreasing food intake.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
inducing satiety.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of obesity.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the prevention of obesity.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
weight management.
Also provided are compounds for use in a method for treatment of the human or animal body
by therapy.
Also provided are compounds for use in a method for decreasing food intake.
Also provided are compounds for use in a method for inducing satiety.
Also provided are compounds for use in a method for the treatment of obesity.
Also provided are compounds for use in a method for the prevention of obesity.
Also provided are compounds for use in weight management.
Provided is a method for reducing the frequency of smoking tobacco in an individual
attempting to reduce frequency of smoking tobacco comprising the step of: prescribing and/or
administering to the individual an effective amount of a compound provided herein.
Also provided is a method for aiding in the cessation or lessening of use of a tobacco product in
an individual attempting to cease or lessen use of a tobacco product comprising the step of: prescribing
and/or administering to the individual an effective amount of a compound provided herein.
Also provided is a method for aiding in smoking cessation and preventing associated weight
gain in an individual attempting to cease smoking and prevent weight gain comprising the step of:
prescribing and/or administering to the individual an effective amount of a compound provided herein.
Also provided is a method for controlling weight gain associated with smoking cessation by an
individual attempting to cease smoking tobacco comprising the step of: prescribing and/or
administering to the individual an effective amount of a compound provided herein.
Also provided is a method of treatment for nicotine dependency, addiction and/or withdrawal in
an individual attempting to treat nicotine dependency, addiction and/or withdrawal comprising the step
of: prescribing and/or administering to the individual an effective amount of a compound provided
herein.
Also provided is a method of reducing the likelihood of relapse use of nicotine by an individual
attempting to cease nicotine use comprising the step of: prescribing and/or administering to the
individual an effective amount of a compound provided herein.
Also provided is a method for reducing weight gain associated with smoking cessation by an
individual attempting to cease smoking tobacco comprising the step of: prescribing and/or
administering to the individual an effective amount of a compound provided herein.
Also provided is a method of reducing the frequency of smoking tobacco in an individual
attempting to reduce frequency of smoking tobacco, aiding in the cessation or lessening of use of a
tobacco product in an individual attempting to cease or lessen use of a tobacco product, aiding in
smoking cessation and preventing associated weight gain, controlling weight gain associated with
smoking cessation by an individual attempting to cease smoking tobacco, reducing weight gain
associated with smoking cessation by an individual attempting to cease smoking tobacco, treating
nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine
dependency, addiction and/or withdrawal, or reducing the likelihood of relapse use of nicotine by an
individual attempting to cease nicotine use, comprising:
selecting an individual with an initial BMI 2': 27 kg/m ; and
prescribing and/or administering to the individual an effective amount of a compound provided
herein.
Also provided is a method of reducing the frequency of smoking tobacco in an individual
attempting to reduce frequency of smoking tobacco, aiding in the cessation or lessening of use of a
tobacco product in an individual attempting to cease or lessen use of a tobacco product, aiding in
smoking cessation and preventing associated weight gain, controlling weight gain associated with
smoking cessation by an individual attempting to cease smoking tobacco, reducing weight gain
associated with smoking cessation by an individual attempting to cease smoking tobacco, treating
nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine
dependency, addiction and/or withdrawal, or reducing the likelihood of relapse use of nicotine by an
individual attempting to cease nicotine use, comprising:
administering a compound provided herein;
monitoring the individual for BMI during said administration; and
discontinuing said administration if the BMI of the individual becomes < 18.5 kg/m during
said administration.
Also provided is a method of reducing the frequency of smoking tobacco in an individual
attempting to reduce frequency of smoking tobacco, aiding in the cessation or lessening of use of a
tobacco product in an individual attempting to cease or lessen use of a tobacco product, aiding in
smoking cessation and preventing associated weight gain, controlling weight gain associated with
smoking cessation by an individual attempting to cease smoking tobacco, reducing weight gain
associated with smoking cessation by an individual attempting to cease smoking tobacco, treating
nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine
dependency, addiction and/or withdrawal, or reducing the likelihood of relapse use of nicotine by an
individual attempting to cease nicotine use, comprising:
administering a compound selected from compound provided herein to an individual with an
initial BMI s:; 25 kg/m ;
monitoring the individual for body weight during said administration; and
discontinuing said administration if the body weight of the individual decreases by more than
about 1 % during said administration.
Also provided is a method of reducing the frequency of smoking tobacco in an individual
attempting to reduce frequency of smoking tobacco, aiding in the cessation or lessening of use of a
tobacco product in an individual attempting to cease or lessen use of a tobacco product, aiding in
smoking cessation and preventing associated weight gain, controlling weight gain associated with
smoking cessation by an individual attempting to cease smoking tobacco, reducing weight gain
associated with smoking cessation by an individual attempting to cease smoking tobacco, treating
nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine
dependency, addiction and/or withdrawal, or reducing the likelihood of relapse use of nicotine by an
individual attempting to cease nicotine use, comprising:
administering a compound provided herein to an individual;
monitoring the individual for body weight during said administration; and
discontinuing said administration if the body weight of the individual decreases by more than
about 1 kg during said administration.
Also provided is a composition comprising a compound provided herein and at least one
supplemental agent.
Also provided is a compound provided herein for use in combination with a supplemental
agent.
Also provided is a supplemental agent chosen from nicotine replacement therapies, for use in
combination with a compound provided herein.
BRIEF DESCRIPTION OF FIGURES
Figure 1 shows a plot of cumulative food intake (g) over time (hours post-administration) for vehicle
and for Compound 1 dosed in Sprague Dawley rats (white bars: vehicle; gray bars: 2 mg/kg of
Compound 1; black bars: 10/kg mg of Compound 1 ).
DETAILED DESCRIPTION
As used in the present specification, the following words and phrases are generally intended to
have the meanings as set forth below, except to the extent that the context in which they are used
indicates otherwise.
Compounds provided herein are compounds selected from the compounds of Table A, and
pharmaceutically acceptable salts, hydrates, and solvates thereof. As an example, the recitations
"compound provided herein", "compound herein", "compound disclosed herein", and "compound
described herein" each refer to a compound selected from compounds of Table A, and pharmaceutically
acceptable salts, hydrates, and solvates thereof. As an example, the recitations "compounds provided
herein", "compounds herein", "compounds disclosed herein", and "compounds described herein" each
refer to compounds selected from compounds of Table A, and pharmaceutically acceptable salts,
hydrates, and solvates thereof.
The term "agonist" refers to a moiety that interacts with and activates a receptor, such as the 5-
HT2c serotonin receptor, and initiates a physiological or pharmacological response characteristic of that
receptor.
The term "composition" refers to a compound, including but not limited to, pharmaceutically
acceptable salts, hydrates, and solvates of a compound of Table A, in combination with at least one
additional component.
The term "pharmaceutical composition" refers to a composition comprising at least one active
ingredient, such as a compound of Table A; including but not limited to, pharmaceutically acceptable
salts, hydrates, and solvates thereof, whereby the composition is amenable to investigation for a
specified, efficacious outcome in a mammal (for example, without limitation, a human). Those of
ordinary skill in the art will understand and appreciate the techniques appropriate for determining
whether an active ingredient has a desired efficacious outcome based upon the needs of the artisan.
The term "individual" refers to a human. An individual can be an adult or prepubertal (a child)
and can be of any gender. The individual can be a patient or other individual seeking treatment. The
methods disclosed herein can also apply to non-human mammals such as livestock or pets.
As used herein, a "plurality of individuals" means more than one individual.
As used herein, "administering" means to provide a compound or other therapy, remedy or
treatment. For example, a health care practitioner can directly provide a compound to an individual in
the form of a sample, or can indirectly provide a compound to an individual by providing an oral or
written prescription for the compound. Also, for example, an individual can obtain a compound by
themselves without the involvement of a health care practitioner. Administration of the compound may
or may not involve the individual actually internalizing the compound. In the case where an individual
internalizes the compound, the body is transformed by the compound in some way.
As used herein, "prescribing" means to order, authorize or recommend the use of a drug or
other therapy, remedy or treatment. In some embodiments, a health care practitioner can orally advise,
recommend or authorize the use of a compound, dosage regimen or other treatment to an individual. In
this case the health care practitioner may or may not provide a prescription for the compound, dosage
regimen or treatment. Further, the health care practitioner may or may not provide the recommended
compound or treatment. For example, the health care practitioner can advise the individual where to
obtain the compound without providing the compound. In some embodiments, a health care
practitioner can provide a prescription for the compound, dosage regimen or treatment to the individual.
For example, a health care practitioner can give a written or oral prescription to an individual. A
prescription can be written on paper or on electronic media such as a computer file, for example, on a
hand-held computer device. For example, a health care practitioner can transform a piece of paper or
electronic media with a prescription for a compound, dosage regimen or treatment. In addition, a
prescription can be called in (oral) or faxed in (written) to a pharmacy or a dispensary. In some
embodiments, a sample of the compound or treatment can be given to the individual. As used herein,
giving a sample of a compound constitutes an implicit prescription for the compound. Different health
care systems around the world use different methods for prescribing and administering compounds or
treatments and these methods are encompassed by the disclosure.
A prescription can include, for example, an individual's name and/or identifying information
such as date of birth. In addition, for example, a prescription can include, the medication name,
medication strength, dose, frequency of administration, route of administration, number or amount to be
dispensed, number of refills, physician name, and/or physician signature. Further, for example, a
prescription can include a DEA number or state number.
A healthcare practitioner can include, for example, a physician, nurse, nurse practitioner, physician
assistant, clinician, or other related healthcare professional who can prescribe or administer compounds
(drugs) for weight management, decreasing food intake, inducing satiety, and treating or preventing
obesity. In addition, a healthcare practitioner can include anyone who can recommend, prescribe,
administer or prevent an individual from receiving a compound or drug including, for example, an
insurance provider.
The term "prevent," "preventing," or "prevention", such as prevention of obesity, refers to the
prevention of the occurrence or onset of one or more symptoms associated with a particular disorder
and does not necessarily mean the complete prevention of a disorder. For example, weight gain may be
prevented even if the individual gains some amount of weight. For example, the terms "prevent,"
"preventing," and "prevention" refer to the administration of therapy on a prophylactic or preventative
basis to an individual who may ultimately manifest at least one symptom of a disease or condition but
who has not yet done so. Such individuals can be identified on the basis of risk factors that are known
to correlate with the subsequent occurrence of the disease. Alternatively, prevention therapy can be
administered without prior identification of a risk factor, as a prophylactic measure. Delaying the onset
of the at least one symptom can also be considered prevention or prophylaxis.
For example,_the term "prevent," "preventing" or "prevention" may refer to prevention of
weight gain associated with smoking cessation.
In some embodiments the salts, hydrates, and solvates described herein are pharmaceutically
acceptable salts, hydrates, and solvates. It is understood that when the phrase "pharmaceutically
acceptable salts, hydrates, and solvates" or the phrase "pharmaceutically acceptable salt, hydrate, or
solvate" is used when referring to compounds described herein, it embraces pharmaceutically
acceptable hydrates and/or solvates of the compounds, pharmaceutically acceptable salts of the
compounds, as well as pharmaceutically acceptable hydrates and/or solvates of pharmaceutically
acceptable salts of the compounds. It is also understood that when the phrase "pharmaceutically
acceptable hydrates and solvates" or the phrase "pharmaceutically acceptable hydrate or solvate" is
used when referring to compounds described herein that are salts, it embraces pharmaceutically
acceptable hydrates and/or solvates of such salts. It is also understood by a person of ordinary skill in
the art that hydrates are a subgenus of solvates.
The term "prodrug" refers to an agent which must undergo chemical or enzymatic
transformation to the active or parent drug after administration, so that the metabolic product or parent
drug can subsequently exhibit the desired pharmacological response.
The term "treat," "treating," or "treatment" includes the administration of therapy to an
individual who already manifests at least one symptom of a disease or condition or who has previously
manifested at least one symptom of a disease or condition. For example, "treating" can include
alleviating, abating or ameliorating a disease or condition symptoms, preventing additional symptoms,
ameliorating or preventing the underlying metabolic causes of symptoms, inhibiting the disease or
condition, e.g., arresting the development of the disease or condition, relieving the disease or condition,
causing regression of the disease or condition, relieving a condition caused by the disease or condition,
or stopping the symptoms of the disease or condition either prophylactically and/or therapeutically. For
example, the term "treating" in reference to a disorder can mean a reduction in severity of one or more
symptoms associated with a particular disorder. Therefore, treating a disorder does not necessarily
mean a reduction in severity of all symptoms associated with a disorder and does not necessarily mean
a complete reduction in the severity of one or more symptoms associated with a disorder. For example,
a method for treatment of obesity can result in weight loss; however, the weight loss does not need to
be enough such that the individual is no longer obese. It has been shown that even modest decreases in
weight or related parameters such as BMI, waist circumference and percent body fat, can result in
improvement of health, for example, lower blood pressure, improved blood lipid profiles, or a reduction
in sleep apnea. As another example, a method for treatment of an addiction can result in a reduction in
the number, frequency, or severity of cravings, seeking behaviors, or relapses, or it can result in
abstention.
As used herein the term "treat," "treating" or "treatment" refers to the administration of therapy to
an individual who already manifests, or who has previously manifested, at least one symptom of a disease,
disorder, condition, dependence, or behavior, such as at least one symptom of a disease or condition. For
example, "treating" can include any of the following with respect to a disease, disorder, condition,
dependence, or behavior: alleviating, abating, ameliorating inhibiting (e.g., arresting the development),
relieving, or causing regression. "Treating" can also include treating the symptoms, preventing additional
symptoms, preventing the underlying physiological causes of the symptoms, or stopping the symptoms
(either prophylactically and/or therapeutically) of a disease, disorder, condition, dependence, or behavior,
such as the symptoms of a disease or condition.
The term "weight management" refers to controlling body weight and in the context of the
present disclosure is directed toward weight loss and the maintenance of weight loss ( also called weight
maintenance herein). In addition to controlling body weight, weight management includes controlling
parameters related to body weight, for example, BMI, percent body fat and waist circumference. For
example, weight management for an individual who is overweight or obese can mean losing weight
with the goal of keeping weight in a healthier range. Also, for example, weight management for an
individual who is overweight or obese can include losing body fat or circumference around the waist
with or without the loss of body weight. Maintenance of weight loss ( weight maintenance) includes
preventing, reducing or controlling weight gain after weight loss. It is well known that weight gain
often occurs after weight loss. Weight loss can occur, for example, from dieting, exercising, illness,
drug treatment, surgery or any combination of these methods, but often an individual that has lost
weight will regain some or all of the lost weight. Therefore, weight maintenance in an individual who
has lost weight can include preventing weight gain after weight loss, reducing the amount of weight
gained after weight loss, controlling weight gain after weight loss or slowing the rate of weight gain
after weight loss. As used herein, "weight management in an individual in need thereof' refers to a
judgment made by a healthcare practitioner that an individual requires or will benefit from weight
management treatment. This judgment is made based on a variety of factors that are in the realm of a
healthcare practitioner's expertise, but that includes the knowledge that the individual has a condition
that is treatable by the methods disclosed herein.
"Weight management" also includes preventing weight gain, controlling weight gain, reducing
weight gain, maintaining weight, or inducing weight loss. Weight management also refers to
controlling weight (also called weight control) and/or controlling parameters related to weight, for
example, BMI, percent body fat and/or waist circumference. In addition, weight management also
includes preventing an increase in BMI, reducing an increase in BMI, maintaining BMI, or reducing
BMI; preventing an increase in percent body fat, reducing an increase in percent body fat, maintaining
percent body fat, or reducing percent body fat; and preventing an increase in waist circumference,
reducing an increase in waist circumference, maintaining waist circumference, or reducing waist
circumference
The term "decreasing food intake in an individual in need thereof' refers to a judgment made
by a healthcare practitioner that an individual requires or will benefit from decreasing food intake. This
judgment is made based on a variety of factors that are in the realm of a healthcare practitioner's
expertise, but that includes the knowledge that the individual has a condition, for example, obesity, that
is treatable by the methods disclosed herein. In some embodiments, an individual in need of decreasing
food intake is an individual who is overweight. In some embodiments, an individual in need of
decreasing food intake is an individual who is obese.
The term "satiety" refers to the quality or state of being fed or gratified to or beyond capacity.
Satiety is a feeling that an individual has and so it is often determined by asking the individual, orally or
in writing, if they feel full, sated, or satisfied at timed intervals during a meal. For example, an
individual who feels sated may report feeling full, feeling a decreased or absent hunger, feeling a
decreased or absent desire to eat, or feeling a lack of drive to eat. While fullness is a physical sensation,
satiety is a mental feeling. An individual who feels full, sated or satisfied is more likely to stop eating
and therefore inducing satiety can result in a decrease in food intake in an individual. As used herein,
"inducing satiety in an individual in need thereof' refers to a judgment made by a healthcare
practitioner that an individual requires or will benefit from inducing satiety. This judgment is made
based on a variety of factors that are in the realm of a healthcare practitioner's expertise, but that
includes the knowledge that the individual has a condition, for example, obesity, that is treatable by the
methods of the disclosure.
The term "treatment of obesity in an individual in need thereof' refers to a judgment made by a
healthcare practitioner that an individual requires or will benefit from treatment of obesity. This
judgment is made based on a variety of factors that are in the realm of a healthcare practitioner's
expertise, but that includes the knowledge that the individual has a condition that is treatable by the
methods of the disclosure. To determine whether an individual is obese one can determine a body
weight, a body mass index (BMI), a waist circumference or a body fat percentage of the individual to
determine if the individual meets a body weight threshold, a BMI threshold, a waist circumference
threshold or a body fat percentage threshold.
The term prevention of obesity in an individual in need thereof' refers to a judgment made by a
healthcare practitioner that an individual requires or will benefit from prevention of obesity. This
judgment is made based on a variety of factors that are in the realm of a healthcare practitioner's
expertise, but that includes the knowledge that the individual has a condition that is treatable by the
methods disclosed herein. In some embodiments, an individual in need of prevention of obesity is an
individual who is overweight (also called pre-obese). In some embodiments, an individual in need of
prevention of obesity is an individual who has a family history of obesity. To determine whether an
individual is overweight one can determine a body weight, a body mass index (BMI), a waist
circumference or a body fat percentage of the individual to determine if the individual meets a body
weight threshold, a BMI threshold, a waist circumference threshold or a body fat percentage threshold.
As used herein, an "adverse event" or "toxic event" is any untoward medical occurrence that
may present itself during treatment. Adverse events associated with treatment may include, for
example, headache, nausea, blurred vision, paresthesias, constipation, fatigue, dry mouth, dizziness,
abnormal dreams, insomnia, nasopharyngitis, toothache, sinusitis, back pain, somnolence, viral
gastroenteritis, seasonal allergy, or pain in an extremity. Additional possible adverse effects include,
for example, gastrointestinal disorders (such as constipation, abdominal distension, and diarrhea),
asthenia, chest pain, fatigue, drug hypersensitivity, fibromyalgia, temporomandibular joint syndrome,
headache, dizziness, migraine, anxiety, depressed mood, irritability, suicidal ideation, bipolar disorder,
depression, drug abuse, and dyspnea. In the methods disclosed herein, the term "adverse event" can be
replaced by other more general terms such as "toxicity". The term "reducing the risk" of an adverse
event means reducing the probability that an adverse event or toxic event could occur.
As used herein, the term "agonist" refers to a moiety that interacts with and activates a receptor,
such as the 5-HT c serotonin receptor, and initiates a physiological or pharmacological response
characteristic of that receptor.
The term "immediate-release dosage form" refers to a formulation which rapidly disintegrates
upon oral administration to a human or other animal releasing an active pharmaceutical ingredient
(API) from the formulation. In some embodiments, the TSO% of the immediate-release dosage form is
less than 3 hours. In some embodiments, the TSO% of the immediate-release dosage form is less than 1
hour. In some embodiments, the TSO% of the immediate-release dosage form is less than 30 minutes. In
some embodiments, the TSO% of the immediate-release dosage form is less than 10 minutes.
The term "TSO%" refers to the time needed to achieve SO% cumulative release of an API from
a particular formulation comprising the APL
The term "modified-release dosage form" refers to any formulation that, upon oral
administration to a human or other animal, releases an API after a given time (i.e., delayed release) or
for a prolonged period of time ( extended release), e.g., at a slower rate over an extended period of time
when compared to an immediate-release dosage-form of the API (e.g., sustained release).
As used herein, "nicotine replacement therapy" (commonly abbreviated to NRT) refers to the
remedial administration of nicotine to the body by means other than a tobacco product. By way of
example, nicotine replacement therapy may include transdermal nicotine delivery systems, including
patches and other systems that are described in the art, for example, in U.S. Pat. Nos. 4,597,961,
,004,610, 4,946,S53, and 4,920,9S9. Inhaled nicotine (e.g., delivery of the nicotine through pulmonary
routes) is also known. Transmucosal administration (e.g., delivery of nicotine to the systemic
circulation through oral drug dosage forms) is also known. Oral drug dosage forms (e.g., lozenge,
capsule, gum, tablet, suppository, ointment, gel, pessary, membrane, and powder) are typically held in
contact with the mucosa! membrane and disintegrate and/or dissolve rapidly to allow immediate
systemic absorption. It will be understood by those skilled in the art that a plurality of different
treatments and means of administration can be used to treat a single individual. For example, an
individual can be simultaneously treated with nicotine by transdermal administration and nicotine
which is administered to the mucosa. In some embodiments, the nicotine replacement therapy is chosen
from nicotine gum (e.g., NICORETTE), nicotine transdermal systems such as nicotine patches (e.g.,
HABITROL and NICODERM), nicotine lozenges (e.g., COMMIT), nicotine microtabs (e.g.,
NICORETTE Microtabs), nicotine sprays or inhalers (e.g., NICOTROL), and other nicotine
replacement therapies known in the art. In some embodiments, nicotine replacement therapy includes
electronic cigarettes, personal vaporizers, and electronic nicotine delivery systems.
As used herein, "combination" as used in reference to drug combinations and/or combinations
of a compound provided herein with at least one supplemental agent refers to (1) a product comprised
of two or more components, i.e., drug/device, biologic/device, drug/biologic, or drug/device/biologic,
that are physically, chemically, or otherwise combined or mixed and produced as a single entity; (2)
two or more separate products packaged together in a single package or as a unit and comprised of drug
and device products, device and biological products, or biological and drug products; (3) a drug, device,
or biological product packaged separately that according to its investigational plan or proposed labeling
is intended for use only with an approved individually specified drug, device, or biological product
where both are required to achieve the intended use, indication, or effect and where upon approval of
the proposed product the labeling of the approved product would need to be changed, e.g., to reflect a
change in intended use, dosage form, strength, route of administration, or significant change in dose; or
(4) any investigational drug, device, or biological product packaged separately that according to its
proposed labeling is for use only with another individually specified investigational drug, device, or
biological product where both are required to achieve the intended use, indication, or effect.
Combinations include without limitation a fixed-dose combination product (FDC) in which two or
more separate drug components are combined in a single dosage form; a co-packaged product
comprising two or more separate drug products in their final dosage forms, packaged together with
appropriate labeling to support the combination use; and an adjunctive therapy in which a patient is
maintained on a second drug product that is used together with (i.e., in adjunct to) the primary
treatment, although the relative doses are not fixed, and the drugs or biologics are not necessarily given
at the same time. Adjunctive therapy products may be co-packaged, and may or may not be labeled for
concomitant use.
As used herein, "responder" refers to an individual who experiences continuous abstinence
from tobacco use during a specified period of administration of a compound provided herein. In some
embodiments, "responder" refers to an individual who reports no smoking or other nicotine use from
Week 9 to Week 12 of administration of a compound provided herein and exhibits an end-expiratory
exhaled carbon monoxide-confirmed measurement of s:; 10 ppm.
As used herein, "tobacco product" refers to a product that incorporates tobacco, i.e., the
agricultural product of the leaves of plants in the genus Nicotiana. Tobacco products can generally be
divided into two types: smoked tobacco including without limitation pipe tobacco, cigarettes (including
electronic cigarettes) and cigars, as well as Mu'assel, Dokha, shisha tobacco, hookah tobacco, or
simply shisha; and smokeless tobacco including without limitation chewing tobacco, dipping tobacco,
also known as dip, moist snuff (or snuff), American moist snuff, snus, Iqmik, Naswar, Gutka,
Toombak, shammah, tobacco water, spit tobacco, creamy snuff or tobacco paste, dissolvable tobacco,
and tobacco gum.
As used herein, "Fagerstrom test" refers to a standard test for nicotine dependence which is a
test for assessing the intensity of nicotine addiction. See Heatherton, T. F., Kozlowski, L. T., Frecker,
R. C., Fagerstrom, K. 0. The Fagerstrom test for Nicotine Dependence: A revision of the Fagerstrom
Tolerance Questionnaire. Br J Addict 1991; 86: 1119-27. The test consists of a brief, self-report survey
that measures nicotine dependence on a scale of 0-10, with 10 being the highest level of dependence. A
score of 0-2 corresponds to very low dependence. A score of 3-4 corresponds to low dependence. A
score of 5 corresponds to moderate dependence. A score of 6-7 corresponds to high dependence. A
score of 8-10 corresponds to very high dependence.
Other methods may be utilized to assess the craving for nicotine, including but not limited to,
the nicotine craving test specified by the Diagnostic and Statistical Manual of Mental Disorders,
Revised Third Edition (DSM-III-R).
As used herein, "Mood and Physical Symptoms Scale" (MPSS) refers to a scale used to assess
cigarette withdrawal symptoms (West R, Hajek P: Evaluation of the mood and physical symptoms scale
(MPSS) to assess cigarette withdrawal. Psychopharmacology 2004, 177(1-2):195-199). The core
elements of MPSS involve a 5-point rating of depressed mood, irritability, restlessness, difficulty
concentrating and hunger and a 6-point rating of strength of urges to smoke and time spent with these
urges.
As used herein, lorcaserin refers to (R)chloromethyl-2,3,4,5-tetrahydro-lH
benzazepine. Similarly, lorcaserin hydrochloride refers to the hydrochloric acid salt of (R)chloro
methyl-2,3,4,5-tetrahydro-lHbenzazepine (see Statement on Nonproprietary Name Adopted by the
USAN Council for Lorcaserin Hydrochloride).
The term "phentermine" refers to 1,1-dimethylphenyl-ethylamine, including phentermine
derivatives and pharmaceutically acceptable salts thereof, such as, but not limited to, chlorphentermine
(2-(4-chloro-phenyl)-1,1-dimethyl-ethylamine) and the like. In one embodiment, phentermine is in the
HCl salt form of 1,1-dimethylphenyl-ethylamine.
The term "amphetamine" refers to 1-phenylpropanamine and salts, hydrates, and solvates
thereof.
The term "a substituted amphetamine" refers to a class of chemicals based on amphetamine
with additional substitutions. Examples of substituted amphetamines include, but are not limited to:
methamphetamine (N-methylphenylpropanamine); ephedrine (2-(methylamino )phenylpropan-
1-ol); cathinone (2-aminophenylpropanone); MOMA (3,4-methylenedioxy-N
methylamphetamine); and DOM (2,5-Dimethoxymethylamphetamine); and salts, hydrates, and
solvates thereof.
The term "a benzodiazepine" includes, but is not limited to alprazolam, bretazenil,
bromazepam, brotizolam, chlordiazepoxide, cinolazepam, clonazepam, clorazepate, clotiazepam,
cloxazolam, cyclobenzaprine, delorazepam, diazepam, estazolam, etizolam, ethyl, loflazepate,
flunitrazepam, 5-(2-bromophenyl)fluoro- lH-benzo[ e] [1,4]diazepin-2(3H)-one, flurazepam,
flutoprazepam, halazepam, ketazolam, loprazolam, lorazepam, lormetazepam, medazepam, midazolam,
nimetazepam, nitrazepam, nordazepam, oxazepam, phenazepam, pinazepam, prazepam, premazepam,
pyrazolam, quazepam, temazepam, tetrazepam, and triazolam and salts, hydrates, and solvates thereof.
The term "an atypical benzodiazepine receptor ligand" includes, but is not limited to clobazam,
DMCM, flumazenil, eszopiclone, zaleplon, zolpidem, and zopiclone and salts, hydrates, and solvates
thereof.
The term "marijuana" refers to a composition comprising one or more compound selected from
tetrahydrocannabinol, cannabidiol, cannabinol, and tetrahydrocannabivarin and salts, hydrates, and
solvates thereof.
The term "cocaine" refers to benzoylmethylecgonine and salts, hydrates, and solvates thereof.
The term "dextromethorphan" refers to ( 4bS,8aR,9S)methoxymethyl-6,7,8,8a,9, 10-
hexahydro-5H-9,4b-(epiminoethano )phenanthrene and salts, hydrates, and solvates thereof.
The term "eszopiclone" refers to (S)(5-chloropyridinyl)oxo-6,7-dihydro-5H
pyrrolo[3,4-b ]pyrazinyl 4-methylpiperazinecarboxylate and salts, hydrates, and solvates thereof.
The term "GHB" refers to 4-hydroxybutanoic acid and salts, hydrates, and solvates thereof.
The term "LSD" refers to lysergic acid diethylamide and salts, hydrates, and solvates thereof.
The term "ketamine" refers to 2-(2-chlorophenyl)(methylamino )cyclohexanone and salts,
hydrates, and solvates thereof.
The term "a monoamine reuptake inhibitor" refers to a drug that acts as a reuptake inhibitor of
one or more of the three major monoamine neurotransmitters serotonin, norepinephrine, and dopamine
by blocking the action of one or more of the respective monoamine transporters. Examples of
monoamine reuptake inhibitors include alaproclate, citalopram, dapoxetine, escitalopram, femoxetine,
fluoxetine, fluvoxamine, ifoxetine, indalpine, omiloxetine, panuramine, paroxetine, pirandamine, RTI-
353, sertraline, zimelidine, desmethylcitalopram, desmethylsertraline, didesmethylcitalopram,
seproxetine, cianopramine, litoxetine, lubazodone, SB-649,915, trazodone, vilazodone, vortioxetine,
dextromethorphan, dimenhydrinate, diphenhydramine, mepyramine, pyrilamine, methadone,
propoxyphene, mesembrine, roxindole, amedalin, tomoxetine, CP-39,332, daledalin, edivoxetine,
esreboxetine, lortalamine, mazindol, nisoxetine, reboxetine, talopram, talsupram, tandamine,
viloxazine, maprotiline, bupropion, ciclazindol, manifaxine, radafaxine, tapentadol, teniloxazine,
ginkgo biloba, altropane, amfonelic acid, benzothiophenylcyclohexylpiperidine, DBL-583,
difluoropine, 1-(2-( diphenylmethoxy)ethyl)(3-phenylpropyl)piperazine, 4-{ 13-methyl-4,6-dioxa-
11, 12-diazatricyclo[7 .5.0.0]tetradeca-1,3(7),8, 1 O-tetraenyl} aniline, iometopane, [( 1R,2S,3S,5S)
( 4-iodophenyl)methylazabicyclo[3.2.1 ]octanyl]-pyrrolidinylmethanone, vanoxerine,
medifoxamine, Chaenomeles speciosa, hyperforin, adhyperforin, bupropion, pramipexole, cabergoline,
venlafaxine, desvenlafaxine, duloxetine, milnacipran, levomilnacipran, bicifadine, 4-
indol y lary lalky I amines, 1-naphthy lary lalky !amines, amineptine, desox ypi pradrol, dexmeth y I phenidate,
difemetorex,diphenylprolinol, ethylphenidate, fencamfamine, fencamine, lefetamine, mesocarb,
methylenedioxypyrovalerone, methylphenidate, nomifensine, methyl 2-cyclopentyl(3,4-
dichlorophenyl)acetate, oxolinic acid, pipradrol, prolintane, pyrovalerone, tametraline, 1-[1-(3-
chlorophenyl)( 4-methylpiperazinyl)ethyl]cyclohexanol, nefopam, amitifadine, EB-1020,
tesofensine, NSD-788, tedatioxetine, RG7166, Lu-AA37096, Lu-AA34893, NS-2360, bicifadine, SEP-
227162, SEP-225289, DOV-216,303, brasofensine, NS-2359, diclofensine, EXP-561, taxil, naphyrone,
-APB, 6-APB, and hyperforin, and salts, hydrates, and solvates thereof.
The term "nicotine" refers to 3-(1-methylpyrrolidinyl)pyridine.
The term "an opiate" includes, but is not limited to the following compounds and salts,
hydrates, and solvates thereof: alfentanil, alphaprodine, anileridine, bezitramide, buprenorphine,
butorphanol, dextropropoxyphene, carfentanil, codeine, diamorphine, dextromoramide, dezocine,
poppy straw, dihydrocodeine, dihydroetorphine, diphenoxylate, ethylmorphine, etorphine,
hydrochloride, fentanyl, hydrocodone, hydromorphone, isomethadone, levo-alphacetylmethadol,
levomethorphan, levorphanol, meptazinol, metazocine, methadone, metopon, morphine, nalbuphine,
opium, oripavine, oxycodone, oxymorphone, pentazocine, pethidine, phenazocine, piminodine,
propoxyphene, racemethorphan, racemorphan, remifentanil, sufentanil, tapentadol, and thebaine.
For example, the term includes the following compounds and salts, hydrates, and solvates
thereof: alfentanil, alphaprodine, anileridine, bezitramide, dextropropoxyphene, carfentanil, codeine,
poppy straw, dihydrocodeine, dihydroetorphine, diphenoxylate, ethylmorphine, etorphine,
hydrochloride, fentanyl, hydrocodone, hydromorphone, isomethadone, levo-alphacetylmethadol,
levomethorphan, levorphanol, metazocine, methadone, metopon, morphine, opium, oripavine,
oxycodone, oxymorphone, pethidine, phenazocine, piminodine, racemethorphan, racemorphan,
remifentanil, sufentanil, tapentadol, and thebaine.
The term "PCP" refers to 1-(1-phenylcyclohexyl)piperidine and salts, hydrates, and solvates
thereof.
The term "a substituted phenethylamine" includes, but is not limited to, the following
compounds and salts, hydrates, and solvates thereof: 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-
methoxyphenyl)methyl]ethanamine, 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-
methoxyphenyl )methyl]ethanamine, 2-( 4-iodo-2,5-dimethoxyphenyl)-N-[ (2-
methoxyphenyl)methyl]ethanamine, 4-bromo-2,5-dimethoxyphenethylamine, 1-( 4-chloro-2,5-
dimethoxyphenyl)aminoethane, 1-(2,5-dimethoxymethylpheny 1)aminoethane, 1-(2,5-
dimethoxyethylpheny l)aminoethane, 4-fluoro-2,5-dimethoxyphenethylamine, 2,5-dimethoxy
iodophenethylamine, 2,5-dimethoxynitrophenethylamine, 2-(2,5-dimethoxy
propylphenyl)ethanamine, 2,5-dimethoxyethylthiophenethylamine, 2-[2,5-dimethoxy(2-
fluoroeth y lthi o )phen y I] ethanamine, 2,5-dimethox yisopropy lthiopheneth y lamine, 2,5-dimethox yn
propy lthiophenethy lamine, 2-[ 4-[ ( cyclopropylmethyl)thio ]-2,5-dimethoxyphenyl]ethanamine, 2-[ 4-
(butylthio )-2,5-dimethoxyphenyl]ethanamine, 6-hydroxydopamine, dopamine, epinephrine, mescaline,
meta-octopamine, meta-tyramine, methylphenidate, n-methylphenethylamine, norepinephrine, para
octopamine, para-tyramine, phentermine, phenylephrine, salbutamol, and ~-methylphenethylamine, and
salts, hydrates, and solvates thereof.
The term "psilocybin" refers to [3-(2-dimethylaminoethyl)-lH-indolyl] dihydrogen
phosphate, and salts, hydrates, and solvates thereof.
The term "an anabolic steroid" includes, but is not limited to, the following compounds and
salts, hydrates, and solvates thereof: 1-androstenediol, androstenediol, 1-androstenedione,
androstenedione, bolandiol, bolasterone, boldenone, boldione, calusterone, clostebol, danazol,
dehydrochlormethyltestosterone, desoxymethyltestosterone, dihydrotestosterone, drostanolone,
ethylestrenol, fluoxymesterone, formebolone, furazabol, gestrinone, 4-hydroxytestosterone,
mestanolone, mesterolone, metenolone, methandienone, methandriol, methasterone, methyldienolone,
methyl- I-testosterone, methylnortestosterone, methyltestosterone, metribolone, mibolerone,
nandrolone, 19-norandrostenedione, norboletone, norclostebol, norethandrolone, oxabolone,
oxandrolone, oxymesterone, oxymetholone, prasterone, prostanozol, quinbolone, stanozolol,
stenbolone, I-testosterone, testosterone, tetrahydrogestrinone, and trenbolone.
As used herein, the term "greater than" is used interchangeably with the symbol > and the term
"less than" is used interchangeably with the symbol<. Likewise the term less than or equal to is used
interchangeably with the symbol::; and the term greater than or equal to is used interchangeably with
the symbol 2':.
When an integer is used in a method disclosed herein, the term "about" can be inserted before
the integer. For example, the term "greater than 29 kg/m " can be substituted with "greater than about
29 kg/m ".
As used in the present specification, the following abbreviations are generally intended to have
the meanings as set forth below, except to the extent that the context in which they are used indicates
otherwise.
Degrees Celsius
AlC Glycated hemoglobin
BID Twice a day
BL Baseline
BMI Body Mass Index
BP Blood pressure
BPM/bpm Beats per minute
CAR Continuous abstinence rate
CI Confidence interval
cm Centimeter
co Carbon monoxide
DOI 2,5-Dimethoxyiodoamphetamine
DBP Diastolic blood pressure
DEA Drug Enforcement Administration
dL Deciliter
Maximum possible effect
Emme
FDA Food and Drug Administration
g Gram
h Hour
HDL High-density lipoprotein
Kg/kg Kilogram
lbs Pounds
Low-density lipoprotein
M Molar
Square Meter
mg Milligram
mm Minute
MITT Modified intention to treat
mmHg Millimeters of Mercury
N/n Number
NDA New Drug Application
Point prevalence
ppm parts per million
QD Once a day
SAE Serious Adverse Events
SE Standard Error
SBP Systolic blood pressure
TGA Thermogravimetric Analysis
wt Weight
PXRD X-ray powder diffraction
Throughout this specification, unless the context requires otherwise, the word "comprise", or
variations such as "comprises" or "comprising" will be understood to imply the inclusion of a stated
step or element or integer or group of steps or elements or integers but not the exclusion of any other
step or element or integer or group of elements or integers.
Throughout this specification, unless specifically stated otherwise or the context requires
otherwise, reference to a single step, composition of matter, group of steps or group of compositions of
matter shall be taken to encompass one and a plurality (i.e. one or more) of those steps, compositions of
matter, groups of steps or group of compositions of matter.
Each embodiment described herein is to be applied mutatis mutandis to each and every other
embodiment unless specifically stated otherwise.
Those skilled in the art will appreciate that the invention(s) described herein is susceptible to
variations and modifications other than those specifically described. It is to be understood that the
invention(s) includes all such variations and modifications. The invention(s) also includes all of the
steps, features, compositions and compounds referred to or indicated in this specification, individually
or collectively, and any and all combinations or any two or more of said steps or features unless
specifically stated otherwise.
The present invention(s) is not to be limited in scope by the specific embodiments described
herein, which are intended for the purpose of exemplification only. Functionally-equivalent products,
compositions and methods are clearly within the scope of the invention(s), as described herein.
It is appreciated that certain features of the invention( s ), which are, for clarity, described in the
context of separate embodiments, can also be provided in combination in a single embodiment.
Conversely, various features of the invention(s), which are, for brevity, described in the context of a
single embodiment, can also be provided separately or in any suitable subcombination. For example, a
method that recites prescribing or administering a compound provided herein can be separated into two
methods; one reciting prescribing a compound provided herein and the other reciting administering a
compound provided herein. In addition, for example, a method that recites prescribing a compound
provided herein and a separate method reciting administering a compound provided herein can be
combined into a single method reciting prescribing and/or administering a compound provided herein.
In addition, for example, a method that recites prescribing or administering a compound provided
herein can be separated into two methods-one reciting prescribing a compound provided herein and
the other reciting administering a compound provided herein. In addition, for example, a method that
recites prescribing a compound provided herein and a separate method of the invention reciting
administering a compound provided herein can be combined into a single method reciting prescribing
and/or administering a compound provided herein.
COMPOUNDS
Some embodiments include every combination of one or more compounds disclosed herein
together/in combination with every combination of one or more weight loss drug chosen from
sodium/glucose cotransporter-2 (SGLT2) inhibitors, lipase inhibitors, monoamine reuptake inhibitors,
anticonvulsants, glucose sensitizers, incretin mimetics, amylin analogs, GLP-1 analogs, Y receptor
peptides, 5-HT c receptor agonists, opioid receptor antagonists, appetite suppressants, anorectics, and
hormones and the like, either specifically disclosed herein or specifically disclosed in any reference
recited herein just as if each and every combination was individually and explicitly recited. In some
embodiments, the weight loss drug is chosen from dapagliflozin, canagliflozin, ipragliflozin,
tofogliflozin, empagliflozin, remogliflozin etabonate, orlistat, cetilistat, alaproclate, citalopram,
dapoxetine, escitalopram, femoxetine, fluoxetine, fluvoxamine, ifoxetine, indalpine, omiloxetine,
panuramine, paroxetine, pirandamine, sertraline, zimelidine, desmethylcitalopram, desmethylsertraline,
didesmethylcitalopram, seproxetine, cianopramine, litoxetine, lubazodone, trazodone, vilazodone,
vortioxetine, dextromethorphan, dimenhydrinate, diphenhydramine, mepyramine, pyrilamine,
methadone, propoxyphene, mesembrine, roxindole, amedalin, tomoxetine, daledalin, edivoxetine,
esreboxetine, lortalamine, mazindol, nisoxetine, reboxetine, talopram, talsupram, tandamine,
viloxazine, maprotiline, bupropion, ciclazindol, manifaxine, radafaxine, tapentadol, teniloxazine,
ginkgo biloba, altropane, difluoropine, iometopane, vanoxerine, medifoxamine, Chaenomeles speciosa,
hyperforin, adhyperforin, bupropion, pramipexole, cabergoline, venlafaxine, desvenlafaxine,
duloxetine, milnacipran, levomilnacipran, bicifadine, amineptine, desoxypipradrol,
dexmethylphenidate, difemetorex, diphenylprolinol, ethylphenidate, fencamfamine, fencamine,
lefetamine, mesocarb, methylenedioxypyrovalerone, methylphenidate, nomifensine, oxolinic acid,
pipradrol, prolintane, pyrovalerone, tametraline, nefopam, amitifadine, tesofensine, tedatioxetine,
bicifadine, brasofensine, diclofensine, taxil, naphyrone, hyperforin, topiramate, zonisamide, metformin,
acarbose, rosiglitazone, pioglitazone, troglitazone, exenatide, liraglutide, taspoglutide, obinepitide,
pramlintide, peptide YY, vabicaserin, naltrexone, naloxone, phentermine, diethylpropion,
oxymetazoline, benfluorex, butenolide cathine, phenmetrazine, phenylpropanolamine, pyroglutamyl
histidyl-glycine, amphetamine, benzphetamine, dexmethylphenidate, dextroamphetamine,
methylenedioxypyrovalerone, glucagon, lisdexamfetamine, methamphetamine, methylphenidate,
phendimetrazine, phenethylamine, caffeine, bromocriptine, ephedrine, pseudoephedrine, rimonabant,
surinabant, mirtazapine, Dietex®, MG Plus Protein™, insulin, and leptin and pharmaceutically
acceptable salts and combinations thereof.
Compounds provided herein can also include tautomeric forms, such as keto-enol tautomers
and the like. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate
substitution. It is understood that the various tautomeric forms are within the scope of the compounds
provided herein.
It is understood that compounds herein represent all individual enantiomers and mixtures
thereof, unless stated or shown otherwise.
Additionally, individual compounds and chemical genera provided herein, including, isomers,
diastereoisomers and enantiomers thereof, encompass all pharmaceutically acceptable salts, hydrates,
and solvates, thereof. Further, mesoisomers of individual compounds and chemical genera provided
herein encompass all pharmaceutically acceptable salts, solvates and particularly hydrates, thereof.
The compounds provided herein may be prepared according to relevant published literature
procedures that are used by one skilled in the art. Exemplary reagents and procedures for these
reactions appear hereinafter in the working Examples. Protection and deprotection may be carried out
by procedures generally known in the art (see, for example, Greene, T. Wand Wuts, P. G. M.,
Protecting Groups in Organic Synthesis, 3rd Edition, 1999 [Wiley]).
It is understood that the present invention(s) embrace, each isomer, each diastereoisomer, each
enantiomer and mixtures thereof of each compound and generic formulae disclosed herein just as if
they were each individually disclosed with the specific stereochemical designation for each chiral
carbon. Separation of the individual isomers and enantiomers ( such as, by chiral HPLC,
recrystallization of diastereoisomeric mixtures and the like) or selective synthesis (such as, by
enantiomeric selective syntheses and the like) of the individual isomers can be accomplished by
application of various methods which are well known to practitioners in the art. In some embodiments,
a compound disclosed herein may exist as a stereoisomer that is substantially free of other
stereoisomers. The term "substantially free of other stereoisomers" as used herein means less than 10%
of other stereoisomers, such as less than 5% of other stereoisomers, such as less than 2% of other
stereoisomers, such as less than 2% of other stereoisomers are present.
Also provided are compounds for use in a method for treatment of the human or animal body
by therapy.
Also provided are compounds for use in a method for decreasing food intake.
Also provided are compounds for use in a method for inducing satiety.
Also provided are compounds for use in a method for the treatment of obesity.
Also provided are compounds for use in a method for the prevention of obesity.
Also provided are compounds for use in weight management.
In some embodiments, the weight management further comprises a surgical weight loss
procedure.
In some embodiments, the weight management comprises weight loss.
In some embodiments, the weight management comprises maintenance of weight loss.
In some embodiments, the weight management further comprises a reduced-calorie diet.
In some embodiments, the weight management further comprises a program of regular
exercise.
In some embodiments, the weight management further comprises both a reduced-calorie diet
and a program of regular exercise.
In some embodiments, the individual in need of weight management is an obese patient with an
initial body mass index 2': 30 kg/m .
In some embodiments, the individual in need of weight management is an overweight patient
with an initial body mass index 2': 27 kg/m in the presence of at least one weight related comorbid
condition.
In some embodiments, the weight related co-morbid condition is selected from: hypertension,
dyslipidemia, cardiovascular disease, glucose intolerance, and sleep apnea.
Also provided are compounds for use in the treatment of antipsychotic-induced weight gain.
Also provided are compounds for use in a method for the treatment of type 2 diabetes.
Also provided are compounds for use in a method for the treatment of type 2 diabetes in
combination with one or more type 2 diabetes medications.
In some embodiments, the need for the one or more type 2 diabetes treatments is reduced.
In some embodiments, the need for the one or more type 2 diabetes treatments is eliminated.
Also provided are compounds for use in a method for the prevention of type 2 diabetes.
In some embodiments the need for other type 2 diabetes treatments is reduced.
In some embodiments the need for other type 2 diabetes treatments is eliminated.
Also provided are compounds for use in a method for the treatment of Prader-Willi syndrome.
Also provided are compounds for the treatment of addiction.
Also provided are compounds for the treatment of drug and alcohol addiction.
Also provided are compounds for the treatment of alcohol addiction.
Also provided are compounds for the treatment of drug addiction.
In some embodiments, the drug is selected from amphetamine, a substituted amphetamine, a
benzodiazepine, an atypical benzodiazepine receptor ligand, marijuana, cocaine, dextromethorphan,
GHB, LSD, ketamine, a monoamine reuptake inhibitor, nicotine, an opiate, PCP, a substituted
phenethylamine, psilocybin, and an anabolic steroid.
In some embodiments, the drug is nicotine.
In some embodiments, the drug is amphetamine.
In some embodiments, the drug is a substituted amphetamine.
In some embodiments, the drug is methamphetamine.
In some embodiments, the drug is a benzodiazepine.
In some embodiments, the drug is an atypical benzodiazepine receptor ligand.
In some embodiments, the drug is marijuana.
In some embodiments, the drug is cocaine.
In some embodiments, the drug is dextromethorphan.
In some embodiments, the drug is GHB.
In some embodiments, the drug is LSD.
In some embodiments, the drug is ketamine.
In some embodiments, the drug is a monoamine reuptake inhibitor.
In some embodiments, the drug is an opiate.
In some embodiments, the drug is PCP.
In some embodiments, the drug is a substituted phenethylamine.
In some embodiments, the drug is psilocybin.
In some embodiments, the drug is an anabolic steroid.
Also provided are compounds for aiding smoking cessation.
Also provided are compounds for the treatment of tobacco dependence.
Also provided are compounds for the treatment of nicotine dependence.
Also provided are compounds for the treatment of alcoholism.
Also provided are compounds for use in a method for the treatment of pathological gambling.
Also provided are compounds for use in a method for the treatment of reward deficiency
syndrome.
Also provided are compounds for use in a method for the treatment of sex addiction.
Also provided are compounds for use in a method for the treatment of an obsessive-compulsive
spectrum disorder.
Also provided are compounds for use in a method for the treatment of an impulse control
disorder.
Also provided are compounds for use in a method for the treatment of nail-biting.
Also provided are compounds for use in a method for the treatment of onychophagia.
Also provided are compounds for use in a method for the treatment of a sleep disorder.
Also provided are compounds for use in a method for the treatment of insomnia.
Also provided are compounds for use in a method for the treatment of fragmented sleep
architecture.
Also provided are compounds for use in a method for the treatment of a disturbance of slow
wave sleep.
Also provided are compounds for use in a method for the treatment of urinary incontinence.
Also provided are compounds for use in a method for the treatment of a psychiatric disorder.
Also provided are compounds for use in a method for the treatment of schizophrenia.
Also provided are compounds for use in a method for the treatment of anorexia nervosa.
Also provided are compounds for use in a method for the treatment of bulimia nervosa.
Also provided are compounds for use in a method for the treatment of Alzheimer disease.
Also provided are compounds for use in a method for the treatment of sexual dysfunction.
Also provided are compounds for use in a method for the treatment of erectile dysfunction.
Also provided are compounds for use in a method for the treatment of epilepsy.
Also provided are compounds for use in a method for the treatment of a movement disorder.
Also provided are compounds for use in a method for the treatment of parkinsonism.
Also provided are compounds for use in a method for the treatment of antipsychotic-induced
movement disorder.
Also provided are compounds for use in a method for the treatment of hypertension.
Also provided are compounds for use in a method for the treatment of dyslipidemia.
Also provided are compounds for use in a method for the treatment of nonalcoholic fatty liver
disease.
Also provided are compounds for use in a method for the treatment of obesity-related renal
disease.
Also provided are compounds for use in a method for the treatment of sleep apnea.
INDICATIONS
Weight Management
FDA approved for weight loss, BEL VIQ is used along with a reduced-calorie diet and
increased physical activity for chronic weight management in adults who are: obese (BMI of 30 kg/m
or greater), or overweight (BMI of 27 kg/m or greater) with at least one weight-related medical
condition (for example, high blood pressure, high cholesterol, or type 2 diabetes) (www.belviq.com).
In some embodiments, an individual in need of weight management is an individual who is
overweight. In some embodiments, an individual in need of weight management is an individual who
has excess visceral adiposity. In some embodiments, an individual in need of weight management is an
individual who is obese. To determine whether an individual is overweight or obese one can determine
a body weight, a body mass index (BMI), a waist circumference or a body fat percentage of the
individual to determine if the individual meets a body weight threshold, a BMI threshold, a waist
circumference threshold or a body fat percentage threshold.
Determination of body weight can be through the use of a visual estimation of body weight, the
use of a weight measuring device, such as an electronic weight scale or a mechanical beam scale. In
some embodiments, an individual in need of weight management is an adult male with a body weight
greater than about 90 kg, greater than about 100 kg, or greater than about 110 kg. In some
embodiments, an individual in need of weight management is an adult female with a body weight
greater than about 80 kg, greater than about 90 kg, or greater than about 100 kg. In some embodiments,
the individual is prepubertal and has a body weight greater than about 30 kg, greater than about 40 kg,
or greater than about 50 kg.
Whether an individual is overweight or obese can be determined on the basis of their body
mass index (BMI) which is calculated by dividing body weight (kg) by height squared (m ). Thus, the
units of BMI are kg/m and it is possible to calculate the BMI range associated with minimum mortality
in each decade of life. According to the classification from the World Health Organization (W.H.0.),
overweight is defined as a BMI in the range 25-30 kg/m , and obesity as a BMI greater than 30 kg/m
(see below for a detailed W.H.O. BMI classification).
The International Classification of Adult Underweight, Overweight, and Obesity
According to BMI (World Health Organization)
BMI (kg/m )
Classification
Principal cut-off points Additional cut-off points
Underweight < 18.50 < 18.50
Severe thinness
< 16.00 < 16.00
Moderate thinness 16.00 - 16.99 16.00 - 16.99
Mild thinness 17.00 - 18.49 17.00 - 18.49
18.50 - 22.99
Normal range 18.50 - 24.99
23.00 - 24.99
Overweight ~ 25.00 ~ 25.00
.00 - 27.49
Pre-obese 25.00 - 29.99
27.50 - 29.99
BMI (kg/m )
Classification
Principal cut-off points Additional cut-off points
Obese ~ 30.00 ~ 30.00
.00 - 32.49
Obese class I 30.00 - 34-99
32.50 - 34.99
.00 - 37.49
Obese class II 35.00 - 39.99
37.50 - 39.99
Obese class III ~ 40.00 ~ 40.00
The healthy range of BMI, and other measures of whether one is overweight or obese, can also
be dependent on genetic or racial differences. For example, since Asian populations develop negative
health consequences at a lower BMI than Caucasians, some nations have redefined obesity for their
populations. For example, in Japan any BMI greater than 25 is defined as obese and in China any BMI
greater than 28 is defined as obese. Similarly, different threshold values for body weight, waist
circumference or body fat percentage can be used for different populations of individuals. The
additional cut-off points included in the table above (for example, 23, 27.5, 32.5 and 37.5) were added
as points for public health action. The WHO recommends that countries should use all categories for
reporting purposes with a view to facilitating international comparisons.
Determination of BMI can be through the use of a visual estimation of BMI, the use of a height
measuring device such as a stadiometer or a height rod and the use of a weight measuring device, such
as an electronic weight scale or a mechanical beam scale. In some embodiments, the individual in need
of weight management is an adult with a BMI of greater than about 25 kg/m , greater than about 26
2 2 2 2
kg/m , greater than about 27 kg/m , greater than about 28 kg/m , greater than about 29 kg/m , greater
2 2 2
than about 30 kg/m , greater than about 31 kg/m , greater than about 32 d kg/m , greater than about 33
2 2 2 2
kg/m , greater than about 34 kg/m , greater than about 35 kg/m , greater than about 36 kg/m , greater
2 2 2
than about 37 kg/m , greater than about 38 kg/m , greater than about 39 kg/m , or greater than about 40
kg/m . In some embodiments, the individual is prepubertal with a BMI of greater than about 20 kg/m ,
2 2 2
greater than about 21 kg/m , greater than about 22 kg/m , greater than about 23 kg/m , greater than
2 2 2 2
about 24 kg/m , greater than about 25 kg/m , greater than about 26 kg/m , greater than about 27 kg/m ,
2 2 2
greater than about 28 kg/m , greater than about 29 kg/m , greater than about 30 kg/m , greater than
2 2 2 2
about 31 kg/m , greater than about 32 kg/m , greater than about 33 kg/m , greater than about 34 kg/m ,
or greater than about 35 kg/m .
Determination of waist circumference can be through the use of a visual estimation of waist
circumference or the use of a waist circumference measuring device such as a tape measure.
Determinations of the healthy range of waist circumference and percentage body fat in an
individual are dependent on gender. For example, women typically have smaller waist circumferences
than men and so the waist circumference threshold for being overweight or obese is lower for a woman.
In addition, women typically have a greater percentage of body fat than men and so the percentage
body fat threshold for being overweight or obese for a woman is higher than for a man. Further, the
healthy range of BMI and other measures of whether one is overweight or obese can be dependent on
age. For example, the body weight threshold for considering whether one is overweight or obese is
lower for a child (prepubertal individual) than an adult.
In some embodiments, the individual in need of weight management is an adult male with a
waist circumference of greater than about 100 cm, greater than about 110 cm, greater than about 120
cm, greater than about 110 cm or an adult female with a waist circumference of greater than about 80
cm, greater than about 90 cm, or greater than about 100 cm. In some embodiments, the individual is
prepubertal with a waist circumference of about of greater than about 60 cm, greater than about 70 cm,
or greater than about 80 cm.
Determination of body fat percentage can be through the use of a visual estimation of body fat
percentage or the use of a body fat percentage measuring device such as bioelectric impedance,
computed tomography, magnetic resonance imaging, near infrared interactance, dual energy X ray
absorptiometry, use of ultrasonic waves, use of body average density measurement, use of skinfold
methods, or use of height and circumference methods. In some embodiments, the individual in need of
weight management is an adult male with a body fat percentage of greater than about 25%, greater than
about 30%, or greater than about 35% or an adult female with a body fat percentage of greater than
about 30%, greater than about 35%, or greater than about 40%. In some embodiments, the individual is
prepubertal with a body fat percentage of greater than about 30%, greater than about 35%, or greater
than about 40%.
In some embodiments, modifying the administration of the compounds provided herein
comprises prescribing or administering a weight loss drug or procedure to the individual to be used in
combination with the compounds provided herein.
Antipsychotic-induced Weight Gain
Antipsychotic-induced weight gain is a serious side effect of antipsychotic medication that can
lead to increased morbidity, mortality, and non-compliance in patients. The mechanisms underlying
weight gain resulting from antipsychotic drugs are not fully understood, although antagonism of the 5-
HT2c receptor is likely to contribute. Animal studies indicate that the drugs most likely to cause weight
gain, clozapine and olanzapine, have direct effects on the neuropeptide Y-containing neurons of the
hypothalamus; these neurons mediate the effects of the circulating anorexigenic hormone leptin on the
control of food intake (Association Between Early and Rapid Weight Gain and Change in Weight Over
One Year of Olanzapine Therapy in Patients with Schizaphrenia and Related Disorders; Kinon, B. J. et
al., Journal of Clinical Psychopharmacology (2005), 25(3), 255-258). Furthermore, significant overall
weight gain has been found in schizophrenic or related disorder patients undergoing therapy with the 5-
HT c-receptor antagonist, olanzapine (The 5-HT c Receptor and Antipsychotic-Induced Weight Gain -
Mechanisms and Genetics; Reynolds G. P. et al.; Journal of Psychopharmacology (2006), 20( 4 Suppl),
-8). Accordingly, 5-HT c-receptor agonists such as compounds provided herein are useful for treating
antipsychotic-induced weight gain.
Diabetes
It is known that 5-HT c-receptor agonists significantly improve glucose tolerance and reduce
plasma insulin in murine models of obesity and type 2 diabetes at concentrations of agonist that have no
effect on ingestive behavior, energy expenditure, locomotor activity, body weight, or fat mass
(Serotonin 2C Receptor Agonists Improve Type 2 Diabetes via Melanocortin-4 Receptor Signaling
Pathways; Ligang, Z. et al., Cell Metab. 2007 November 7; 6(5): 398-405).
As a part of a phase 3 clinical trial program, BELVIQ was evaluated in a randomized, placebo
controlled, multi-site, double-blind trial of 604 adults with poorly controlled type 2 diabetes mellitus
treated with oral hyperglycemic agents ("BLOOM-OM"). Within the glycemic, lipid and blood
pressure families, patients in the BELVIQ group achieved statistically significant improvements
relative to placebo in HbAlc and fasting glucose. BELVIQ (10 mg BID) patients achieved a 0.9%
reduction in HbAlc, compared to a 0.4% reduction for the placebo group (p < 0.0001) and a 27.4%
reduction in fasting glucose, compared to a 11.9% reduction for the placebo group (p < 0.001). Among
patients with type 2 diabetes, the use of medications to treat diabetes decreased in patients taking
BELVIQ concurrently with mean improvement in glycemic control. In particular, mean daily doses of
sulfonylureas and thiazolidinediones decreased 16-24% in the BELVIQ groups, and increased in the
placebo group (Effect of Lorcaserin on the Use of Concomitant Medications for Dyslipidemia,
Hypertension and Type 2 Diabetes during Phase 3 Clinical Trials Assessing Weight Loss in Patients
with Type 2 Diabetes; Vargas, E. et al.; Abstracts of Papers, Obesity Society 30 h Annual Scientific
Meeting, San Antonio, Texas, Sept. 20-24 2012, (2012), 471-P). In studies that excluded patients with
diabetes the population was insulin resistant, as indicated by baseline homeostasis model of assessment
- insulin resistance (HOMA-IR) values greater than 1.5. Mean fasting glucose was statistically
significantly decreased by BELVIQ (-0.2 mg/dL) compared to placebo (+0.6 mg/dL), and BELVIQ
caused a small but statistically significant decrease in HbAlc. In one study, fasting insulin decreased
significantly in the BELVIQ group (-3.3 µIU/mL) relative to placebo (-1.3 µIU/mL), resulting in
significant improvement in insulin resistance (indicated by HOMA-IR) in the BELVIQ group (-0.4)
compared with placebo (-0.2). Accordingly the compounds provided herein are useful for the
prevention and treatment of type 2 diabetes.
Prader-Willi Syndrome
Prader-Willi syndrome (PWS) is a maternally imprinted human disorder resulting from a loss
of paternal gene expression on chromosome 15q 11-13 that is characterized by a complex phenotype
including cognitive deficits, infantile hypotonia and failure to thrive, short stature, hypogonadism and
hyperphagia which can lead to morbid obesity (Goldstone, 2004; Nicholls and Knepper, 2001). There is
support in the literature for the use of 5-HT c-receptor agonists such as compounds provided herein for
treating PWS (Mice with altered serotonin 2C receptor RNA editing display characteristics of Prader
Willi syndrome. Morabito, M.V. et al., Neurobiology of Disease 39 2010) 169-180; and Self-injurious
behavior and serotonin in Prader-Willi syndrome. Hellings, J. A. and Warnock, J. K.
Psychopharmacology bulletin (1994), 30(2), 245-50).
Substance Abuse and other Addiction
Addiction is a primary, chronic disease of brain reward, motivation, memory, and related
circuitry. Dysfunction in these circuits leads to characteristic biological, psychological, social, and
spiritual manifestations. This is reflected in an individual pathologically pursuing reward and/or relief
by substance use and other behaviors. Addiction is characterized by inability to consistently abstain,
impairment in behavioral control, craving, diminished recognition of significant problems with one's
behaviors and interpersonal relationships, and a dysfunctional emotional response. Like other chronic
diseases, addiction often involves cycles of relapse and remission. Without treatment or engagement in
recovery activities, addiction is progressive and can result in disability or premature death.
The power of external cues to trigger craving and drug use, as well as to increase the frequency
of engagement in other potentially addictive behaviors, is also a characteristic of addiction, with the
hippocampus being important in memory of previous euphoric or dysphoric experiences, and with the
amygdala being important in having motivation concentrate on selecting behaviors associated with
these past experiences. Although some believe that the difference between those who have addiction,
and those who do not, is the quantity or frequency of alcohol/drug use, engagement in addictive
behaviors (such as gambling or spending), or exposure to other external rewards (such as food or sex), a
characteristic aspect of addiction is the qualitative way in which the individual responds to such
exposures, stressors and environmental cues. A particularly pathological aspect of the way that persons
with addiction pursue substance use or external rewards is that preoccupation with, obsession with
and/or pursuit of rewards (e.g., alcohol and other drug use) persist despite the accumulation of adverse
consequences. These manifestations can occur compulsively or impulsively, as a reflection of impaired
control.
Agonists of the 5-HT c receptor such as the compounds provided herein are active in rodent
models of substance abuse, addiction and relapse, and there is strong support in the literature that such
agonists act via modulation of dopamine function.
1. Smoking & Tobacco Use
Tobacco use can lead to tobacco/nicotine dependence and serious health problems. Cessation
can significantly reduce the risk of suffering from smoking-related diseases. Tobacco/nicotine
dependence is a chronic condition that often requires repeated interventions.
2. Drug addiction
There is support in the literature for the use of 5-HT c-receptor agonists such as compounds
provided herein for treating drug addiction (Novel Phannacotherapeutic Approaches for the Treatment
of Drug Addiction and Craving; Heidbreder et al, Current Opinion in Pharmacology (2005), 5(1), 107-
118).
3. Alcoholism
There is support in the literature for the use of 5-HT c-receptor agonists such as compounds
provided herein for treating alcoholism (An Investigation of the Role of 5-HT c Receptors in Modifying
Ethanol Self-Administration Behaviour; Tomkins et al. Pharmacology, biochemistry, and behavior
(2002), 71(4), 735-44).
4. Pathological Gambling
There is support in the literature for the use of 5-HT c-receptor agonists such as compounds
provided herein for treating pathological gambling. Marazziti, D. et al. found that the maximum
binding capacity of the platelet 5-HT transporter pathological gambling patients was significantly lower
than that of healthy subjects. Pathological gambling patients showed a dysfunction at the level of the
platelet 5-HT transporter that would suggest the involvement of the 5-HT system in this condition.
(Decreased Density of the Platelet Serotonin Transporter in Pathological Gamblers; Marazziti, D. et
al., Neuropsychobiology (2008), 57(1-2), 38-43.)
. Reward Deficiency Syndrome; Sex Addiction
The dopaminergic system, and in particular the dopamine D2 receptor, has been implicated in
reward mechanisms. The net effect of neurotransmitter interaction at the mesolimbic brain region
induces "reward" when dopamine (DA) is released from the neuron at the nucleus accumbens and
interacts with a dopamine D2 receptor. "The reward cascade" involves the release of serotonin, which
in turn at the hypothalamus stimulates enkephalin, which in turn inhibits GABA at the substania nigra,
which in turn fine tunes the amount of DA released at the nucleus accumbens or "reward site." It is well
known that under normal conditions in the reward site DA works to maintain our normal drives. In fact,
DA has become to be known as the "pleasure molecule" and/or the "antistress molecule." When DA is
released into the synapse, it stimulates a number a DA receptors (Dl-D5) which results in increased
feelings of well-being and stress reduction. A consensus of the literature suggests that when there is a
dysfunction in the brain reward cascade, which could be caused by certain genetic variants (polygenic),
especially in the DA system causing a hypodopaminergic trait, the brain of that person requires a DA
fix to feel good. This trait leads to multiple drug-seeking behavior. This is so because alcohol, cocaine,
heroin, marijuana, nicotine, and glucose all cause activation and neuronal release of brain DA, which
could heal the abnormal cravings. Certainly after ten years of study we could say with confidence that
carriers of the DAD2 receptor Al allele have compromised D2 receptors. Therefore lack of D2
receptors causes individuals to have a high risk for multiple addictive, impulsive and compulsive
behavioral propensities, such as severe alcoholism, cocaine, heroin, marijuana and nicotine use, glucose
bingeing, pathological gambling, sex addiction, ADHD, Tourette's Syndrome, autism, chronic violence,
posttraumatic stress disorder, schizoid/avoidant cluster, conduct disorder and antisocial behavior. In
order to explain the breakdown of the reward cascade due to both multiple genes and environmental
stimuli (pleiotropism) and resultant aberrant behaviors, Blum united this hypodopaminergic trait under
the rubric of a reward deficiency syndrome. (Reward Deficiency Syndrome: a Bio genetic Model for the
Diagnosis and Treatment of Impulsive, Addictive, and Compulsive Behaviors; Blum K. et al.; Journal of
psychoactive drugs (2000), 32 Suppl, i-iv, 1-112.) Accordingly, compounds provided herein are useful
for the treatment of reward deficiency syndrome, multiple addictive, impulsive and compulsive
behavioral propensities, such as severe alcoholism, cocaine, heroin, marijuana and nicotine use, glucose
bingeing, pathological gambling, sex addiction, ADHD, Tourette's Syndrome, autism, chronic violence,
posttraumatic stress disorder, schizoid/avoidant cluster, conduct disorder and antisocial behavior. In
some embodiments, compounds provided herein are useful for the treatment of sex addiction.
Obsessive-compulsive Spectrum Disorders; Impulse Control Disorders; Onychophagia
The morbidity of obsessive-compulsive spectrum disorders (OCSD), a group of conditions
related to obsessive-compulsive disorder (OCD) by phenomenological and etiological similarities, is
increasingly recognized. Serotonin reuptake inhibitors (SRis) have shown benefits as first-line, short
term treatments for body dysmorphic disorder, hypochondriasis, onychophagia, and psychogenic
excoriation, with some benefits in trichotillomania, pathological gambling, and compulsive buying.
( Obsessive-Compulsive Spectrum Disorders: a Review of the Evidence-Based Treatments. Ravindran
A. V., et al., Canadian journal of psychiatry, (2009), 54(5), 331-43). Furthermore, impulse control
disorders such as trichotillomania (hair-pulling), pathological gambling, pyromania, kleptomania, and
intermittent explosive disorder, as well as onychophagia (nail-biting), are treated by administering a
serotonin reuptake inhibitor such as clomipramine, fluvoxamine, fluoxetine, zimelidine, and sertraline
or their salts. Significant improvement was noted with clomipramine in a 5-week trial (Method of
Treating Trichotillomania and Onychophagia, Swedo, S. E. et al., PCT Int. Appl. (1992), WO 9218005
Al 19921029). Accordingly, compounds provided herein are useful for the treatment of body
dysmorphic disorder, hypochondriasis, onychophagia, psychogenic excoriation, trichotillomania,
pathological gambling, compulsive buying, pyromania, kleptomania, and intermittent explosive
disorder. In some embodiments, compounds provided herein are useful for the treatment of
onychophagia.
Sleep
There is support in the literature for the use of 5-HT c-receptor agonists such as compounds
provided herein for treating insomnia, for increasing slow-wave sleep, for sleep consolidation, and for
treating fragmented sleep architecture. (The Role of Dorsal Raphe Nucleus Serotonergic and Non
Serotonergic Neurons, and of their Receptors, in Regulating Waking and Rapid Eye Movement (REM)
Sleep; Monti, J.M.; Sleep medicine reviews (2010), 14(5), 319-27). Furthermore, 5-HT c-receptor
knockout mice exhibit more wakefulness and less slow wave sleep than do wild-types (Serotonin 1 B
and 2C Receptor Interactions in the Modulation of Feeding Behaviour in the Mouse; Dalton, G. L. et
al., Psychopharmacology (2006), 185(1), 45-57). However, the 5-HT c-receptor agonist, m-
chlorophenylpiperazine (mCPP) has been shown to decrease slow-wave sleep in humans (Decreased
Tryptophan Availability but Normal Post-Synaptic 5-HT2C Receptor Sensitivity in Chronic Fatigue
Syndrome; Vassallo, C. M. et al., Psychological medicine (2001), 31(4), 585-91).
Urinary Incontinence
The serotoninergic system has been widely implicated in the control of urinary bladder
function. It has been demonstrated that preganglionic fibers and ganglionic serotoninergic neurons,
expressing the 5-HT and 5-HT receptors, and the effector smooth muscle cells, expressing 5-HT and
3 4 1
-HT receptors, are actively involved in the regulation of the bladder contractile activity in rabbits
(Role of Serotonin Receptors in Regulation of Contractile Activity of Urinary Bladder in Rabbits;
Lychkova, A. E. and Pavone, L. M., Urology 2013 Mar;81(3):696). Furthermore, there is support in the
literature for the use of 5-HT c-receptor agonists such as compounds provided herein for treating
urinary incontinence (Discovery of a Novel Azepine Series of Potent and Selective 5-HT c Agonists as
Potential Treatments for Urinary Incontinence; Brennan et al.; Bioorganic & medicinal chemistry
letters (2009), 19(17), 4999-5003).
Psychiatric Disorders
There is support in the literature for the use of 5-HT c-receptor agonists such as compounds
provided herein for and prodrugs thereof for treating psychiatric disorders (5-HT c Receptor Agonists
as an Innovative Approach for Psychiatric Disorders; Rosenzweig-Lipson et al., Drug news &
perspectives (2007), 20(9), 565-71; and Naughton et al., Human Psychopharmacology (2000), 15(6),
397-415).
1. Schizophrenia
The 5-HT c receptor is a highly complex, highly regulated receptor which is widely distributed
throughout the brain. The 5-HT c receptor couples to multiple signal transduction pathways leading to
engagement of a number of intracellular signaling molecules. Moreover, there are multiple allelic
variants of the 5-HT c receptor and the receptor is subject to RNA editing in the coding regions. The
complexity of this receptor is further emphasized by the studies suggesting the utility of either agonists
or antagonists in the treatment of schizophrenia. The preclinical profile of 5-HT c agonists from a
neurochemical, electrophysiological, and a behavioral perspective is indicative of antipsychotic-like
efficacy without extrapyramidal symptoms or weight gain. Recently, the selective 5-HT c agonist
vabicaserin demonstrated clinical efficacy in a Phase II trial in schizophrenia patients without weight
gain and with low extrapyramidal side effects liability. These data are highly encouraging and suggest
that the compounds provided herein are useful for the treatment of psychiatric disorders, such as
schizophrenia (5-HT c Agonists as Therapeutics for the Treatment of Schizaphrenia. Rosenzweig
Lipson, S. et al., Handbook of Experimental Pharmacology (2012), 213 (Novel Antischizophrenia
Treatments), 147-165).
2. Eating Disorders
-HT c receptor agonists such as compounds provided herein are useful for the treatment of
psychiatric symptoms and behaviors in individuals with eating disorders such as, but not limited to,
anorexia nervosa and bulimia nervosa. Individuals with anorexia nervosa often demonstrate social
isolation. Anorexic individuals often present symptoms of being depressed, anxious, obsession,
perfectionistic traits, and rigid cognitive styles as well as sexual disinterest. Other eating disorders
include, anorexia nervosa, bulimia nervosa, binge eating disorder (compulsive eating) and ED-NOS
(i.e., eating disorders not otherwise specified - an official diagnosis). An individual diagnosed with ED
NOS possess atypical eating disorders including situations in which the individual meets all but a few
of the criteria for a particular diagnosis. What the individual is doing with regard to food and weight is
neither normal nor healthy.
Alzheimer Disease
The 5-HT c receptor plays a role in Alzheimer Disease (AD). Therapeutic agents currently
prescribed AD are cholinomimetic agents that act by inhibiting the enzyme acetylcholinesterase. The
resulting effect is increased levels of acetylcholine, which modestly improves neuronal function and
cognition in patients with AD. Although, dysfunction of cholinergic brain neurons is an early
manifestation of AD, attempts to slow the progression of the disease with these agents have had only
modest success, perhaps because the doses that can be administered are limited by peripheral
cholinergic side effects, such as tremors, nausea, vomiting, and dry mouth. In addition, as AD
progresses, these agents tend to lose their effectiveness due to continued cholinergic neuronal loss.
Therefore, there is a need for agents that have beneficial effects in AD, particularly in
alleviating symptoms by improving cognition and slowing or inhibiting disease progression, without
the side effects observed with current therapies. Therefore, serotonin 5-HT c receptors, which are
exclusively expressed in brain, are attractive targets and agonists of 5-HT c receptors such as
compounds provided herein are useful for the treatment of AD.
Sexual Dysfunction; Erectile dysfunction
Another disease, disorder or condition that can is associated with the function of the 5-HT c
receptor is erectile dysfunction (ED). Erectile dysfunction is the inability to achieve or maintain an
erection sufficiently rigid for intercourse, ejaculation, or both. An estimated 20-30 million men in the
United States have this condition at some time in their lives. The prevalence of the condition increases
with age. Five percent of men 40 years of age report ED. This rate increases to between 15% and 25%
by the age of 65, and to 55% in men over the age of 75 years.
Erectile dysfunction can result from a number of distinct problems. These include loss of desire
or libido, the inability to maintain an erection, premature ejaculation, lack of emission, and inability to
achieve an orgasm. Frequently, more than one of these problems presents themselves simultaneously.
The conditions may be secondary to other disease states (typically chronic conditions), the result of
specific disorders of the urogenital system or endocrine system, secondary to treatment with
pharmacological agents (e.g. antihypertensive drugs, antidepressant drugs, antipsychotic drugs, etc.) or
the result of psychiatric problems. Erectile dysfunction, when organic, is primarily due to vascular
irregularities associated with atherosclerosis, diabetes, and hypertension.
There is evidence for use of a serotonin 5-HT c agonist for the treatment of sexual dysfunction
in males and females. The serotonin 5-HT c receptor is involved with the processing and integration of
sensory information, regulation of central monoaminergic systems, and modulation of neuroendocrine
responses, anxiety, feeding behavior, and cerebrospinal fluid production (Tecott, L. H., et al. Nature
374: 542-546 (1995)). In addition, the serotonin 5-HT c receptor has been implicated in the mediation
of penile erections in rats, monkeys, and humans. Accordingly the compounds provided herein are
useful for the treatment of sexual dysfunction and erectile dysfunction.
Seizure Disorders
Evidence suggests a role for the monoamines, norepinephrine and serotonin, in the
pathophysiology of seizure disorders (Electrophysiological Assessment of Monoamine Synaptic
Function in Neuronal Circuits of Seizure Susceptible Brains; Waterhouse, B. D.; Life Sciences (1986),
39(9), 807-18). Accordingly, 5-HT c receptor agonists such as compounds provided herein, are useful
for the treatment of seizure disorders.
Epilepsy is a syndrome of episodic brain dysfunction characterized by recurrent unpredictable,
spontaneous seizures. Cerebellar dysfunction is a recognized complication of temporal lobe epilepsy
and it is associated with seizure generation, motor deficits and memory impairment. Serotonin is known
to exert a modulatory action on cerebellar function through 5-HT c receptors. (Down-regulation of
Cerebellar 5-HT c Receptors in Pilocarpine-Induced Epilepsy in Rats: Therapeutic Role of Bacopa
monnieri Extract; Krishnakumar, A. et al., Journal of the Neurological Sciences (2009), 284(1-2), 124-
128). Mutant mice lacking functional 5-HT2C-receptors are also prone to spontaneous death from
seizures (Eating Disorder and Epilepsy in Mice Lacking 5-HT c Serotonin Receptors; Tecott, L. H. et
al., Nature. 1995 Apr 6;374(6522):542-6). Furthermore, in a preliminary trial of the selective serotonin
reuptake inhibitor citalopram as an add on treatment in non-depressed patients with poorly controlled
epilepsy, the median seizure frequency dropped by 55.6% (The Anticonvulsant Effect of Citalopram as
an Indirect Evidence of Serotonergic Impairment in Human Epileptogenesis; Favale, E. et al., Seizure.
2003 Jul;12(5):316-8). Accordingly, 5-HT c receptor agonists such as compounds provided herein, are
useful for the treatment of epilepsy. For example, 5-HT c receptor agonists such as compounds
provided herein, are useful for the treatment of generalized nonconvulsive epilepsy, generalized
convulsive epilepsy, petit mal status epilepticus, grand mal status epilepticus, partial epilepsy with or
without impairment of consciousness, infantile spasms, or epilepsy partialis continua.
Dravet Syndrome, also known as severe myoclonic epilepsy of infancy (SMEI), is a
catastrophic form of childhood epilepsy in which children are unresponsive to standard anti-epilepsy
drugs. The average age of death is 4-6 years. If patients survive beyond this age they will be likely
mentally retarded. Data from case studies over twenty years demonstrates that administering a low-dose
of the indirectly-acting serotonin agonist fenfluramine stops patients with Dravet Syndrome fitting.
Accordingly, 5-HT c receptor agonists, such as compounds provided herein, are useful for the treatment
of Dravet Syndrome.
Lennox-Gastaut syndrome (also known as Lennox syndrome) is a difficult-to-treat form of
childhood-onset epilepsy that most often appears between the second and sixth year of life, and is
characterized by frequent seizures and different seizure types. A West syndrome is an uncommon to
rare epileptic disorder in infants that is characterized by frequent seizures and different seizure types. A
status epilepticus (SE) is a life-threatening condition in which the brain is in a state of persistent
seizure. Definitions vary, but traditionally it is defined as one continuous unremitting seizure lasting
longer than 30 minutes, or recurrent seizures without regaining consciousness between seizures for
greater than 30 minutes (or shorter with medical intervention). Other types of seizures can cause
confusion, upset stomach, or emotional distress. Administration of fenfluramine to a patient with
Lennox-Gastaut syndrome demonstrated a two-thirds reduction in seizure frequency during treatment.
Accordingly, 5-HT c receptor agonists, such as compounds provided herein, are useful for the treatment
of Lennox-Gastaut syndrome.
Movement Disorders
The basal ganglia are a highly interconnected group of subcortical nuclei in the vertebrate brain
that play a critical role not only in the control of movements but also in some cognitive and behavioral
functions. Several recent studies have emphasized that serotonergic pathways in the central nervous
system (CNS) are intimately involved in the modulation of the basal ganglia and in the pathophysiology
of human involuntary movement disorders. These observations are supported by anatomical evidence
demonstrating large serotonergic innervation of the basal ganglia. In fact, serotonergic terminals have
been reported to make synaptic contacts with dopamine (DA)-containing neurons and y-aminobutyric
acid (GABA)-containing neurons in the striatum, globus pallidus, subthalamus and substantia nigra.
These brain areas contain the highest concentration of serotonin (5-HT), with the substantia nigra pars
reticulata receiving the greatest input. Furthermore, in these structures a high expression of 5-HT
different receptor subtypes has been revealed (Serotonin Involvement in the Basal Ganglia
Pathophysiology: Could the 5-HT c Receptor be a New Target for Therapeutic Strategies? Di
Giovanni, G. et al., Current medicinal Chemistry (2006), 13(25), 3069-81). Accordingly, 5-HT c
receptor agonists such as compounds provided herein, are useful for the treatment of movement
disorders. In some embodiments, compounds provided herein are useful for the treatment of
parkisonism. In some embodiments, compounds provided herein are useful for the treatment of
movement disorders associated with antipsychotic drug use.
Hypertension
In clinical trials in patients without type 2 diabetes, 2.2 % of patients on BELVIQ and 1. 7% of
patients on placebo decreased total daily dose of antihypertensive medications, while 2.2% and 3.0%,
respectively, increased total daily dose. In patients without type 2 diabetes, numerically more patients
who were treated with placebo initiated dyslipidemia and hypertension therapy as compared to those
treated with BELVIQ. In patients with type 2 diabetes, 8.2% on BELVIQ and 6.0% of patients on
placebo decreased total daily dose of antihypertensive medications, while 6.6% and 6.3%, respectively,
increased total daily dose (Effect of Lorcaserin on the Use of Concomitant Medications for
Dyslipidemia, Hypertension and Type 2 Diabetes during Phase 3 Clinical Trials Assessing Weight Loss
in Patients with Type 2 Diabetes; Vargas, E. et al.; Abstracts of Papers, Obesity Society 30th Annual
Scientific Meeting, San Antonio, Texas, Sept. 20-24 2012, (2012), 471-P). Accordingly, 5-HT c
receptor agonists such as compounds provided herein, are useful for the treatment of hypertension.
Dyslipidemia
In clinical trials in patients without type 2 diabetes, 1.3% of patients on BELVIQ and 0. 7% of
patients on placebo decreased the total daily dose of medications used for treatment of dyslipidemia;
2.6% and 3.4%, respectively, increased use of these medications during the trials. In patients without
type 2 diabetes, numerically more patients who were treated with placebo initiated dyslipidemia and
hypertension therapy as compared to those treated with BELVIQ. In patients with type 2 diabetes, 5.5%
of patients on BELVIQ BID and 2.4% of patients on placebo decreased the total daily dose of
medications used for treatment of dyslipidemia; 3.1 % and 6.7%, respectively, increased use of these
medications during the trials. (Effect of Lorcaserin on the Use of Concomitant Medications for
Dyslipidemia, Hypertension and Type 2 Diabetes during Phase 3 Clinical Trials Assessing Weight Loss
in Patients with Type 2 Diabetes; Vargas, E. et al.; Abstracts of Papers, Obesity Society 30th Annual
Scientific Meeting, San Antonio, Texas, Sept. 20-24 2012, (2012), 471-P). Accordingly, 5-HT c
receptor agonists such as compounds provided herein, are useful for the treatment of dyslipidemia.
Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease encompasses a range of liver diseases. Simple steatosis, or fatty
liver, is now found in up to 31 % of adults and 16% of children. Of those with steatosis, approximately
5% will develop nonalcoholic steatohepatitis (NASH), in which steatosis is accompanied by
inflammation and fibrosis. Up to 25% of NASH patients will progress to cirrhosis. NASH is the third
leading indication for liver transplantation in the United States and will become the most common if
current trends continue. Therefore, understanding its pathogenesis and treatment is of utmost
importance. Overall reductions in body weight, through reduced-calorie intake and increased physical
activity, are the current mainstays of NASH treatment (Dietary Treatment of Nonalcoholic
Steatohepatitis; Perito, E. R., et al.; Disclosures Curr Opin Gastroenterol, 2013; 29(2): 170-176).
Accordingly, by virtue of their ability to decrease food intake and induce satiety, 5-HT c receptor
agonists such as compounds provided herein, are useful for the treatment of nonalcoholic fatty liver
disease.
Obesity-related Renal Disease
Obesity is established as an important contributor of increased diabetes mellitus, hypertension,
and cardiovascular disease, all of which can promote chronic kidney disease. Recently, there is a
growing appreciation that, even in the absence of these risks, obesity itself significantly increases
chronic kidney disease and accelerates its progression. (Scope and mechanisms of obesity-related renal
disease; Hunley, T. E. et al.; Current Opinion in Nephrology & Hypertension (2010), 19(3), 227-234).
Accordingly, by virtue of their ability to treat obesity, 5-HT c receptor agonists such as compounds
provided herein, are useful for the treatment of obesity-related kidney disease.
Catecholamine Suppression
Administering a compound provided herein to an individual causes a reduction of the
individual's norepinephrine level independently of weight-loss. 5-HT c receptor agonists such as
compounds provided herein are useful for the treatment of disorders ameliorated by reduction of an
individual's norepinephrine level, wherein said disorders include but are not limited to
hypernorepinephrinemia, cardiomyopathy, cardiac hypertrophy, cardiomyocyte hypertrophy in post
myocardial infarction remodeling, elevated heart rate, vasoconstriction, acute pulmonary
vasoconstriction, hypertension, heart failure, cardiac dysfunction after stroke, cardiac arrhythmia,
metabolic syndrome, abnormal lipid metabolism, hyperthermia, Cushing syndrome,
pheochromocytoma, epilepsy, obstructive sleep apnea, insomnia, glaucoma, osteoarthritis, rheumatoid
arthritis, and asthma.
Also provided is a method for aiding in the cessation or lessening of use of a tobacco product in
an individual attempting to cease or lessen use of a tobacco product comprising the step of: prescribing
and/or administering to the individual an effective amount of a compound provided herein. In some
embodiments, aiding in the cessation of use of a tobacco product is aiding smoking cessation, and the
individual attempting to cease use of the tobacco product is an individual attempting to cease smoking.
Also provided is a method for aiding in the cessation of use of a tobacco product and the
prevention of associated weight gain comprising the step of: prescribing and/or administering an
effective amount of a compound provided herein to an individual attempting to cease use of the tobacco
product. In some embodiments, aiding in the cessation of use of a tobacco product is aiding smoking
cessation, and the individual attempting to cease use of the tobacco product is an individual attempting
to cease smoking.
Also provided is a method for reducing the frequency of smoking tobacco in an individual
attempting to reduce frequency of smoking tobacco comprising the step of: prescribing and/or
administering to the individual an effective amount of a compound provided herein.
Also provided is a method for controlling weight gain associated with smoking cessation by an
individual attempting to cease smoking tobacco comprising the step of: prescribing and/or
administering to the individual an effective amount of a compound provided herein.
Also provided is a method for reducing weight gain associated with smoking cessation by an
individual attempting to cease smoking tobacco comprising the step of: prescribing and/or
administering to the individual an effective amount of a compound provided herein.
Also provided is a method of treatment for nicotine dependency, addiction and/or withdrawal in
an individual attempting to treat nicotine dependency, addiction and/or withdrawal comprising the step
of: prescribing and/or administering to the individual an effective amount of a compound provided
herein.
Also provided is a method of reducing the likelihood of relapse use of nicotine by an individual
attempting to cease nicotine use comprising the step of:
prescribing and/or administering to the individual an effective amount of a compound provided herein.
Methods related to nicotine addiction and smoking cessation
Also provided is a method of reducing the frequency of smoking tobacco in an individual
attempting to reduce frequency of smoking tobacco, aiding in the cessation or lessening of use of a
tobacco product in an individual attempting to cease or lessen use of a tobacco product, aiding in
smoking cessation and preventing associated weight gain, controlling weight gain associated with
smoking cessation by an individual attempting to cease smoking tobacco, reducing weight gain
associated with smoking cessation by an individual attempting to cease smoking tobacco, treating
nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine
dependency, addiction and/or withdrawal, or reducing the likelihood of relapse use of nicotine by an
individual attempting to cease nicotine use, comprising:
selecting an individual with an initial BMI 2': 27 kg/m ; and
prescribing and/or administering to the individual an effective amount of a compound selected
from compounds of Table A, and salts, hydrates, and solvates thereof for at least one year.
Also provided is a method of reducing the frequency of smoking tobacco in an individual
attempting to reduce frequency of smoking tobacco, aiding in the cessation or lessening of use of a
tobacco product in an individual attempting to cease or lessen use of a tobacco product, aiding in
smoking cessation and preventing associated weight gain, controlling weight gain associated with
smoking cessation by an individual attempting to cease smoking tobacco, reducing weight gain
associated with smoking cessation by an individual attempting to cease smoking tobacco, treating
nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine
dependency, addiction and/or withdrawal, or reducing the likelihood of relapse use of nicotine by an
individual attempting to cease nicotine use, comprising:
administering a compound selected from compounds of Table A, and salts, hydrates, and
solvates thereof to an individual;
monitoring the individual for BMI during said administration; and
discontinuing said administration if the BMI of the individual becomes < 18.5 kg/m during
said administration.
Also provided is a method of reducing the frequency of smoking tobacco in an individual
attempting to reduce frequency of smoking tobacco, aiding in the cessation or lessening of use of a
tobacco product in an individual attempting to cease or lessen use of a tobacco product, aiding in
smoking cessation and preventing associated weight gain, controlling weight gain associated with
smoking cessation by an individual attempting to cease smoking tobacco, reducing weight gain
associated with smoking cessation by an individual attempting to cease smoking tobacco, treating
nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine
dependency, addiction and/or withdrawal, or reducing the likelihood of relapse use of nicotine by an
individual attempting to cease nicotine use, comprising:
administering a compound selected from compounds of Table A, and salts, hydrates, and
solvates thereof to an individual with an initial BMI s:; 25 kg/m ;
monitoring the individual for body weight during said administration; and
discontinuing said administration if the body weight of the individual decreases by more than
about 1 % during said administration.
In some embodiments, administration is discontinued if the body weight of the individual
decreases by more than about 2% during said administration. In some embodiments, administration is
discontinued if the body weight of the individual decreases by more than about 3% during said
administration. In some embodiments, administration is discontinued if the body weight of the
individual decreases by more than about 4% during said administration. In some embodiments,
administration is discontinued if the body weight of the individual decreases by more than about 5%
during said administration.
Also provided is a method of reducing the frequency of smoking tobacco in an individual
attempting to reduce frequency of smoking tobacco, aiding in the cessation or lessening of use of a
tobacco product in an individual attempting to cease or lessen use of a tobacco product, aiding in
smoking cessation and preventing associated weight gain, controlling weight gain associated with
smoking cessation by an individual attempting to cease smoking tobacco, reducing weight gain
associated with smoking cessation by an individual attempting to cease smoking tobacco, treating
nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine
dependency, addiction and/or withdrawal, or reducing the likelihood of relapse use of nicotine by an
individual attempting to cease nicotine use, comprising:
administering a compound selected from compounds of Table A, and salts, hydrates, and
solvates thereof to an individual;
monitoring the individual for body weight during said administration; and
discontinuing said administration if the body weight of the individual decreases by more than
about 1 kg during said administration.
In some embodiments, the compound is for use as an aid to smoking cessation treatment. In
some embodiments, the compound is for use as an aid for cessation of cigarette smoking. In some
embodiments, the compound is for use as an aid to smoking cessation treatment and the prevention of
associated weight gain. In some embodiments, the compound is for use as a weight-neutral
intervention for smoking cessation. In some embodiments, the weight gain occurs during smoking
cessation. In some embodiments, the weight gain occurs post-smoking cessation.
Any embodiment of the invention directed to smoking cessation or the cessation or lessening of
use of a tobacco product can be adapted to the cessation or lessening of use of nicotine administration
from any and all sources or any individual source, including tobacco products ( or specific examples
thereof), tobacco replacement therapy ( or specific examples thereof), and/or any electronic nicotine
delivery system (e.g., electronic cigarettes or personal vaporizers). The present invention specifically
embraces all such embodiments.
In some embodiments, prior to administration of the compound selected from compounds of
Table A, and salts, hydrates, and solvates thereof, the individual smokes 2': 10 cigarettes per day. In
some embodiments, prior to administration of the compound selected from compounds of Table A, and
salts, hydrates, and solvates thereof , the individual smokes 11-20 cigarettes per day. In some
embodiments, prior to administration of the compound selected from compounds of Table A, and salts,
hydrates, and solvates thereof, the individual smokes 21-30 cigarettes per day. In some embodiments,
prior to administration of the compound selected from compounds of Table A, and salts, hydrates, and
solvates thereof, the individual smokes 2': 31 cigarettes per day.
In some embodiments, the individual has an initial BMI selected from one of the following: 2':
2 2 2 2 2 2 2 2
24 kg/m , 2': 23 kg/m , 2': 22.5 kg/m , 2': 22 kg/m , 2': 21 kg/m , 2': 20 kg/m , 2': 19 kg/m , or 2': 18.5 kg/m .
In some embodiments, prior to administration, the individual has an initial BMI 2': 23 kg/m . In some
embodiments, prior to administration, the individual has an initial BMI 2': 22.5 kg/m . In some
embodiments, prior to administration, the individual has an initial BMI 2': 22 kg/m . In some
embodiments, prior to administration, the individual has an initial BMI 2': 18.5 kg/m . In some
embodiments, prior to administration, the individual has an initial BMI 2': 18 kg/m . In some
embodiments, prior to administration, the individual has an initial BMI 2': 17 .5 kg/m . In some
embodiments, prior to administration, the individual has an initial body mass index 2': 25 kg/m and at
least one weight-related comorbid condition.
In some embodiments, prior to administration, the individual has an initial body mass index 2':
27 kg/m . In some embodiments, prior to administration, the individual has an initial body mass index
2': 27 kg/m and at least one weight-related comorbid condition.
In some embodiments, the weight-related comorbid condition is selected from: hypertension,
dyslipidemia, cardiovascular disease, glucose intolerance and sleep apnea. In some embodiments, the
weight-related comorbid condition is selected from: hypertension, dyslipidemia, and type 2 diabetes.
In some embodiments, prior to administration, the individual has an initial body mass index 2::
30 kg/m .
In some embodiments, the initial BMI of the individual prior to administration is 18.5 to 25
In some embodiments, the individual is suffering from depression prior to being administered
the compound selected from compounds of Table A, and salts, hydrates, and solvates thereof.
In some embodiments, the individual is suffering from a preexisting psychiatric disease prior to
being administered the compound selected from compounds of Table A, and salts, hydrates, and
solvates thereof.
In some embodiments, the preexisting psychiatric disease is chosen from schizophrenia, bipolar
disorder, or major depressive disorder.
In some embodiments, individuals are assessed for nicotine dependence based on the
Fagerstrom score. In some embodiments, the individual has a score of 0, 1, or 2. In some
embodiments, the individual has a score of 3 or 4. In some embodiments, the individual has a score of
. In some embodiments, the individual has a score of 6 or 7. In some embodiments, the individual has
a score of 8, 9, or 10. In some embodiments, the individual has a score 2:: 3. In some embodiments, the
individual has a score 2:: 5. In some embodiments, the individual has a score > 6. In some
embodiments, the individual has a score 2:: 8.
In some embodiments, the individual has a Fagerstrom score of 0, 1, or 2 and a BMI < 25
kg/m . In some embodiments, the individual has a Fagerstrom score of 0, 1, or 2 and a BMI 2". 25 kg/m
and< 30 kg/m . In some embodiments, the individual has a Fagerstrom score of 0, 1, or 2 and a BMI 2".
30 kg/m .
In some embodiments, the individual has a Fagerstrom score of 3 or 4 and a BMI < 25 kg/m .
In some embodiments, the individual has a Fagerstrom score of 3 or 4 and a BMI 2". 25 kg/m and < 30
kg/m . In some embodiments, the individual has a Fagerstrom score of 3 or 4 and a BMI 2". 30 kg/m .
In some embodiments, the individual has a Fagerstrom score of 5 and a BMI < 25 kg/m . In
some embodiments, the individual has a Fagerstrom score of 5 and a BMI 2". 25 kg/m and < 30 kg/m .
In some embodiments, the individual has a Fagerstrom score of 5 and a BMI 2". 30 kg/m .
In some embodiments, the individual has a Fagerstrom score of 6 or 7 and a BMI < 25 kg/m .
In some embodiments, the individual has a Fagerstrom score of 6 or 7 and a BMI 2". 25 kg/m and < 30
kg/m . In some embodiments, the individual has a Fagerstrom score of 6 or 7 and a BMI 2". 30 kg/m .
In some embodiments, the individual has a Fagerstrom score of 8, 9, or 10 and a BMI < 25
kg/m . In some embodiments, the individual has a Fagerstrom score of 8, 9, or 10 and a BMI 2". 25
kg/m and< 30 kg/m . In some embodiments, the individual has a Fagerstrom score of 8, 9, or 10 and
a BMI 2". 30 kg/m .
In some embodiments, the individual has a Fagerstrom score of 2:: 3 and a BMI < 25 kg/m . In
some embodiments, the individual has a Fagerstrom score of2:: 3 and a BMI 2". 25 kg/m and< 30 kg/m .
In some embodiments, the individual has a Fagerstrom score of 2:: 3 and a BMI 2". 30 kg/m .
In some embodiments, the individual has a Fagerstrom score of 2:: 5 and a BMI < 25 kg/m . In
some embodiments, the individual has a Fagerstrom score of2:: 5 and a BMI 2". 25 kg/m and< 30 kg/m .
In some embodiments, the individual has a Fagerstrom score of 2:: 5 and a BMI 2". 30 kg/m .
In some embodiments, the individual has a Fagerstrom score of 2:: 6 and a BMI < 25 kg/m . In
some embodiments, the individual has a Fagerstrom score of2:: 6 and a BMI 2". 25 kg/m and< 30 kg/m •
In some embodiments, the individual has a Fagerstrom score of 2:: 6 and a BMI 2". 30 kg/m .
In some embodiments, the individual has a Fagerstrom score of 2:: 8 and a BMI < 25 kg/m . In
some embodiments, the individual has a Fagerstrom score of 2:: 8 and a BMI 2". 25 kg/m and< 30 kg/m .
In some embodiments, the individual has a Fagerstrom score of 2:: 8 and a BMI 2". 30 kg/m .
In some embodiments, a questionnaire is used to evaluate symptoms experienced during quit,
such as the urge to smoke, withdrawal, or reinforcing effects. In some embodiments, the questionnaire
is selected from: the Minnesota Nicotine Withdrawal Score (MNWS), Brief Questionnaire of Smoking
Urges (QSU-Brief), McNett Coping Effectiveness Questionnaire (mCEQ), Three-Factor Eating
Questionnaire (TFEQ), and Food Craving Inventory (FCI).
In some embodiments, the nicotine dependency, addiction and/or withdrawal results from the
use of tobacco products. In some embodiments, the nicotine dependency, addiction, and/or withdrawal
results from cigarette smoking.
In some embodiments, the nicotine dependency, addiction and/or withdrawal results from the
use of nicotine replacement therapies.
In some embodiments, the individual 1s first administered the compound selected from
compounds of Table A, and salts, hydrates, and solvates thereof on the target quit day. In some
embodiments, the individual is administered the compound at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,
13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 days prior to
the target quit day. In some embodiments, the individual is administered the compound at least 7 days
prior to the target quit day. In some embodiments, the individual is administered the compound about 7
to about 35 days prior to the target quit day. In some embodiments, the individual is administered the
compound at least 14 days prior to the target quit day. In some embodiments, the individual is
administered the compound about 14 to about 35 days prior to the target quit day.
In some embodiments, the individual quits smoking between days 8 and 35 of treatment. In
some embodiments, the individual quits smoking between days 15 and 35 of treatment. In some
embodiments, the individual quits smoking between days 22 and 35 of treatment. In some
embodiments, the individual quits smoking on day 8 of treatment. In some embodiments, the
individual quits smoking on day 15 of treatment. In some embodiments, the individual quits smoking
on day 22 of treatment.
In some embodiments, prior to administering the compound selected from compounds of Table
A, and salts, hydrates, and solvates thereof, the method further comprises the step of: instructing the
individual to set a date to cease smoking tobacco. In some embodiments, administration of the
compound is initiated about 7 days prior to the date set to cease smoking tobacco.
In some embodiments, after administering the compound selected from compounds of Table A,
and salts, hydrates, and solvates thereof, the method further comprises the step of: instructing the
individual to set a date to cease smoking tobacco. In some embodiments, the date set to cease smoking
tobacco occurs after at least 7 days of administration of the compound selected from compounds of
Table A, and salts, hydrates, and solvates thereof. In some embodiments, the date set to cease smoking
tobacco occurs prior to 35 days of administration of the compound.
In some embodiments, the individual previously attempted to cease smoking tobacco but did
not succeed in ceasing smoking tobacco. In some embodiments, the individual previously attempted to
cease smoking tobacco but subsequently relapsed and resumed smoking tobacco.
In some embodiments, the administration leads to a statistically significant improvement in the
ability to tolerate the cessation of smoking as measured by analysis of data from the MPSS test.
In some embodiments, the individual has abstained from nicotine use for 12 weeks prior to
prescribing and/or administering the compound selected from compounds of Table A, and salts,
hydrates, and solvates thereof.
In some embodiments, the individual has abstained from nicotine use for 24 weeks prior to
prescribing and/or administering the compound selected from compounds of Table A, and salts,
hydrates, and solvates thereof.
In some embodiments, the individual has abstained from nicotine use for 9 months prior to
prescribing and/or administering the compound selected from compounds of Table A, and salts,
hydrates, and solvates thereof.
In some embodiments, the individual has abstained from nicotine use for 52 weeks prior to
prescribing and/or administering the compound selected from compounds of Table A, and salts,
hydrates, and solvates thereof.
In some embodiments, abstinence is self-reported. In some embodiments, the self-reporting
based on response to a questionnaire. In some embodiments, the questionnaire is a Nicotine Use
Inventory. In some embodiments, an individual self-reports as not having smoking any cigarettes (even
a puff). In some embodiments, the individual self-reports as not having used any other nicotine
containing products. In some embodiments, the individual self-reports as not having smoking any
cigarettes (even a puff) and not having used any other nicotine-containing products.
In some embodiments, the duration of treatment is selected from: 12 weeks, 6 months, 9
months, 1 year, 18 months, 2 years, 3 years, 4 years, and 5 years.
In some embodiments, the compound selected from compounds of Table A, and salts,
hydrates, and solvates thereof is administered for at least about 2 weeks. In some embodiments, the
compound is administered for at least about 4 weeks. In some embodiments, the compound is
administered for at least about 8 weeks. In some embodiments, the compound is administered for at
least about 12 weeks. In some embodiments, the compound is administered for at least about 6 months.
In some embodiments, the compound is administered for at least about 1 year. In some embodiments,
the compound is administered for at least about 2 years. In some embodiments, the compound is
administered for between about 7 weeks to about 12 weeks. In some embodiments, the compound is
administered for between about 12 weeks to about 52 weeks. In some embodiments, the compound is
administered for between about 6 months to about 1 year.
In some embodiments, the individual receives treatment for a first treatment period. In some
embodiments, the individual receives treatment for an additional treatment period, e.g., to increase the
likelihood of long-term abstinence. In some embodiments, an individual who fails in a first treatment
period is administered the compound selected from compounds of Table A, and salts, hydrates, and
solvates thereof optionally in combination with a supplemental agent for a second treatment period. In
some embodiments, an individual who relapses during a first treatment is administered the compound
selected from compounds of Table A, and salts, hydrates, and solvates thereof optionally m
combination with a supplemental agent for a second treatment period. In some embodiments, an
individual who relapses following a first treatment is administered the compound selected from
compounds of Table A, and salts, hydrates, and solvates thereof optionally in combination with a
supplemental agent for a second treatment period. In some embodiments, the first treatment period is
12 weeks. In some embodiments, the second treatment period is 12 weeks or less. In some
embodiments, the second treatment period is 12 weeks. In some embodiments, the second treatment
period is more than 12 weeks. In some embodiments, the first treatment period is one year. In some
embodiments, the second treatment period is one year or less. In some embodiments, the second
treatment period is one year. In some embodiments, the first treatment period is longer than the second
treatment period. In some embodiments, the first treatment period is shorter than the second treatment
period. In some embodiments, the first treatment period and the second period are of the same length
of time.
In some embodiments, the prevention or reduction of weight gain, or inducement of weight
loss, is measured relative to the amount of weight gain or loss typically experienced when an individual
attempts smoking cessation. In some embodiments, the prevention or reduction of weight gain, or
inducement of weight loss, is measured relative the amount of weight gain or loss typically experienced
when an individual attempts smoking cessation with another drug.
In some embodiments, controlling weight gain comprises preventing weight gain. In some
embodiments, controlling weight gain comprises inducing weight loss. In some embodiments,
controlling weight gain comprises inducing weight loss of at least about 0.5%, 1 %, 1.5%, 2%, 2.5%,
3%, 3.5%, 4%, 4.5%, 5%, 6%, 7%, 8%, 9%, 10%, 11 %, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%,
or 20%. In some embodiments, the weight loss is at least 1 %. In some embodiments, the weight loss
is at least 1.5%. In some embodiments, the weight loss is at least about 2%. In some embodiments,
the weight loss is at least 3%. In some embodiments, the weight loss is at least 4%. In some
embodiments, the weight loss is at least 5%. In some embodiments, controlling weight gain comprises
decreasing BMI. In some embodiments, controlling weight gain comprises decreasing in percent body
fat. In some embodiments, controlling weight gain comprises decreasing waist circumference. In some
embodiments, controlling weight gain comprises decreasing BMI by at least about 0.25, 0.5, 1, 1.5, 2,
2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 kg/m . In some
embodiments, BMI is decreased by at least 1 kg/m . In some embodiments, BMI is decreased by at
least 1.5 kg/m . In some embodiments, BMI is decreased by at least 2 kg/m . In some embodiments,
BMI is decreased by at least 2.5 kg/m . In some embodiments, BMI is decreased by at least 5 kg/m .
In some embodiments, BMI is decreased by at least 10 kg/m . In some embodiments, controlling
weight gain comprises decreasing percent body fat by at least about 0.5%, 1 %, 1.5%, 2%, 2.5%, 3%,
3.5%, 4%, 4.5%, 5%, 6%, 7%, 8%, 9%, 10%, 11 %, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or
%. In some embodiments, the decrease in percent body fat is at least 1 %. In some embodiments, the
decrease in percent body fat is at least 2.5%. In some embodiments, the decrease in percent body fat is
at least 5%. In some embodiments, controlling weight gain comprises decreasing waist circumference
by at least about 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, or 10 cm. In some embodiments, the
decrease in waist circumference is at least 1 cm. In some embodiments, the decrease in waist
circumference is at least 2.5 cm. In some embodiments, the decrease in waist circumference is at least 5
cm. In some embodiments, controlling weight gain comprises decreasing body weight by at least about
0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, or 10 kg. In some embodiments, the decrease in body
weight is at least 1 kg. In some embodiments, the decrease in body weight is at least 2.5 kg. In some
embodiments, the decrease in body weight is at least 5 kg.
In some embodiments, the BMI of the individual becomes a BMI selected from one of the
2 2 2 2 2
following: 2': 18 kg/m , 2': 17.5 kg/m , 2': 17 kg/m , 2': 16 kg/m , and 2': 15 kg/m .
In some embodiments, the decrease in body weight is selected from one of the following: more
than about 1.5%, more than about 2%, more than about 2.5%, more than about 3%, more than about
3.5%, more than about 4%, more than about 4.5%, and more than about 5%.
In some embodiments, the decrease in body weight is selected from one of the following: more
than about 1.5 kg, more than about 2 kg, more than about 2.5 kg, more than about 3 kg, more than about
3.5 kg, more than about 4 kg, more than about 4.5 kg, and more than about 5 kg.
In some embodiments, the individual in need of treatment has a BMI selected from: 2': 25
2 2 2 2 2 2 2 2
kg/m , 2': 24 kg/m , 2': 23 kg/m , 2': 22 kg/m , 2': 21 kg/m , 2': 20 kg/m , 2': 19 kg/m , and 2': 18.5 kg/m . In
some embodiments, BMI is not decreased by more than about 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5,
6, 7, 8, 9, 10, 11, 12, 13, 14,15, 16, 17, 18, 19, or 20 kg/m . In some embodiments, BMI is not
decreased by more than 1 kg/m . In some embodiments, BMI is not decreased by more than 1.5 kg/m .
In some embodiments, BMI is not decreased by more than 2 kg/m . In some embodiments, BMI is not
decreased by more than 2.5 kg/m . In some embodiments, BMI is not decreased by more than 5 kg/m .
In some embodiments, BMI is not decreased by more than 10 kg/m . In some embodiments, percent
body fat is not decreased by more than about 0.5%, 1 %, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%,
6%, 7%, 8%, 9%, 10%, 11 %, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20%. In some
embodiments, percent body fat is not decreased by more than 1 %. In some embodiments, percent body
fat is not decreased by more than 2.5%. In some embodiments, percent body fat is not decreased by
more than 5%. In some embodiments, waist circumference is not decreased by more than about 0.5, 1,
1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, or 10 cm. In some embodiments, waist circumference is not
decreased by more than 1 cm. In some embodiments, waist circumference is not decreased by more
than 2.5 cm. In some embodiments, waist circumference is not decreased by more than 5 cm. In some
embodiments, body weight is not decreased by more than about 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7,
8, 9, or 10 kg. In some embodiments, the decrease in body weight is not more than 1 kg. In some
embodiments, the decrease in body weight is not more than 2.5 kg. In some embodiments, the decrease
in body weight is not more than 5 kg.
In some embodiments, controlling weight gain comprises maintaining at least some weight loss
for at least about 12 weeks, at least about 6 months, at least about 9 months, at least about one year, at
least about 18 months, or at least about two years. For example, in some embodiments, an individual
loses 5 kg during a first treatment and maintains at least 1 kg of that weight loss during a second
treatment. In some embodiments, an individual loses 3 kg during the first 12 weeks of a treatment, and
loses a total of 5 kg after one year of the treatment.
In some embodiments, use of the compound selected from compounds of Table A, and salts,
hydrates, and solvates thereof is discontinued. For example, in some embodiments, use of the
compound selected from compounds of Table A, and salts, hydrates, and solvates thereof is
discontinued if the BMI of an individual becomes s:; about 15 kg/m , s:; about 15.5 kg/m , s:; about 16
2 2 2 2 2
kg/m , s:; about 16.5 kg/m , s:; about 17 kg/m , s:; about 17.5 kg/m , s:; about 18 kg/m , s:; about 18.5
2 2 2 2 2 2
kg/m , s:; about 19 kg/m , s:; about 19.5 kg/m s:; about 20 kg/m , s:; about 20.5 kg/m , s:; about 21 kg/m , s:;
2 2 2 2
about 21.5 kg/m , s:; about 22 kg/m , s:; about 22.5 kg/m , ors:; about 23 kg/m .
In some embodiments, the individual experiences one or more additional beneficial effects as a
result of the administration of the compound selected from compounds of Table A, and salts, hydrates,
and solvates thereof, optionally in combination with at least one supplemental agent, as described
herein.
In some embodiments, the one or more additional beneficial effects are chosen from a decrease
m an assessment of weight, an improvement in cardiovascular indications, and/or an improved
glycemia. In some embodiments, the one or more additional beneficial effects are chosen from a
decrease in an assessment of weight, an improvement in cardiovascular indications, and/or an improved
lipidemia.
In some embodiments, the one or more additional beneficial effects comprise a decrease in an
assessment of weight. In some embodiments, the decrease in an assessment of weight comprises
weight loss. In some embodiments, the one or more beneficial effects comprises a decrease in hunger, a
decrease in food cravings, or an increase in intermeal interval.
In some embodiments, the one or more additional beneficial effects comprise an improvement
in one or more cardiovascular indications. In some embodiments, the improvement in one or more
cardiovascular indications comprises one or more of a reduction in systolic and diastolic blood pressure
(SBP and DBP, respectively), a decrease in heart rate, a decrease in total cholesterol, a decrease in LDL
cholesterol, a decrease in HDL cholesterol, and/or a decrease in triglyceride levels.
In some embodiments, the one or more additional beneficial effects comprise a reduction in SBP.
In some embodiments, the reduction in SBP in an individual without type 2 diabetes is at least about 2
mmHg. In some embodiments, the reduction in SBP in an individual without type 2 diabetes is between 2
and 5 mmHg. In some embodiments, the reduction in SBP in an individual with type 2 diabetes is at least
about 2 mmHg. In some embodiments, the reduction in SBP in an individual with type 2 diabetes is
between about 2 and 5 mmHg. In some embodiments, the reduction in SBP in an individual with baseline
impaired fasting glucose is at least about 1 mmHg. In some embodiments, the reduction in SBP in an
individual with baseline impaired fasting glucose is between about 1 and 5 mmHg.
In some embodiments, the one or more additional beneficial effects comprise a reduction in
DBP. In some embodiments, the reduction in DBP in an individual without type 2 diabetes is at least about
1 mmHg. In some embodiments, the reduction in DBP in an individual without type 2 diabetes is at least
between about 1 and 5 mmHg. In some embodiments, the reduction in DBP in an individual with type 2
diabetes is at least about 1 mmHg. In some embodiments, the reduction in DBP in an individual with type
2 diabetes is between about 1 and 5 mmHg. In some embodiments, the reduction in DBP in an individual
with baseline impaired fasting glucose is at least about 1 mmHg. In some embodiments, the reduction in
DBP in an individual with baseline impaired fasting glucose is between about 1 and 5 mmHg.
In some embodiments, the one or more additional beneficial effects comprise a reduction in heart
rate. In some embodiments, the reduction in heart rate in an individual without type 2 diabetes is at least
about 2 BPM. In some embodiments, the reduction in heart rate in an individual without type 2 diabetes is
between about 2 and 5 BPM. In some embodiments, the reduction in heart rate in an individual with type 2
diabetes is at least about 2 BPM. In some embodiments, the reduction in heart rate in an individual with
type 2 diabetes is between about 2 and 5 BPM. In some embodiments, the reduction in heart rate in an
individual with baseline impaired fasting glucose is at least about 2 BPM. In some embodiments, the
reduction in heart rate in an individual with baseline impaired fasting glucose is between about 2 and 5
BPM.
In some embodiments, the improvement in lipidemia comprises a decrease in total cholesterol
level. In some embodiments, the decrease in total cholesterol level in individuals without type 2 diabetes
is at least about 1 mg/dL. In some embodiments, the decrease in total cholesterol level in individuals
without type 2 diabetes is between about 1.5 and 2 mg/dL. In some embodiments, the decrease in total
cholesterol level in individuals with type 2 diabetes is at least about 0.5 mg/dL. In some embodiments,
the decrease in total cholesterol level in individuals with type 2 diabetes is between about 0.5 and 1
mg/dL. In some embodiments, the decrease in total cholesterol level in individuals with baseline
impaired fasting glucose is at least about 2 mg/dL. In some embodiments, the decrease in total
cholesterol level in individuals with baseline impaired fasting glucose is between about 2 and 3 mg/dL.
In some embodiments, the improvement in lipidemia comprises a decrease in LDL cholesterol
level. In some embodiments, the decrease in LDL cholesterol level in individuals without type 2
diabetes is at least about 1 mg/dL. In some embodiments, the decrease in LDL cholesterol level in
individuals without type 2 diabetes is between about 1 and 2 mg/dL. In some embodiments, the
decrease in LDL cholesterol level in individuals with type 2 diabetes is at least about 1 mg/dL. In some
embodiments, the decrease in LDL cholesterol level in individuals with type 2 diabetes is between about
1 and 1.5 mg/dL. In some embodiments, the decrease in LDL cholesterol level in individuals with
baseline impaired fasting glucose is at least about 2 mg/dL. In some embodiments, the decrease in LDL
cholesterol level in individuals with baseline impaired fasting glucose is between about 2 and 3 mg/dL.
In some embodiments, the improvement in lipidemia comprises a decrease in HDL cholesterol
level. In some embodiments, the decrease in HDL cholesterol level in individuals without type 2
diabetes is at least about 4 mg/dL. In some embodiments, the decrease in HDL cholesterol level in
individuals without type 2 diabetes is between about 3 and 6 mg/dL. In some embodiments, the
decrease in HDL cholesterol level in individuals with type 2 diabetes is at least about 5 mg/dL. In some
embodiments, the decrease in HDL cholesterol level in individuals with type 2 diabetes is between about
7 and 10 mg/dL. In some embodiments, the decrease in HDL cholesterol level in individuals with
baseline impaired fasting glucose is at least about 2 mg/dL. In some embodiments, the decrease in HDL
cholesterol level in individuals with baseline impaired fasting glucose is between about 2 and 3 mg/dL.
In some embodiments, the one or more additional beneficial effects comprise an improvement
in glycemia. In some embodiments, the improvement in glycemia comprises a reduction in fasting
plasma glucose and/or a reduction in glycated hemoglobin (Al C) levels. In some embodiments, the
improvement in glycemia comprises a reduction in fasting plasma glucose. In some embodiments, the
improvement in glycemia comprises a reduction in glycated hemoglobin (AlC) levels. In some
embodiments, the improvement in glycemia comprises a decrease in triglyceride levels.
The compounds provided herein can be administered in a wide variety of dosage forms.
In some embodiments, the compound selected from compounds of Table A, and salts,
hydrates, and solvates thereof is administered in a tablet suitable for oral administration.
In some embodiments, the active ingredient is formulated as an immediate-release dosage form
using, e.g., techniques known in the art. In some embodiments, the active ingredient is formulated as a
modified-release dosage form using, e.g., techniques known in the art. In some embodiments, the
active ingredient is formulated as a sustained-release dosage form using, e.g., techniques known in the
art. In some embodiments, the active ingredient is formulated as a delayed-release dosage form using,
e.g., techniques known in the art.
In some embodiments, the method comprises a plurality of administrations of the modified
release dosage form, with a frequency wherein the average interval between any two sequential
administrations is: at least about 24 hours; or about 24 hours.
In some embodiments, the method comprises a plurality of administrations of the modified
release dosage form, and the modified-release dosage form is administered once-a-day.
In some embodiments, the plurality of administrations is: at least about 30; at least about 180;
at least about 365; or at least about 730.
COMBINATION THERAPY
A compound or a pharmaceutically acceptable salt, hydrate or solvate thereof can be
administered as the sole active pharmaceutical agent (i.e., mono-therapy), or it can be used in
combination with one or more weight loss drug either administered together or separately. Provided are
methods for weight management, inducing satiety, decreasing food intake, aiding smoking cessation,
and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader
Willi syndrome, tobacco dependence, nicotine dependence, drug addiction, alcohol addiction,
pathological gambling, reward deficiency syndrome, sex addiction, obsessive-compulsive spectrum
disorders, impulse control disorders, nail-biting, onychophagia, sleep disorders, insomnia, fragmented
sleep architecture, disturbances of slow-wave sleep, urinary incontinence, psychiatric disorders,
schizophrenia, anorexia nervosa, bulimia nervosa, Alzheimer disease, sexual dysfunction, erectile
dysfunction, epilepsy, movement disorder, parkinsonism, antipsychotic-induced movement disorder,
hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep
apnea, comprising administering to an individual in need thereof a therapeutically effective amount of a
compound described herein, in combination with one or more weight loss drugs as described herein.
Also provided are methods for decreasing food intake in an individual in need thereof,
comprising administering to said individual a therapeutically effective amount of a compound described
herein, in combination with one or more weight loss drugs as described herein.
Also provided are methods for inducing satiety in an individual in need thereof, comprising
administering to said individual a therapeutically effective amount of a compound described herein, in
combination with one or more weight loss drugs as described herein.
Also provided are methods for the treatment of obesity in an individual in need thereof,
comprising administering to said individual a therapeutically effective amount of a compound described
herein, in combination with one or more weight loss drugs as described herein.
Also provided are methods for the prevention of obesity in an individual in need thereof,
comprising administering to said individual a therapeutically effective amount of a compound described
herein, in combination with one or more weight loss drugs as described herein.
Also provided are methods for weight management in an individual in need thereof, comprising
administering to said individual a therapeutically effective amount of a compound described herein, in
combination with one or more weight loss drugs as described herein.
Also provided are methods for preventing type 2 diabetes in an individual in need thereof,
comprising administering to said individual a therapeutically effective amount of a compound described
herein, in combination with one or more weight loss drugs as described herein.
When a compound disclosed herein is administered as a combination therapy with a weight loss
drug the compound and the weight loss drug can be formulated as separate pharmaceutical
compositions given at the same time or at different times; or the compound disclosed herein and the
pharmaceutical agent can be formulated together as a single unit dosage.
Provided are the compounds described herein for use in combination with a weight loss drug
for use in a method of treatment of the human or animal body by therapy.
Also provided are the compounds described herein for use in combination with a weight loss
drug for weight management, inducing satiety, decreasing food intake, aiding smoking cessation, and
for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi
syndrome, addiction, tobacco dependence, nicotine dependence, drug addiction, alcohol addiction,
pathological gambling, reward deficiency syndrome, sex addiction, obsessive-compulsive spectrum
disorders, impulse control disorders, nail-biting, onychophagia, sleep disorders, insomnia, fragmented
sleep architecture, disturbances of slow-wave sleep, urinary incontinence, psychiatric disorders,
schizophrenia, anorexia nervosa, bulimia nervosa, Alzheimer disease, sexual dysfunction, erectile
dysfunction, epilepsy, movement disorder, parkinsonism, antipsychotic-induced movement disorder,
hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep
apnea, comprising administering to an individual in need thereof a therapeutically effective amount of a
compound described herein, in combination with one or more weight loss drugs as described herein.
Also provided are the compounds described herein for use in combination with a weight loss
drug for decreasing food intake in an individual in need thereof, comprising administering to said
individual a therapeutically effective amount of a compound described herein, in combination with one
or more weight loss drugs as described herein.
Also provided are the compounds described herein for use in combination with a weight loss
drug for inducing satiety in an individual in need thereof, comprising administering to said individual a
therapeutically effective amount of a compound described herein, in combination with one or more
weight loss drugs as described herein.
Also provided are the compounds described herein for use in combination with a weight loss
drug for the treatment of obesity in an individual in need thereof, comprising administering to said
individual a therapeutically effective amount of a compound described herein, in combination with one
or more weight loss drugs as described herein.
Also provided are the compounds described herein for use in combination with a weight loss
drug for the prevention of obesity in an individual in need thereof, comprising administering to said
individual a therapeutically effective amount of a compound described herein, in combination with one
or more weight loss drugs as described herein.
Also provided are the compounds described herein for use in combination with a weight loss
drug for weight management in an individual in need thereof, comprising administering to said
individual a therapeutically effective amount of a compound described herein, in combination with one
or more weight loss drugs as described herein.
Also provided are the compounds described herein for use in combination with a weight loss
drug for treating type 2 diabetes in an individual in need thereof, comprising administering to said
individual a therapeutically effective amount of a compound described herein, in combination with one
or more weight loss drugs as described herein.
Also provided are the compounds described herein for use in combination with a weight loss
drug for preventing type 2 diabetes in an individual in need thereof, comprising administering to said
individual a therapeutically effective amount of a compound described herein, in combination with one
or more weight loss drugs as described herein.
In some embodiments, the compound described herein and the weight loss drug are
administered simultaneously.
In some embodiments, the compound described herein and the weight loss drug are
administered separately.
In some embodiments, the compound described herein and the weight loss drug are
administered sequentially.
In some embodiments, the weight loss drug chosen from sodium/glucose cotransporter-2
(SGLT2) inhibitors, lipase inhibitors, monoamine reuptake inhibitors, anticonvulsants, glucose
sensitizers, incretin mimetics, amylin analogs, GLP-1 analogs, Y receptor peptides, 5-HT c receptor
agonists, opioid receptor antagonists, appetite suppressants, anorectics, and hormones and the like,
either specifically disclosed herein or specifically disclosed in any reference recited herein just as if
each and every combination was individually and explicitly recited. In some embodiments, the weight
loss drug is chosen from dapagliflozin, canagliflozin, ipragliflozin, tofogliflozin, empagliflozin,
remogliflozin etabonate, orlistat, cetilistat, alaproclate, citalopram, dapoxetine, escitalopram,
femoxetine, fluoxetine, fluvoxamine, ifoxetine, indalpine, omiloxetine, panuramine, paroxetine,
pirandamine, sertraline, zimelidine, desmethylcitalopram, desmethylsertraline, didesmethylcitalopram,
seproxetine, cianopramine, litoxetine, lubazodone, trazodone, vilazodone, vortioxetine,
dextromethorphan, dimenhydrinate, diphenhydramine, mepyramine, pyrilamine, methadone,
propoxyphene, mesembrine, roxindole, amedalin, tomoxetine, daledalin, edivoxetine, esreboxetine,
lortalamine, mazindol, nisoxetine, reboxetine, talopram, talsupram, tandamine, viloxazine, maprotiline,
bupropion, ciclazindol, manifaxine, radafaxine, tapentadol, teniloxazine, ginkgo biloba, altropane,
difluoropine, iometopane, vanoxerine, medifoxamine, Chaenomeles speciosa, hyperforin, adhyperforin,
bupropion, pramipexole, cabergoline, venlafaxine, desvenlafaxine, duloxetine, milnacipran,
levomilnacipran, bicifadine, amineptine, desoxypipradrol, dexmethylphenidate, difemetorex,
diphenylprolinol, ethylphenidate, fencamfamine, fencamine, lefetamine, mesocarb,
methylenedioxypyrovalerone, methylphenidate, nomifensine, oxolinic acid, pipradrol, prolintane,
pyrovalerone, tametraline, nefopam, amitifadine, tesofensine, tedatioxetine, bicifadine, brasofensine,
diclofensine, taxil, naphyrone, hyperforin, topiramate, zonisamide, metformin, rosiglitazone,
pioglitazone, troglitazone, exenatide, liraglutide, taspoglutide, obinepitide, pramlintide, peptide YY,
vabicaserin, naltrexone, naloxone, phentermine, diethylpropion, oxymetazoline, benfluorex, butenolide
cathine, phenmetrazine, phenylpropanolamine, pyroglutamyl-histidyl-glycine, amphetamine,
benzphetamine, dexmethylphenidate, dextroamphetamine, methylenedioxypyrovalerone, glucagon,
lisdexamfetamine, methamphetamine, methylphenidate, phendimetrazine, phenethylamine, caffeine,
bromocriptine, ephedrine, pseudoephedrine, rimonabant, surinabant, mirtazapine, Dietex®, MG Plus
Protein™, insulin, and leptin and pharmaceutically acceptable salts and combinations thereof. In some
embodiments, the weight loss drug is phentermine.
In some embodiments, the weight management further comprises a surgical weight loss
procedure.
In some embodiments, the weight management further comprises a reduced-calorie diet.
In some embodiments, the weight management further comprises a program of regular
exercise.
In some embodiments, the individual has an initial body mass index 2': 25 kg/m .
In some embodiments, the individual has an initial body mass index 2': 27 kg/m .
In some embodiments, the individual has at least one weight related comorbid condition.
In some embodiments, the weight related comorbid condition is selected from: hypertension,
dyslipidemia, cardiovascular disease, glucose intolerance and sleep apnea.
In some embodiments, the weight related comorbid condition is selected from: hypertension,
dyslipidemia, and type 2 diabetes.
In some embodiments, the individual has an initial body mass index 2': 30 kg/m .
Also provided are methods for treating type 2 diabetes in an individual in need thereof,
comprising administering to said individual a therapeutically effective amount of a compound described
herein, in combination with one or more weight loss drugs as described herein.
REPRESENTATIVE METHODS
Provided are methods for decreasing food intake in an individual in need thereof, comprising
administering to said individual a therapeutically effective amount of a compound provided herein.
Also provided are methods for inducing satiety in an individual in need thereof, comprising
administering to said individual a therapeutically effective amount of a compound provided herein.
Also provided are methods for the treatment of obesity in an individual in need thereof,
comprising administering to said individual a therapeutically effective amount of a compound provided
herein.
Also provided are methods for the prevention of obesity in an individual in need thereof,
comprising administering to said individual a therapeutically effective amount of a compound provided
herein.
Also provided are methods for weight management in an individual in need thereof, comprising
administering to said individual a therapeutically effective amount of a compound provided herein.
In some embodiments, the weight management further comprises a surgical weight loss
procedure.
In some embodiments, the weight management further comprises a surgical weight loss
procedure.
In some embodiments, the weight management comprises weight loss.
In some embodiments, the weight management comprises maintenance of weight loss.
In some embodiments, the weight management further comprises a reduced-calorie diet.
In some embodiments, the weight management further comprises a program of regular
exercise.
In some embodiments, the weight management further comprises both a reduced-calorie diet
and a program of regular exercise.
In some embodiments, the individual in need of weight management is an obese patient with an
initial body mass index 2': 30 kg/m .
In some embodiments, the individual in need of weight management is an overweight patient
with an initial body mass index 2': 27 kg/m in the presence of at least one weight related comorbid
condition.
In some embodiments, the weight related co-morbid condition is selected from: hypertension,
dyslipidemia, cardiovascular disease, glucose intolerance and sleep apnea.
Also provided are methods for the treatment of antipsychotic-induced weight gain in an
individual in need thereof, comprising administering to said individual a therapeutically effective
amount of a compound provided herein.
Also provided are methods for the treatment of type 2 diabetes in an individual in need thereof,
comprising administering to said individual a therapeutically effective amount of a compound provided
herein.
Also provided are methods for the treatment of type 2 diabetes in an individual in need thereof,
comprising administering to said individual a therapeutically effective amount of a compound provided
herein combination with one or more type 2 diabetes medications.
In some embodiments, the need for the one or more type 2 diabetes treatments is reduced.
In some embodiments, the need for the one or more type 2 diabetes treatments is eliminated.
Also provided are methods for the prevention of type 2 diabetes in an individual in need
thereof, comprising administering to said individual a therapeutically effective amount of a compound
provided herein.
Also provided are methods for the treatment of Prader-Willi syndrome in an individual in need
thereof, comprising administering to said individual a therapeutically effective amount of a compound
provided herein.
Also provided are methods for the treatment of addiction in an individual in need thereof,
comprising administering to said individual a therapeutically effective amount of a compound provided
herein.
Also provided are methods for the treatment of drug and alcohol addiction in an individual in
need thereof, comprising administering to said individual a therapeutically effective amount of a
compound provided herein.
Also provided are methods for the treatment of alcohol addiction in an individual in need
thereof, comprising administering to said individual a therapeutically effective amount of a compound
provided herein.
Also provided are methods for the treatment of drug addiction in an individual in need thereof,
comprising administering to said individual a therapeutically effective amount of a compound provided
herein.
In some embodiments, the drug is selected from amphetamine, a substituted amphetamine, a
benzodiazepine, an atypical benzodiazepine receptor ligand, marijuana, cocaine, dextromethorphan,
GHB, LSD, ketamine, a monoamine reuptake inhibitor, nicotine, an opiate, PCP, a substituted
phenethylamine, psilocybin, and an anabolic steroid.
In some embodiments, the drug is nicotine.
In some embodiments, the drug is amphetamine.
In some embodiments, the drug is a substituted amphetamine.
In some embodiments, the drug is methamphetamine.
In some embodiments, the drug is a benzodiazepine.
In some embodiments, the drug is an atypical benzodiazepine receptor ligand.
In some embodiments, the drug is marijuana.
In some embodiments, the drug is cocaine.
In some embodiments, the drug is dextromethorphan.
In some embodiments, the drug is eszopiclone.
In some embodiments, the drug is GHB.
In some embodiments, the drug is LSD.
In some embodiments, the drug is ketamine.
In some embodiments, the drug is a monoamine reuptake inhibitor.
In some embodiments, the drug is an opiate.
In some embodiments, the drug is PCP.
In some embodiments, the drug is a substituted phenethylamine.
In some embodiments, the drug is psilocybin.
In some embodiments, the drug is an anabolic steroid.
In some embodiments, the drug is zolpidem.
Also provided are methods for aiding smoking cessation in an individual in need thereof,
comprising administering to said individual a therapeutically effective amount of a compound provided
herein.
Also provided are methods for the treatment of tobacco dependence in an individual in need
thereof, comprising administering to said individual a therapeutically effective amount of a compound
provided herein.
Also provided are methods for the treatment of nicotine dependence in an individual in need
thereof, comprising administering to said individual a therapeutically effective amount of a compound
provided herein.
Also provided are methods for the treatment of alcoholism in an individual in need thereof,
comprising administering to said individual a therapeutically effective amount of a compound provided
herein.
Also provided are methods for the treatment of pathological gambling in an individual in need
thereof, comprising administering to said individual a therapeutically effective amount of a compound
provided herein.
Also provided are methods for the treatment of reward deficiency syndrome in an individual in
need thereof, comprising administering to said individual a therapeutically effective amount of a
compound provided herein.
Also provided are methods for the treatment of sex addiction in an individual in need thereof,
comprising administering to said individual a therapeutically effective amount of a compound provided
herein.
Also provided are methods for the treatment of an obsessive-compulsive spectrum disorder in
an individual in need thereof, comprising administering to said individual a therapeutically effective
amount of a compound provided herein.
Also provided are methods for the treatment of an impulse control disorder in an individual in
need thereof, comprising administering to said individual a therapeutically effective amount of a
compound provided herein.
Also provided are methods for the treatment of nail-biting in an individual in need thereof,
comprising administering to said individual a therapeutically effective amount of a compound provided
herein.
Also provided are methods for the treatment of onychophagia in an individual in need thereof,
comprising administering to said individual a therapeutically effective amount of a compound provided
herein.
Also provided are methods for the treatment of a sleep disorder in an individual in need thereof,
comprising administering to said individual a therapeutically effective amount of a compound provided
herein.
Also provided are methods for the treatment of insomnia in an individual in need thereof,
comprising administering to said individual a therapeutically effective amount of a compound provided
herein.
Also provided are methods for the treatment of fragmented sleep architecture in an individual
in need thereof, comprising administering to said individual a therapeutically effective amount of a
compound provided herein.
Also provided are methods for the treatment of disturbances of slow-wave sleep in an
individual in need thereof, comprising administering to said individual a therapeutically effective
amount of a compound provided herein.
Also provided are methods for the treatment of urinary incontinence in an individual in need
thereof, comprising administering to said individual a therapeutically effective amount of a compound
provided herein.
Also provided are methods for the treatment of a psychiatric disorder in an individual in need
thereof, comprising administering to said individual a therapeutically effective amount of a compound
provided herein.
Also provided are methods for the treatment of schizophrenia in an individual in need thereof,
comprising administering to said individual a therapeutically effective amount of a compound provided
herein.
Also provided are methods for the treatment of anorexia nervosa in an individual in need
thereof, comprising administering to said individual a therapeutically effective amount of a compound
provided herein.
Also provided are methods for the treatment of bulimia nervosa in an individual in need
thereof, comprising administering to said individual a therapeutically effective amount of a compound
provided herein.
Also provided are methods for the treatment of Alzheimer disease in an individual in need
thereof, comprising administering to said individual a therapeutically effective amount of a compound
provided herein.
Also provided are methods for the treatment of sexual dysfunction in an individual in need
thereof, comprising administering to said individual a therapeutically effective amount of a compound
provided herein.
Also provided are methods for the treatment of erectile dysfunction in an individual in need
thereof, comprising administering to said individual a therapeutically effective amount of a compound
provided herein.
Also provided are methods for the treatment of a seizure disorder in an individual in need
thereof, comprising administering to said individual a therapeutically effective amount of a compound
provided herein.
Also provided are methods for the treatment of epilepsy in an individual in need thereof,
comprising administering to said individual a therapeutically effective amount of a compound provided
herein.
Also provided are methods for the treatment of Dravet syndrome in an individual in need
thereof, comprising administering to said individual a therapeutically effective amount of a compound
provided herein.
Also provided are methods for the treatment of Lennox-Gastaut syndrome in an individual in
need thereof, comprising administering to said individual a therapeutically effective amount of a
compound provided herein.
Also provided are methods for the treatment of a movement disorder in an individual in need
thereof, comprising administering to said individual a therapeutically effective amount of a compound
provided herein.
Also provided are methods for the treatment of parkinsonism in an individual in need thereof,
comprising administering to said individual a therapeutically effective amount of a compound provided
herein.
Also provided are methods for the treatment of antipsychotic-induced movement disorder in an
individual in need thereof, comprising administering to said individual a therapeutically effective
amount of a compound provided herein.
Also provided are methods for the treatment of hypertension in an individual in need thereof,
comprising administering to said individual a therapeutically effective amount of a compound provided
herein.
Also provided are methods for the treatment of dyslipidemia in an individual in need thereof,
comprising administering to said individual a therapeutically effective amount of a compound provided
herein.
Also provided are methods for the treatment of nonalcoholic fatty liver disease in an individual
in need thereof, comprising administering to said individual a therapeutically effective amount of a
compound provided herein.
Also provided are methods for the treatment of obesity-related renal disease in an individual in
need thereof, comprising administering to said individual a therapeutically effective amount of a
compound provided herein.
Also provided are methods for the treatment of sleep apnea in an individual in need thereof,
comprising administering to said individual a therapeutically effective amount of a compound provided
herein.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
decreasing food intake.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
inducing satiety of a compound provided herein.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of obesity.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the prevention of obesity.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
weight management.
In some embodiments, the weight management further comprises a surgical weight loss
procedure.
In some embodiments, the weight management comprises weight loss.
In some embodiments, the weight management comprises maintenance of weight loss.
In some embodiments, the weight management further comprises a reduced-calorie diet.
In some embodiments, the weight management further comprises a program of regular
exercise.
In some embodiments, the weight management further comprises both a reduced-calorie diet
and a program of regular exercise.
In some embodiments, the individual in need of weight management is an obese patient with an
initial body mass index 2': 30 kg/m .
In some embodiments, the individual in need of weight management is an overweight patient
with an initial body mass index 2': 27 kg/m in the presence of at least one weight related comorbid
condition.
In some embodiments, the weight related co-morbid condition is selected from: hypertension,
dyslipidemia, cardiovascular disease, glucose intolerance and sleep apnea.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of antipsychotic-induced weight gain.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of type 2 diabetes.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of type 2 diabetes in combination with one or more type 2 diabetes medications.
In some embodiments, the need for the one or more type 2 diabetes treatments is reduced.
In some embodiments, the need for the one or more type 2 diabetes treatments is eliminated.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the prevention of type 2 diabetes.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of Prader-Willi syndrome.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of addiction.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of drug and alcohol addiction.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of alcohol addiction.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of drug addiction.
In some embodiments, the drug is selected from amphetamine, a substituted amphetamine, a
benzodiazepine, an atypical benzodiazepine receptor ligand, marijuana, cocaine, dextromethorphan,
GHB, LSD, ketamine, a monoamine reuptake inhibitor, nicotine, an opiate, PCP, a substituted
phenethylamine, psilocybin, and an anabolic steroid.
In some embodiments, the drug is nicotine.
In some embodiments, the drug is amphetamine.
In some embodiments, the drug is a substituted amphetamine.
In some embodiments, the drug is methamphetamine.
In some embodiments, the drug is a benzodiazepine.
In some embodiments, the drug is an atypical benzodiazepine receptor ligand.
In some embodiments, the drug is marijuana.
In some embodiments, the drug is cocaine.
In some embodiments, the drug is dextromethorphan.
In some embodiments, the drug is eszopiclone.
In some embodiments, the drug is GHB.
In some embodiments, the drug is LSD.
In some embodiments, the drug is ketamine.
In some embodiments, the drug is a monoamine reuptake inhibitor.
In some embodiments, the drug is an opiate.
In some embodiments, the drug is PCP.
In some embodiments, the drug is a substituted phenethylamine.
In some embodiments, the drug is psilocybin.
In some embodiments, the drug is an anabolic steroid.
In some embodiments, the drug is zolpidem.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
aiding smoking cessation.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of tobacco dependence.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of nicotine dependence.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of alcoholism.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of pathological gambling.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of reward deficiency syndrome.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of sex addiction.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of an obsessive-compulsive spectrum disorder.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of an impulse control disorder.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of nail-biting.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of onychophagia.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of a sleep disorder.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of insomnia.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of fragmented sleep architecture.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of disturbances of slow-wave sleep.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of urinary incontinence.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of a psychiatric disorder.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of schizophrenia.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of anorexia nervosa.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of bulimia nervosa.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of Alzheimer disease.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of sexual dysfunction.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of erectile dysfunction.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of a seizure disorder.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of epilepsy.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of Dravet syndrome.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of Lennox-Gastaut syndrome.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of a movement disorder.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of parkinsonism.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of antipsychotic-induced movement disorder.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of hypertension.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of dyslipidemia.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of nonalcoholic fatty liver disease.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of obesity-related renal disease.
Also provided are uses of a compound provided herein for the manufacture of a medicament for
the treatment of sleep apnea.
In some embodiments, the individual is also being prescribed and/or administered a
supplemental agent.
Also provided is a composition comprising a compound selected from compounds of Table A,
and salts, hydrates, and solvates thereof and at least one supplemental agent.
As used herein, "supplemental agent" refers to an additional therapeutic agent which
complements the activity of the 5-HT c agonists described herein as it relates to methods for reducing
the frequency of smoking tobacco in an individual attempting to reduce frequency of smoking tobacco;
aiding in the cessation or lessening of use of a tobacco product in an individual attempting to cease or
lessen use of a tobacco product; aiding in smoking cessation and preventing associated weight gain;
controlling weight gain associated with smoking cessation by an individual attempting to cease
smoking tobacco; reducing weight gain associated with smoking cessation by an individual attempting
to cease smoking tobacco; treating nicotine dependency, addiction and/or withdrawal in an individual
attempting to treat nicotine dependency, addiction and/or withdrawal; or reducing the likelihood of
relapse use of nicotine by an individual attempting to cease nicotine use. In some embodiments, the
"supplemental agent" is not phentermine.
Supplemental agents include nicotine replacement therapies, antidepressants and anxiolytics
such as selective serotonin reuptake inhibitors, e.g., citalopram, escitalopram, fluoxetine, paroxetine,
sertraline, and the like. Serotonin and norepinephrine reuptake inhibitors, such as duloxetine,
venlafaxine, and the like may also be used. Norepinephrine and dopamine reuptake inhibitors such as
bupropion may also be used. Tetracyclic antidepressants such as mirtazapine; combined reuptake
inhibitors and receptor blockers such as trazodone, nefazodone, maprotiline; tricyclic antidepressants,
such as amitriptyline, amoxapine, desipramine, doxepin, imipramine, nortriptyline, protriptyline and
trimipramine; monoamine oxidase inhibitors, such as phenelzine, tranylcypromine, isocarboxazid,
selegiline; benzodiazepines such as lorazepam, clonazepam, alprazolam, and diazepam; serotonin IA
receptor agonists such as buspirone, aripiprazole, quetiapine, tandospirone and bifeprunox; and a beta
adrenergic receptor blocker, such as propranolol may also be used. Other supplemental agents include
other pharmacologic agents such as UTP, amiloride, antibiotics, bronchodilators, anti-inflammatory
agents, and mucolytics (e.g., n-acetyl-cysteine).
In some embodiments, the supplemental agent is chosen from nicotine replacement therapies.
In some embodiments, the nicotine replacement therapy is chosen from nicotine gum, nicotine
transdermal systems, nicotine lozenges, nicotine microtabs, and nicotine sprays or inhalers. In some
embodiments, the supplemental agent is an electronic cigarette.
In some embodiments, the supplemental agent is nicotine gum, and the composition is a
composition comprising a compound selected from compounds of Table A, and salts, hydrates, and
solvates thereof and nicotine gum.
In some embodiments, the supplemental agent is a nicotine transdermal system, and the
composition is a composition comprising a compound selected from compounds of Table A, and salts,
hydrates, and solvates thereof and a nicotine transdermal system.
In some embodiments, the supplemental agent is nicotine lozenges, and the composition is a
composition comprising a compound selected from compounds of Table A, and salts, hydrates, and
solvates thereof and nicotine lozenges.
In some embodiments, the supplemental agent is nicotine microtabs, and the composition is a
composition comprising a compound selected from compounds of Table A, and salts, hydrates, and
solvates thereof and nicotine microtabs.
In some embodiments, the supplemental agent is nicotine sprays or inhalers, and the
composition is a composition comprising a compound selected from compounds of Table A, and salts,
hydrates, and solvates thereof and nicotine sprays or inhalers.
In some embodiments, the supplemental agent is an electronic cigarette, and the composition is
a composition comprising a compound selected from compounds of Table A, and salts, hydrates, and
solvates thereof and an electronic cigarette.
In some embodiments, the supplemental agent is chosen from antidepressants, and the
composition is a composition comprising a compound selected from compounds of Table A, and salts,
hydrates, and solvates thereof and a supplemental agent chosen from antidepressants.
In some embodiments, the supplemental agent is an antidepressant, and the composition is a
composition comprising a compound selected from compounds of Table A, and salts, hydrates, and
solvates thereof and an antidepressant.
In some embodiments, the compound selected from compounds of Table A, and salts, hydrates,
and solvates thereof and the antidepressant are formulated as a fixed dose combination product.
In some embodiments, the compound selected from compounds of Table A, and salts, hydrates,
and solvates thereof and the antidepressant are formulated as a co-packaged product.
In some embodiments, the compound selected from compounds of Table A, and salts, hydrates,
and solvates thereof and the antidepressant are formulated for adjunctive therapy.
In some embodiments, the supplemental agent is nortriptyline, and the composition is a
composition comprising a compound selected from compounds of Table A, and salts, hydrates, and
solvates thereof and nortriptyline.
In some embodiments, the compound selected from compounds of Table A, and salts, hydrates,
and solvates thereof and the nortriptyline are formulated as a fixed dose combination product.
In some embodiments, the compound selected from compounds of Table A, and salts, hydrates,
and solvates thereof and the nortriptyline are formulated as a co-packaged product.
In some embodiments, the compound selected from compounds of Table A, and salts, hydrates,
and solvates thereof and the nortriptyline are formulated for adjunctive therapy.
In some embodiments, the supplemental agent is nortriptyline, and the composition is a
composition comprising a compound selected from compounds of Table A, and salts, hydrates, and
solvates thereof and bupropion.
In some embodiments, the compound selected from compounds of Table A, and salts, hydrates,
and solvates thereof and the bupropion are formulated as a fixed dose combination product.
In some embodiments, the compound selected from compounds of Table A, and salts, hydrates,
and solvates thereof and the bupropion are formulated as a co-packaged product.
In some embodiments, the compound selected from compounds of Table A, and salts, hydrates,
and solvates thereof and the bupropion are formulated for adjunctive therapy.
In some embodiments, the supplemental agent is nortriptyline, and the composition is a
composition comprising a compound selected from compounds of Table A, and salts, hydrates, and
solvates thereof and clonidine.
In some embodiments, the compound selected from compounds of Table A, and salts, hydrates,
and solvates thereof and the clonidine are formulated as a fixed dose combination product.
In some embodiments, the compound selected from compounds of Table A, and salts, hydrates,
and solvates thereof and the clonidine are formulated as a co-packaged product.
In some embodiments, the compound selected from compounds of Table A, and salts, hydrates,
and solvates thereof and the clonidine are formulated for adjunctive therapy.
In some embodiments, the supplemental agent is nortriptyline, and the composition is a
composition comprising a compound selected from compounds of Table A, and salts, hydrates, and
solvates thereof and varenicline.
In some embodiments, the compound selected from compounds of Table A, and salts, hydrates,
and solvates thereof and the varenicline are formulated as a fixed dose combination product.
In some embodiments, the compound selected from compounds of Table A, and salts, hydrates,
and solvates thereof and the varenicline are formulated as a co-packaged product.
In some embodiments, the compound selected from compounds of Table A, and salts, hydrates,
and solvates thereof and the varenicline are formulated for adjunctive therapy.
In some embodiments, the individual has previously undergone treatment with a supplemental
agent. In some embodiments, the individual was refractory to the previous treatment with the
supplemental agent.
In some embodiments, the individual has previously undergone treatment with a nicotine
replacement therapy. In some embodiments, the individual was refractory to the previous treatment
with the nicotine replacement therapy.
Also provided is a composition comprising a compound selected from compounds of Table A,
and salts, hydrates, and solvates thereof and at least one supplemental agent for:
reducing the frequency of smoking tobacco in an individual attempting to reduce frequency of smoking
tobacco;
aiding in the cessation or lessening of use of a tobacco product in an individual attempting to cease or
lessen use of a tobacco product;
aiding in smoking cessation and preventing associated weight gain;
controlling weight gain associated with smoking cessation by an individual attempting to cease
smoking tobacco;
reducing weight gain associated with smoking cessation by an individual attempting to cease smoking
tobacco;
treating nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine
dependency, addiction and/or withdrawal; or
reducing the likelihood of relapse use of nicotine by an individual attempting to cease nicotine use.
Also provided is a composition comprising a compound selected from compounds of Table A,
and salts, hydrates, and solvates thereof and at least one supplemental agent for use as a medicament
for:
reducing the frequency of smoking tobacco in an individual attempting to reduce frequency of smoking
tobacco;
aiding in the cessation or lessening of use of a tobacco product in an individual attempting to cease or
lessen use of a tobacco product;
aiding in smoking cessation and preventing associated weight gain;
controlling weight gain associated with smoking cessation by an individual attempting to cease
smoking tobacco;
reducing weight gain associated with smoking cessation by an individual attempting to cease smoking
tobacco;
treating nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine
dependency, addiction and/or withdrawal; or
reducing the likelihood of relapse use of nicotine by an individual attempting to cease nicotine use.
Also provided is a composition comprising a compound selected from compounds of Table A,
and salts, hydrates, and solvates thereof and at least one supplemental agent in the manufacture of a
medicament for: reducing the frequency of smoking tobacco in an individual attempting to reduce
frequency of smoking tobacco; aiding in the cessation or lessening of use of a tobacco product in an
individual attempting to cease or lessen use of a tobacco product; aiding in smoking cessation and
preventing associated weight gain; controlling weight gain associated with smoking cessation by an
individual attempting to cease smoking tobacco; reducing weight gain associated with smoking
cessation by an individual attempting to cease smoking tobacco; treating nicotine dependency,
addiction and/or withdrawal in an individual attempting to treat nicotine dependency, addiction and/or
withdrawal; or reducing the likelihood of relapse use of nicotine by an individual attempting to cease
nicotine use.
Also provided is a unit dosage form of a composition comprising a compound selected from
compounds of Table A, and salts, hydrates, and solvates thereof and at least one supplemental agent.
Also provided is a compound selected from compounds of Table A, and salts, hydrates, and
solvates thereof for use in combination with a supplemental agent, for: reducing the frequency of
smoking tobacco in an individual attempting to reduce frequency of smoking tobacco; aiding in the
cessation or lessening of use of a tobacco product in an individual attempting to cease or lessen use of a
tobacco product; aiding in smoking cessation and preventing associated weight gain; controlling
weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco;
reducing weight gain associated with smoking cessation by an individual attempting to cease smoking
tobacco; treating nicotine dependency, addiction and/or withdrawal in an individual attempting to treat
nicotine dependency, addiction and/or withdrawal; or reducing the likelihood of relapse use of nicotine
by an individual attempting to cease nicotine use.
Also provided is a supplemental agent chosen from nicotine replacement therapies, for use in
combination with a compound selected from compounds of Table A, and salts, hydrates, and solvates
thereof.
Also provided is a supplemental agent for use in combination with a compound selected from
compounds of Table A, and salts, hydrates, and solvates thereof for: reducing the frequency of
smoking tobacco in an individual attempting to reduce frequency of smoking tobacco; aiding in the
cessation or lessening of use of a tobacco product in an individual attempting to cease or lessen use of a
tobacco product; aiding in smoking cessation and preventing associated weight gain; controlling weight
gain associated with smoking cessation by an individual attempting to cease smoking tobacco; reducing
weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco;
treating nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine
dependency, addiction and/or withdrawal; or reducing the likelihood of relapse use of nicotine by an
individual attempting to cease nicotine use.
In some embodiments, the compound is formulated as an immediate-release dosage form and
the supplemental agent is also formulated as an immediate-release dosage form. In some embodiments,
the 5-HTc agonist is formulated as an immediate-release dosage form and the supplemental agent is
formulated as a modified-release dosage form. In some embodiments, the compound is formulated as a
modified-release dosage form and the supplemental agent is formulated as an immediate-release dosage
form. In some embodiments, the compound selected from compounds of Table A, and salts, hydrates,
and solvates thereof is formulated as a modified-release dosage form and the supplemental agent is also
formulated as a modified-release dosage form.
The compound selected from compounds of Table A, and salts, hydrates, and solvates thereof
may be administered sequentially or concurrently with the one or more other supplemental agents
identified herein. The amounts of formulation and pharmacologic agent depend, for example, on what
type of pharmacologic agent(s) are used, and the scheduling and routes of administration
Supplemental agents may be delivered concomitantly with the compounds selected from
compounds of Table A, and salts, hydrates, and solvates thereof, or may be administered independently.
Supplemental agent delivery may be via any suitable method known in the art including orally,
inhalation, injection, etc.
In some embodiments, the methods described herein further comprise the step of: providing the
individual with educational materials and/or counseling. In some embodiments, the counseling relates
to smoking cessation. In some embodiments, the counseling relates to weight management, including
without limitation counseling regarding diet and exercise. In some embodiments, the counseling relates
to both smoking cessation and weight management, including without limitation counseling regarding
diet and exercise.
In some embodiments, the methods described herein further comprise the step of: providing the
individual with biochemical feedback; acupuncture; hypnosis; behavioral intervention; support services;
and/or psychosocial treatment.
It will be apparent to those skilled in the art that the dosage forms described herein may
comprise, as the active component, either a compound described herein, a pharmaceutically acceptable
salt of a compound described herein, a solvate or hydrate of a compound described herein, or a solvate
or hydrate of a pharmaceutically acceptable salt of a compound described herein. Moreover, various
hydrates and solvates of the compounds described herein and their salts will find use as intermediates in
the manufacture of pharmaceutical compositions. Typical procedures for making and identifying
suitable hydrates and solvates, outside those mentioned herein, are well known to those in the art; see
for example, pages 202-209 of K.J. Guillory, "Generation of Polymorphs, Hydrates, Solvates, and
Amorphous Solids," in: Polymorphism in Pharmaceutical Solids, ed. Harry G. Britain, Vol. 95, Marcel
Dekker, Inc., New York, 1999. Accordingly, one aspect of the present disclosure pertains to methods of
administering hydrates and solvates of compounds described herein and/or their pharmaceutically
acceptable salts, that can be isolated and characterized by methods known in the art, such as,
thermogravimetric analysis (TGA), TGA-mass spectroscopy, TGA-Infrared spectroscopy, powder X
ray diffraction (XRPD), Karl Fisher titration, high resolution X-ray diffraction, and the like. There are
several commercial entities that provide quick and efficient services for identifying solvates and
hydrates on a routine basis. Example companies offering these services include Wilmington
PharmaTech (Wilmington, DE), Avantium Technologies (Amsterdam) and Aptuit (Greenwich, CT).
PSUEDOPOLYMORPHISM
Polymorphism is the ability of a substance to exist as two or more crystalline phases that have
different arrangements and/or conformations of the molecules in the crystal lattice. Polymorphs show
the same properties in the liquid or gaseous state but they may behave differently in the solid state.
Besides single-component polymorphs, drugs can also exist as salts and other multicomponent
crystalline phases. For example, solvates and hydrates may contain an API host and either solvent or
water molecules, respectively, as guests. Analogously, when the guest compound is a solid at room
temperature, the resulting form is often called a cocrystal. Salts, solvates, hydrates, and cocrystals may
show polymorphism as well. Crystalline phases that share the same API host, but differ with respect to
their guests, may be referred to as pseudopolymorphs of one another.
Solvates contain molecules of the solvent of crystallization in a definite crystal lattice. Solvates,
in which the solvent of crystallization is water, are termed hydrates. Because water is a constituent of
the atmosphere, hydrates of drugs may be formed rather easily.
Recently, polymorph screens of 245 compounds revealed that about 90% of them exhibited
multiple solid forms. Overall, approximately half the compounds were polymorphic, often having one
to three forms. About one-third of the compounds formed hydrates, and about one-third formed
solvates. Data from cocrystal screens of 64 compounds showed that 60% formed cocrystals other than
hydrates or solvates. (G. P. Stahly, Crystal Growth & Design (2007), 7(6), 1007-1026.)
ISOTOPES
The present disclosure includes all isotopes of atoms occurring in the present salts and
crystalline forms thereof. Isotopes include those atoms having the same atomic number but different
mass numbers. One aspect of the present invention includes every combination of one or more atoms in
the present salts and crystalline forms thereof that is replaced with an atom having the same atomic
number but a different mass number. One such example is the replacement of an atom that is the most
1 12
naturally abundant isotope, such as H or C, found in one the present salts and crystalline forms
thereof, with a different atom that is not the most naturally abundant isotope, such as H or H
1 11 13 14 12
(replacing H), or C, C, or C (replacing C). A salt wherein such a replacement has taken place is
commonly referred to as being isotopically-labeled. Isotopic-labeling of the present salts and crystalline
forms thereof can be accomplished using any one of a variety of different synthetic methods know to
those of ordinary skill in the art and they are readily credited with understanding the synthetic methods
and available reagents needed to conduct such isotopic-labeling. By way of general example, and
without limitation, isotopes of hydrogen include H (deuterium) and H (tritium). Isotopes of carbon
11 13 14 13 15 15 17
include C, C, and C. Isotopes of nitrogen include N and N. Isotopes of oxygen include 0, 0,
18 18 35
and C. An isotope of fluorine includes F. An isotope of sulfur includes S. An isotope of chlorine
36 75 76 77 82 123 124
. 1 d Cl I f b . . 1 d B B B d B I f . ct· . 1 d I I
me u es . sotopes o rorrnne me u e r, r, r, an r. sotopes o 10 me me u e , ,
12 131
5r, and I. Another aspect of the present invention includes compositions, such as, those prepared
during synthesis, preformulation, and the like, and pharmaceutical compositions, such as, those
prepared with the intent of using in a mammal for the treatment of one or more of the disorders
described herein, comprising one or more of the present salts and crystalline forms thereof, wherein the
naturally occurring distribution of the isotopes in the composition is perturbed. Another aspect of the
present invention includes compositions and pharmaceutical compositions comprising salts and
crystalline forms thereof as described herein wherein the salt is enriched at one or more positions with
an isotope other than the most naturally abundant isotope. Methods are readily available to measure
such isotope perturbations or enrichments, such as, mass spectrometry, and for isotopes that are radio
isotopes additional methods are available, such as, radio-detectors used in connection with HPLC or
Improving absorption, distribution, metabolism, excretion and toxicity (ADMET) properties
while maintaining a desired pharmacological profile is a major challenge in drug development.
Structural changes to improve ADMET properties often alter the pharmacology of a lead compound.
While the effects of deuterium substitution on ADMET properties are unpredictable, in select cases
deuterium can improve a compound's AD MET properties with minimal perturbation of its
pharmacology. Two examples where deuterium has enabled improvements in therapeutic entities are:
CTP-347 and CTP-354. CTP-347 is a deuterated version of paroxetine with a reduced liability for
mechanism-based inactivation of CYP2D6 that is observed clinically with paroxetine. CTP-354 is a
deuterated version of a promising preclinical gamma-aminobutyric acid A receptor (GABAA)
modulator (L-838417) that was not developed due to poor pharmacokinetic (PK) properties. In both
cases, deuterium substitution resulted in improved AD MET profiles that provide the potential for
improved safety, efficacy, and/or tolerability without significantly altering the biochemical potency and
selectivity versus the all-hydrogen compounds. Provided are deuterium substituted compounds of the
present invention with improved ADMET profiles and substantially similar biochemical potency and
selectivity versus the corresponding all-hydrogen compounds.
OTHER UTILITIES
Provided are radio-labeled compounds provided herein useful not only in radio-imaging but
also in assays, both in vitro and in vivo, for localizing and quantitating 5-HT c receptors in tissue
samples, including human, and for identifying 5-HT c receptor ligands by inhibition binding of a radio
labeled compound. Also provided are novel 5-HT c receptor assays of which comprise such radio
labeled compounds.
Certain isotopically-labeled compounds provided herein are useful in compound and/or
3 14
substrate tissue distribution assays. In some embodiments the radionuclide H and/or C isotopes are
useful in these studies. Further, substitution with heavier isotopes such as deuterium (i.e., H) may
afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo
half-life or reduced dosage requirements) and hence may be preferred in some circumstances.
Isotopically labeled compounds provided herein can generally be prepared by following procedures
analogous to those disclosed in the Drawings and Examples infra, by substituting an isotopically
labeled reagent for a non-isotopically labeled reagent. Other synthetic methods that are useful are
discussed infra.
Synthetic methods for incorporating radio-isotopes into organic compounds are applicable to
compounds provided herein and are well known in the art. These synthetic methods, for example,
incorporating activity levels of tritium into target molecules, include the following:
A. Catalytic Reduction with Tritium Gas: This procedure normally yields high specific activity
products and requires halogenated or unsaturated precursors.
B. Reduction with Sodium Borohydride [ H]: This procedure is rather inexpensive and requires
precursors containing reducible functional groups such as aldehydes, ketones, lactones, esters and the
like.
C. Reduction with Lithium Aluminum Hydride [3H]: This procedure offers products at almost
theoretical specific activities. It also requires precursors containing reducible functional groups such as
aldehydes, ketones, lactones, esters and the like.
D. Tritium Gas Exposure Labeling: This procedure involves exposing precursors containing
exchangeable protons to tritium gas in the presence of a suitable catalyst.
E. N-Methylation using Methyl Iodide [3H]: This procedure is usually employed to prepare 0-
methyl or N-methyl (3H) products by treating appropriate precursors with high specific activity methyl
iodide (3H). This method in general allows for higher specific activity, such as for example, about 70-
90 Ci/mmol.
Synthetic methods for incorporating activity levels of I into target molecules include:
A. Sandmeyer and like reactions: This procedure transforms an aryl amine or a heteroaryl
amine into a diazonium salt, such as a diazonium tetrafluoroborate salt and subsequently to I labeled
compound using Na I. A represented procedure was reported by Zhu, G-D. and co-workers in J. Org.
Chem., 2002, 67, 943-948.
125 125
B. Ortho Iodination of phenols: This procedure allows for the incorporation of I at the
ortho position of a phenol as reported by Collier, T. L. and co-workers in J. Labelled Compd.
Radiopharm., 1999, 42, S264-S266.
C. Aryl and heteroaryl bromide exchange with I: This method is generally a two step
process. The first step is the conversion of the aryl or heteroaryl bromide to the corresponding tri
alkyltin intermediate using for example, a Pd catalyzed reaction [e.g. Pd(Ph P) ] or through an aryl or
heteroaryl lithium, in the presence of a tri-alkyltinhalide or hexaalkylditin [e.g., (CH ) SnSn(CH ) ]. A
3 3 3 3
representative procedure was reported by Le Bas, M.-D. and co-workers in J. Labelled Compd.
Radiopharm. 2001, 44, S280-S282.
A radiolabeled compound disclosed herein can be used in a screening assay to identify/evaluate
compounds. In general terms, a newly synthesized or identified compound (i.e., test compound) can be
evaluated for its ability to reduce binding of a radio-labeled compound to a 5-HT c receptor. The ability
of a test compound to compete with a radio-labeled compound disclosed herein for the binding to a 5-
HT c receptor direct! y correlates to its binding affinity.
Certain labeled compounds provided herein bind to certain 5-HT c receptors. In one
embodiment the labeled compound has an IC less than about 500 µM. In one embodiment the labeled
compound has an IC less than about 100 µM. In one embodiment the labeled compound has an IC
50 50
less than about 10 µM. In one embodiment the labeled compound has an IC less than about 1 µM. In
one embodiment the labeled compound has an IC less than about 0.1 µM. In one embodiment the
labeled compound has an IC less than about 0.01 µM. In one embodiment the labeled compound has
an IC less than about 0.005 µM.
Other uses of the disclosed receptors and methods will become apparent to those skilled in the
art based upon, inter alia, a review of this disclosure.
COMPOSITIONS AND FORMULA TIO NS
Formulations may be prepared by any suitable method, typically by uniformly mixing the
active compound(s) with liquids or finely divided solid carriers, or both, in the required proportions and
then, if necessary, forming the resulting mixture into a desired shape.
Conventional excipients, such as binding agents, fillers, acceptable wetting agents, tabletting
lubricants and disintegrants can be used in tablets and capsules for oral administration. Liquid
preparations for oral administration can be in the form of solutions, emulsions, aqueous or oily
suspensions and syrups. Alternatively, the oral preparations can be in the form of dry powder that can
be reconstituted with water or another suitable liquid vehicle before use. Additional additives such as
suspending or emulsifying agents, non-aqueous vehicles (including edible oils), preservatives and
flavorings and colorants can be added to the liquid preparations. Parenteral dosage forms can be
prepared by dissolving the compound provided herein in a suitable liquid vehicle and filter sterilizing
the solution before filling and sealing an appropriate vial or ampule. These are just a few examples of
the many appropriate methods well known in the art for preparing dosage forms.
A compound provided herein can be formulated into pharmaceutical compositions using
techniques well known to those in the art. Suitable pharmaceutically-acceptable carriers, outside those
mentioned herein, are known in the art; for example, see Remington, The Science and Practice of
Phannacy, 20 h Edition, 2000, Lippincott Williams & Wilkins, (Editors: Gennaro et al.).
While it is possible that, for use in the prophylaxis or treatment, a compound provided herein
can, in an alternative use, be administered as a raw or pure chemical, it is preferable however to present
the compound or active ingredient as a pharmaceutical formulation or composition further comprising a
pharmaceutically acceptable carrier.
Pharmaceutical formulations include those suitable for oral, rectal, nasal, topical (including
buccal and sub-lingual), vaginal or parenteral (including intramuscular, sub-cutaneous and intravenous)
administration or in a form suitable for administration by inhalation, insufflation or by a transdermal
patch. Transdermal patches dispense a drug at a controlled rate by presenting the drug for absorption in
an efficient manner with minimal degradation of the drug. Typically, transdermal patches comprise an
impermeable backing layer, a single pressure sensitive adhesive and a removable protective layer with a
release liner. One of ordinary skill in the art will understand and appreciate the techniques appropriate
for manufacturing a desired efficacious transdermal patch based upon the needs of the artisan.
The compounds provided herein, together with a conventional adjuvant, carrier, or diluent, can
thus be placed into the form of pharmaceutical formulations and unit dosages thereof and in such form
may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions,
emulsions, elixirs, gels or capsules filled with the same, all for oral use, in the form of suppositories for
rectal administration; or in the form of sterile injectable solutions for parenteral (including
subcutaneous) use. Such pharmaceutical compositions and unit dosage forms thereof can comprise
conventional ingredients in conventional proportions, with or without additional active compounds or
principles and such unit dosage forms may contain any suitable effective amount of the active
ingredient commensurate with the intended daily dosage range to be employed.
For oral administration, the pharmaceutical composition may be in the form of, for example, a
tablet, capsule, suspension or liquid. The pharmaceutical composition is preferably made in the form of
a dosage unit containing a particular amount of the active ingredient. Examples of such dosage units are
capsules, tablets, powders, granules or a suspension, with conventional additives such as lactose,
mannitol, corn starch or potato starch; with binders such as crystalline cellulose, cellulose derivatives,
acacia, corn starch or gelatins; with disintegrators such as corn starch, potato starch or sodium
carboxymethyl-cellulose; and with lubricants such as talc or magnesium stearate. The active ingredient
may also be administered by injection as a composition wherein, for example, saline, dextrose or water
may be used as a suitable pharmaceutically acceptable carrier.
Compounds provided herein can be used as active ingredients in pharmaceutical compositions,
specifically as 5-HT c receptor modulators. The term "active ingredient", defined in the context of a
"pharmaceutical composition"," refers to a component of a pharmaceutical composition that provides
the primary pharmacological effect, as opposed to an "inactive ingredient" which would generally be
recognized as providing no pharmaceutical benefit.
The dose when using the compounds provided herein can vary within wide limits and as is
customary and is known to the physician, it is to be tailored to the individual conditions in each
individual case. It depends, for example, on the nature and severity of the illness to be treated, on the
condition of the individual, such as a patient, on the compound employed, on whether an acute or
chronic disease state is treated, or prophylaxis conducted, or on whether further active compounds are
administered in addition to the compounds provided herein. Representative doses include, but are not
limited to, about 0.001 mg to about 5000 mg, about 0.001 mg to about 2500 mg, about 0.001 mg to
about 1000 mg, about 0.001 mg to about 500 mg, about 0.001 mg to about 250 mg, about 0.001 mg to
100 mg, about 0.001 mg to about 50 mg and about 0.001 mg to about 25 mg. Multiple doses may be
administered during the day, especially when relatively large amounts are deemed to be needed, for
example 2, 3 or 4 doses. Depending on the individual and as deemed appropriate from the healthcare
provider it may be necessary to deviate upward or downward from the doses described herein.
All dosage amounts disclosed herein are calculated with respect to the active moiety, i.e., the
molecule or ion that gives the intended pharmacologic or physiologic action.
The amount of active ingredient, or an active salt or derivative thereof, required for use in
treatment will vary not only with the particular salt selected but also with the route of administration,
the nature of the condition being treated and the age and condition of the individual and will ultimately
be at the discretion of the attendant physician or clinician. In general, one skilled in the art understands
how to extrapolate in vivo data obtained in a model system, typically an animal model, to another, such
as a human. In some circumstances, these extrapolations may merely be based on the weight of the
animal model in comparison to another, such as a mammal, preferably a human, however, more often,
these extrapolations are not simply based on weights, but rather incorporate a variety of factors.
Representative factors include the type, age, weight, sex, diet and medical condition of the individual,
the severity of the disease, the route of administration, pharmacological considerations such as the
activity, efficacy, pharmacokinetic and toxicology profiles of the particular compound employed,
whether a drug delivery system is utilized, whether an acute or chronic disease state is being treated or
prophylaxis conducted or whether further active compounds are administered in addition to the
compounds provided herein such as part of a drug combination. The dosage regimen for treating a
disease condition with the compounds and/or compositions provided herein is selected in accordance
with a variety factors as cited above. Thus, the actual dosage regimen employed may vary widely and
therefore may deviate from a preferred dosage regimen and one skilled in the art will recognize that
dosage and dosage regimen outside these typical ranges can be tested and, where appropriate, may be
used in the methods disclosed herein.
The desired dose may conveniently be presented in a single dose or as divided doses
administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The
sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations.
The daily dose can be divided, especially when relatively large amounts are administered as deemed
appropriate, into several, for example 2, 3 or 4 part administrations. If appropriate, depending on
individual behavior, it may be necessary to deviate upward or downward from the daily dose indicated.
The compounds provided herein can be administered in a wide variety of oral and parenteral
dosage forms.
For preparing pharmaceutical compositions from the compounds provided herein, the selection
of a suitable pharmaceutically acceptable carrier can be either solid, liquid or a mixture of both. Solid
form preparations include powders, tablets, pills, capsules, cachets, suppositories and dispersible
granules. A solid carrier can be one or more substances which may also act as diluents, flavoring
agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents,
or an encapsulating material.
In powders, the carrier is a finely divided solid which is in a mixture with the finely divided
active component.
In tablets, the active component is mixed with the carrier having the necessary binding capacity
in suitable proportions and compacted to the desire shape and size.
The powders and tablets may contain varying percentage amounts of the active compound. A
representative amount in a powder or tablet may contain from 0.5 to about 90 percent of the active
compound; however, an artisan would know when amounts outside of this range are necessary. Suitable
carriers for powders and tablets are magnesium carbonate, magnesium stearate, talc, sugar, lactose,
pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low
melting wax, cocoa butter and the like. The term "preparation" refers to the formulation of the active
compound with encapsulating material as carrier providing a capsule in which the active component,
with or without carriers, is surrounded by a carrier, which is thus in association with it. Similarly,
cachets and lozenges are included. Tablets, powders, capsules, pills, cachets and lozenges can be used
as solid forms suitable for oral administration.
For preparing suppositories, a low melting wax, such as an admixture of fatty acid glycerides or
cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by
stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool
and thereby to solidify.
Formulations suitable for vaginal administration may be presented as pessaries, tampons,
creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are
known in the art to be appropriate.
Liquid form preparations include solutions, suspensions and emulsions, for example, water or
water-propylene glycol solutions. For example, parenteral injection liquid preparations can be
formulated as solutions in aqueous polyethylene glycol solution. Injectable preparations, for example,
sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art
using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation
may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or
solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that
may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile,
fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland
fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as
oleic acid find use in the preparation of injectables.
The compounds provided herein may thus be formulated for parenteral administration (e.g. by
injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in
ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added
preservative. The pharmaceutical compositions may take such forms as suspensions, solutions, or
emulsions in oily or aqueous vehicles and may contain formulatory agents such as suspending,
stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form,
obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a
suitable vehicle, e.g. sterile, pyrogen-free water, before use.
Aqueous formulations suitable for oral use can be prepared by dissolving or suspending the
active component in water and adding suitable colorants, flavors, stabilizing and thickening agents, as
desired.
Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active
component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose,
sodium carboxymethylcellulose, or other well-known suspending agents.
Also included are solid form preparations which are intended to be converted, shortly before
use, to liquid form preparations for oral administration. Such liquid forms include solutions,
suspensions and emulsions. These preparations may contain, in addition to the active component,
colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners,
solubilizing agents and the like.
For topical administration to the epidermis the compounds provided herein may be formulated
as ointments, creams or lotions, or as a transdermal patch.
Ointments and creams may, for example, be formulated with an aqueous or oily base with the
addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or
oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing
agents, suspending agents, thickening agents, or coloring agents.
Formulations suitable for topical administration in the mouth include lozenges comprising
active agent in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active
ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes
comprising the active ingredient in a suitable liquid carrier.
Solutions or suspensions are applied directly to the nasal cavity by conventional means, for
example with a dropper, pipette or spray. The formulations may be provided in single or multi-dose
form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an
appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be
achieved for example by means of a metering atomizing spray pump.
Administration to the respiratory tract may also be achieved by means of an aerosol
formulation in which the active ingredient is provided in a pressurized pack with a suitable propellant.
If the compounds provided herein or pharmaceutical compositions comprising them are administered as
aerosols, for example as nasal aerosols or by inhalation, this can be carried out, for example, using a
spray, a nebulizer, a pump nebulizer, an inhalation apparatus, a metered inhaler or a dry powder inhaler.
Pharmaceutical forms for administration of the compounds provided herein as an aerosol can be
prepared by processes well known to the person skilled in the art. For their preparation, for example,
solutions or dispersions of the compounds provided herein in water, water/alcohol mixtures or suitable
saline solutions can be employed using customary additives, for example benzyl alcohol or other
suitable preservatives, absorption enhancers for increasing the bioavailability, solubilizers, dispersants
and others and, if appropriate, customary propellants, for example include carbon dioxide, CFCs, such
as, dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane; and the like. The
aerosol may conveniently also contain a surfactant such as lecithin. The dose of drug may be controlled
by provision of a metered valve.
In formulations intended for administration to the respiratory tract, including intranasal
formulations, the compound will generally have a small particle size for example of the order of 10
microns or less. Such a particle size may be obtained by means known in the art, for example by
micronization. When desired, formulations adapted to give sustained release of the active ingredient
may be employed.
Alternatively the active ingredients may be provided in the form of a dry powder, for example,
a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such
as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP). Conveniently the powder carrier
will form a gel in the nasal cavity. The powder composition may be presented in unit dose form for
example in capsules or cartridges of, e.g., gelatin, or blister packs from which the powder may be
administered by means of an inhaler.
The pharmaceutical preparations are preferably in unit dosage forms. In such form, the
preparation is subdivided into unit doses containing appropriate quantities of the active component. The
unit dosage form can be a packaged preparation, the package containing discrete quantities of
preparation, such as packeted tablets, capsules and powders in vials or ampoules. Also, the unit dosage
form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of
these in packaged form.
Tablets or capsules for oral administration and liquids for intravenous administration are
preferred compositions.
The compounds provided herein may optionally exist as pharmaceutically acceptable salts
including pharmaceutically acceptable acid addition salts prepared from pharmaceutically acceptable
non-toxic acids including inorganic and organic acids. Representative acids include, but are not limited
to, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, dichloroacetic, formic,
fumaric, gluconic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic,
mandelic, methanesulfonic, mucic, nitric, oxalic, pamoic, pantothenic, phosphoric, succinic, sulfiric,
tartaric, oxalic, p-toluenesulfonic and the like. Certain compounds provided herein which contain a
carboxylic acid functional group may optionally exist as pharmaceutically acceptable salts containing
non-toxic, pharmaceutically acceptable metal cations and cations derived from organic bases.
Representative metals include, but are not limited to, aluminium, calcium, lithium, magnesium,
potassium, sodium, zinc and the like. In some embodiments the pharmaceutically acceptable metal is
sodium. Representative organic bases include, but are not limited to, benzathine (N ,N -dibenzylethane-
1,2-diamine ), chloroprocaine (2-( diethylamino )ethyl 4-( chloroamino )benzoate ), choline,
diethanolamine, ethylenediamine, meglumine ( (2R,3R,4R,5S)(methylamino )hexane-1,2,3,4,5-
pentaol), procaine (2-(diethylamino)ethyl 4-aminobenzoate), and the like. Certain pharmaceutically
acceptable salts are listed in Berge, et al., Journal of Phannaceutical Sciences, 66: 1-19 (1977).
The acid addition salts may be obtained as the direct products of compound synthesis. In the
alternative, the free base may be dissolved in a suitable solvent containing the appropriate acid and the
salt isolated by evaporating the solvent or otherwise separating the salt and solvent. The compounds
provided herein may form solvates with standard low molecular weight solvents using methods known
to the skilled artisan.
Compounds provided herein can be converted to "pro-drugs." The term "pro-drugs" refers to
compounds that have been modified with specific chemical groups known in the art and when
administered into an individual these groups undergo biotransformation to give the parent compound.
Pro-drugs can thus be viewed as compounds provided herein containing one or more specialized non
toxic protective groups used in a transient manner to alter or to eliminate a property of the compound.
In one general aspect, the "pro-drug" approach is utilized to facilitate oral absorption. A thorough
discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems Vol. 14 of the
A.C.S. Symposium Series; and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche,
American Pharmaceutical Association and Pergamon Press, 1987.
Some embodiments include a method of producing a pharmaceutical composition for
"combination-therapy" comprising admixing at least one compound according to any of the compound
embodiments disclosed herein, together with at least one known pharmaceutical agent as described
herein and a pharmaceutically acceptable carrier.
It is noted that when the 5-HT c receptor modulators are utilized as active ingredients in
pharmaceutical compositions, these are not intended for use in humans only, but in non-human
mammals as well. Recent advances in the area of animal health-care mandate that consideration be
given for the use of active agents, such as 5-HT c receptor modulators, for the treatment of a 5-HT c
receptor-associated disease or disorder in companionship animals (e.g., cats, dogs, etc.) and in livestock
animals (e.g., horses, cows, etc.) Those of ordinary skill in the art are readily credited with
understanding the utility of such compounds in such settings.
As will be recognized, the steps of the methods provided herein need not be performed any
particular number of times or in any particular sequence. Additional objects, advantages and novel
features of the invention(s) will become apparent to those skilled in the art upon examination of the
following examples thereof, which are intended to be illustrative and not intended to be limiting.
EXAMPLES
The compounds disclosed herein and their syntheses are further illustrated by the following
examples. The following examples are provided to further define the invention without, however,
limiting the invention to the particulars of these examples. The compounds described herein, supra and
infra, are named according to the AutoNom version 2.2, CS ChemDraw Ultra Version 9.0.7, or
ChemBioDraw Ultra 12.0.2.1076. In certain instances common names are used and it is understood that
these common names would be recognized by those skilled in the art.
Chemistry: Proton nuclear magnetic resonance (1H NMR) spectra were recorded on a Bruker
Avance III-400 equipped with a 5 mm BBFO probe. Chemical shifts are given in parts per million
(ppm) with the residual solvent signal used as reference. NMR abbreviations are used as follows: s =
singlet, d = doublet, dd = doublet of doublets, t = triplet, q = quartet, m = multiplet, bs = broad singlet,
sxt = sextet. Microwave irradiations were carried out using a Smith Synthesizer™ or an Emrys
Optimizer™ (Biotage). Thin-layer chromatography (TLC) was performed on silica gel 60 F (Merck),
preparatory thin-layer chromatography (prep TLC) was performed on PK6F silica gel 60 A 1 mm plates
(Whatman) and column chromatography was carried out on a silica gel column using Kieselgel 60,
0.063-0.200 mm (Merck). Evaporation was done under reduced pressure on a Biichi rotary evaporator.
Celite ® 545 was used for filtration of palladium.
LCMS spec: HPLC- Agilent 1200; pumps: G1312A; DAD:G1315B; Autosampler: G1367B;
Mass spectrometer-Agilent G1956A; ionization source: ESI; Drying Gas Flow:10 Umin; Nebulizer
Pressure: 40 psig; Drying Gas Temperature: 350 °C; Capillary Voltage: 2500 V) Software: Agilent
Chemstation Rev.B.04.03.
Example 1: Syntheses of Compounds of Table A
Example 1.1: Preparation of N-(2,2-difluoroethyl)methyl-1,2,3,4,6,7-hexahydro
[1,4]diazepino[ 6, 7 ,1-hi]indolecarboxamide ( Compound 1)
Step A: Preparation of methyl 3-formyl-lH-indolecarboxylate
2M solution of oxalyl dichloride in dichloromethane (DCM) (1.712 ml, 3.425 mmol) was
added to DCM (15 mL) cooled down in an ice-water bath. N,N-dimethylformamide (0.250 g, 3.425
mmol) was added dropwise under nitrogen. The reaction mixture was stirred at O °C for 30 min. Then
methyl lH-indolecarboxylate (0.5 g, 2.854 mmol) in DCM (10 mL) was added. The reaction mixture
was warmed to room temperature and stirred for 1 h. The solvent was removed. THF (15 mL) and 20%
aqueous ammonium acetate were added. The reaction mixture was stirred under reflux ( - 70 °C) for 30
min. The reaction mixture was then extracted with ethyl acetate. The combined organics ( organic
phases) were concentrated; the residue was purified by silica gel column chromatography with 90%
ethyl acetate/hexanes to give the title compound (551 mg, 95.0 % ) as white solid. LCMS m/z = 204.2
[M+H]\ H NMR (400 MHz, CDCh) o ppm 4.00 (s, 3H), 7.34 (t, J = 7.8 Hz, lH), 7.63 (dd, J = 8.0 and
1.0 Hz, lH), 7.87 (dd, J = 7.5 and 1.0 Hz, lH), 8.10 (d, J = 3.2 Hz, lH), 9.08 (br s, lH), 10.53 (s, lH).
Step B: Preparation of methyl 3-methyl-lH-indolecarboxylate
To a stirred solution of methyl 3-formyl-lH-indolecarboxylate (551 mg, 2.712 mmol) in
DMF (8 mL) was added 4-methylbenzenesulfonohydrazide (0.657 g, 3.525 mmol) followed by p-
toluenesulfonic acid monohydrate (77.37 mg, 0.407 mmol) and tetramethylene sulfone (sulfolane, 8
mL). The reaction mixture was stirred at 100 °C for 1 h, cooled to room temperature. Sodium
cyanoborohydride (0.682 g, 10.85 mmol) was added portionwise. Then the mixture was stirred at 100
°C for 2 h. The reaction mixture was cooled down, diluted with water, and extracted with 50% ethyl
acetate in hexanes. The organics were concentrated; the residue was purified by silica gel column
chromatography with 20% ethyl acetate/hexanes to give the title compound (355 mg, 69.2 % ) as off
white solid. LCMS m/z = 190.4 [M+H]\ H NMR (400 MHz, CDCh) o ppm 2.41 (d, J = 1.0 Hz, 3H),
3.96 (s, 3H), 7.07-7.10 (m, lH), 7.18 (t, J = 7.8 Hz, lH), 7.50 (dd, J = 8.0 and 1.0 Hz, lH), 7.64 (dd, J
= 7.5 and 1.0 Hz, lH), 8.12 (bs, lH).
Step C: Preparation of methyl 3-methylindolinecarboxylate
To a solution of methyl 3-methyl-lH-indolecarboxylate (1.253 g, 6.622 mmol) in TFA
(trifluoroacetic acid) (4.06 mL) in an ice-water bath was added triethylsilane (4.231 ml, 26.49 mmol)
dropwise under N . The reaction mixture was warmed to room temperature and stirred overnight. The
mixture was concentrated and added water. After adjusting pH to 8 with saturated aqueous NaHC0
solution, the mixture was extracted with ethyl acetate. The combined organics were concentrated. The
residue was purified by silica gel column chromatography with 25% ethyl acetate/hexanes (column
prewashed with 0.1 % Et N/hexanes) to give the title compound (1.013 g, 80.0 %) as orange-red oil.
LCMS m/z = 192.2 [M+H]\ H NMR (400 MHz, CDC1 ) o ppm 1.25 (d, J = 6.9 Hz, 3H), 3.25 (dd, J =
8.6 and 1.7 Hz, lH), 3.68 (t, J = 8.5 Hz, lH), 3.83-3.92 (m, lH), 3.90 (s, 3H), 6.78 (dd, J = 7.8 and 1.0
Hz, lH), 7.07 (t, J = 7.8 Hz, lH), 7.34 (dd, J = 7.8 and 1.0 Hz, lH).
Step D: Preparation of 2-tert-butyl 8-methyl 7-methyl-3,4,6,7-tetrahydro
[1,4]diazepino[ 6, 7 ,1-hi]indole-2,8(1H)-dicarboxylate
A mixture of methyl 3-methylindolinecarboxylate (1.013 g, 5.297 mmol) and 2-
bromoethanamine hydrobromide (1.302 g, 6.357 mmol) was heated at 115 °C overnight. The residue
was dissolved in methanol and purified by preparative HPLC (5-60% CH CN/H 0 with 0.1 % TFA over
min). The combined fractions were then concentrated to give methyl 1-(2-aminoethyl)
methylindolinecarboxylate. LCMS m/z = 235.4 [M+H]\ H NMR (400 MHz, CDC1 ) o ppm 1.24
(d, J = 7.0 Hz, 3H), 2.92-3.00 (m, 3H), 3.25 (dd, J = 8.5 and 1.7 Hz, lH), 3.30-3.40 (m, 2H), 3.80-3.90
(m, lH), 3.88 (s, 3H), 6.64 (d, J = 7.7 Hz, lH), 7.11 (t, J = 7.8 Hz, lH), 7.27 (dd, J = 7.9 and 0.8 Hz,
lH).
Methyl 1-(2-aminoethyl)methylindolinecarboxylate obtained above was dissolved in
methanol (10 mL), 37% formaldehyde in water (1.183 ml, 15.89 mmol) was added, followed by TFA
( 1.217 ml, 15 .89 mmol). The reaction mixture was heated at 80 °C for lh and concentrated. The residue
was dissolved in THF (8 mL), and added saturated aqueous NaHC0 (8 mL) solution and di-tert-butyl
dicarbonate (0.776 ml, 5.297 mmol). The reaction mixture was stirred at room temperature overnight,
diluted with water, and extracted with ethyl acetate. The combined organics were concentrated. The
residue was purified by silica gel column chromatography with 25% ethyl acetate/hexanes to give the
title compound (1.212 g, 66.0 %) as colorless oil. LCMS m/z = 347.2 [M+H]\ H NMR (400 MHz,
CDCh) o ppmrotamers 1.20 (d, J = 6.9 Hz, 3H), 1.35-1.45 (br, 9H), 2.80-2.95 (m, lH), 3.08-3.18
(m,lH), 3.24-3.35 (m, 2H), 3.35-3.45 (m, lH), 3.85-3.95 (m, lH), 3.86 (s, 3H), 3.97-4.08 (m, 2H),
4.62-4.88 (m, lH), 6.91-7.06 (m, lH), 7.36 (d, J = 8.0 Hz, lH).
Step E: Preparation of 2-( tert-butoxycarbonyl)methyl-1,2,3,4,6, 7-hexahydro
[1,4]diazepino[ 6,7 ,1-hi]indolecarboxylic acid
To a solution of 2-tert-butyl 8-methyl 7-methyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-
hi]indole-2,8(1H)-dicarboxylate (1.212 g, 3.499 mmol) in dioxane (10 mL) was added a IM solution of
lithium hydroxide in water (13.99 ml, 13.99 mmol). The reaction mixture was stirred at 80 °C for 2 h.
Organic solvent was evaporated. The residue was diluted with water, adjusted pH to 3-4 with aqueous
% citric acid. The off-white precipitate was collected and dried to give the title compound (1.116 g,
96.0 % ) as off-white solid. LCMS m/z = 333.4 [M+Ht.
Step F: Preparation of N-(2,2-difluoroethyl)methyl-1,2,3,4,6,7-hexahydro
[1,4]diazepino[ 6, 7 ,1-hi]indolecarboxamide
To the solution of 2-(tert-butoxycarbonyl)methyl-1,2,3,4,6,7-hexahydro
[1,4]diazepino[6,7,1-hi]indolecarboxylic acid (25 mg, 75.21 µmol), HATU (42.87 mg, 0.113 mmol)
and triethylamine (20.97 µL, 0.150 mmol) in DMF (2 mL) was added 2,2-difluoroethanamine (9.146
mg, 0.113 mmol). The reaction was stirred at room temperature overnight. The mixture was purified by
semi preparative HPLC (15-85% CH CN/H 0 with 0.1 % TFA over 30 min). The combined fractions
were lyophilized to give tert-butyl 8-((2,2-difluoroethyl)carbamoyl)methyl-3,4,6,7-tetrahydro
[1,4]diazepino[6,7, 1-hi]indole-2(1H)-carboxylate, which was dissolved in dioxane (0.5 mL). A solution
of 4M HCl in dioxane (0.5 mL) was added. The reaction mixture was stirred at room temperature for 4
hand concentrated. The residue was purified by semi preparative HPLC (5-60% CH CN/H 0 with
0.1 % TFA over 30 min). The combined fractions were lyophilized to give the title compound as TFA
salt (17 mg, 55.2 %). LCMS m/z = 296.2 [M+H]\ H NMR (400 MHz, CD 0D) o ppm 1.18 (d, J =
6.9 Hz, 3H), 3.10-3.20 (m, lH), 3.26-3.40 (m, 2H), 3.40-3.64 (m, 3H), 3.65-3.85 (m, 3H), 4.21 (d, J =
14.9 Hz, lH), 4.40 (d, J = 14.9 Hz, lH), 6.00 (tt, J = 56.0 and 3.9 Hz, lH), 6.99 (d, J = 7.8 Hz, lH),
7.12 (d, J = 7.9 Hz, lH).
Example 1.2: Preparation of (S)- N-(2,2-difluoroethyl)methyl-1,2,3,4,6,7-hexahydro
[1,4]diazepino[ 6,7 ,1-hi]indolecarboxamide (Compound 2) and (R)- N-(2,2-difluoroethyl)
methyl-1,2,3,4,6,7-hexahydro-[1,4]diazepino[ 6, 7 ,1-hi]indolecarboxamide ( Compound 3)
Enantiomers of N-(2,2-difluoroethyl)methyl-1,2,3,4,6, 7-hexahydro-[ 1,4 ]diazepino[6,7, 1-hi]indole
carboxamide were obtained by chiral HPLC separation using following conditions.
Column: Chiralpak IC column 250 x 20 mm (L x I.D.)
Flow: 12 mL/min
Eluent: 12 % ethanol/8 % mTBE/80 % hexanes with 0.1 % Et N
Detector: UV 254 nm
Retention time: 1st eluting enantiomer 22.0 min, 2nd eluting enantiomer 23.5 min
After separation, both enantiomers were further purified by semi preparative HPLC (5-60%
CH CN/H 0 with 0.1 % TFA (trifluoroacetic acid) over 30 min). The combined fractions were
lyophilized to give the title compounds as the TFA salt.
Example 1.3: Preparation of N-(2,2-difluoroethyl)-7, 7-dimethyl-1,2,3,4,6, 7-hexahydro
[1,4]diazepino[ 6, 7 ,1-hi]indolecarboxamide ( Compound 6)
Step A: Preparation of 3,3-dimethyl-3H-indolecarboxylic acid.
3-Hydrazinylbenzoic acid (3 g, 19.72 mmol) was added to a solution of isobutyraldehyde
(1.564 g, 21.69 mmol) in AcOH : H 0 (100 mL, 1: 1 ratio). The reaction mixture was heated at 60 °C
for 3 hours. After the mixture was cooled down in an ice-water bath, the precipitate was collected,
washed with ether, and dried to give the title compound (2.218 g) as a beige solid with about 90%
purity. LCMS m/z = 190.2 [M+H]\ H NMR (400 MHz, CD 0D) o 1.57 (s, 6H), 7.48 (t, J = 7.8 Hz,
lH), 7.76 (dd, J = 7.7 and 1.0 Hz, lH), 7.96 (dd, J = 7.9 and 0.9 Hz, lH), 8.16 (s, lH).
Step B: Preparation of methyl 3,3-dimethyl-3H-indolecarboxylate.
To a suspension of 3,3-dimethyl-3H-indolecarboxylic acid (1 g, 5.285 mmol) in 10 mL
DCM:MeOH (7:3) was added a 2M solution of (diazomethyl)trimethylsilane in ether (3.964 mL, 7.928
mmol) dropwise in an ice-water bath under nitrogen. The reaction mixture was stirred for 2 hours while
slowly warmed to room temperature. The reaction was quenched with water and extracted with DCM.
The combined organic fractions were concentrated. The residue was purified by silica gel column
chromatography to give the title compound (888 mg) as a colorless oil. LCMS m/z = 204.2 [M+H]\ H
NMR (400 MHz, CDCh) o 1.53 (s, 3H), 1.56 (s, 3H), 3.94 (s, 3H), 7.41 (t, J = 7.8 Hz, lH), 7.80 (dd, J
= 7.7 and 1.0 Hz, lH), 7.90 (dd, J = 7.9 and 0.9 Hz, lH), 8.00 (s, lH).
Step C: Preparation of methyl 3,3-dimethylindolinecarboxylate.
To a solution of methyl 3,3-dimethyl-3H-indolecarboxylate (888 mg, 4.369 mmol) in DCM
(15 mL) was added sodium triacetoxyborohydride (1.852 g, 8.739 mmol) under nitrogen in an ice-water
bath, then acetic acid (1.251 mL, 21.85 mmol) was added. The reaction was warmed to room
temperature and stirred for 2 hours. The reaction was quenched with saturated aqueous NaHC0
solution and extracted with DCM. The combined organic fractions were concentrated. The residue was
purified by silica gel column chromatography to give the title compound (761 mg) as colorless oil.
LCMS m/z = 206.2 [M+H]\ H NMR (400 MHz, CDCh) o 1.43 (s, 6H), 3.29 (s, 2H), 3.89 (s, 3H),
6.76 (dd, J = 7.7 and 1.1 Hz, lH), 7.06 (t, J = 7.7 Hz, lH), 7.13 (dd, J = 7.8 and 1.1 Hz, lH).
Step D: Preparation of methyl l-(2-aminoethyl)-3,3-dimethylindolinecarboxylate.
Methyl 3,3-dimethylindolinecarboxylate (0.43 g, 2.095 mmol) and 2-bromoethanamine
hydrobromide (0.451 g, 2.200 mmol) were heated neat (i.e., without solvent) at 120 °C for 15
hours. The solid mixture was dissolved in DMSO and purified by HPLC (10-70% CH CN/H 0 with
0.1 % TFA over 30 minutes). The combined fractions were adjusted to basic pH using saturated
NaHC0 , partially concentrated, extracted with ethyl acetate. The combined organic fractions were
dried over anhydrous Na S0 , filtered, then concentrated to give the title compound (243 mg). LCMS
m/z = 249.2 [M+H]\ H NMR (400 MHz, CD 0D) o 1.42 (s, 6H), 2.89 (t, J = 6.3 Hz, 2H), 3.13 (s,
2H), 3.17 (t, J = 6.4 Hz, 2H), 3.87 (s, 3H), 6.74 (dd, J = 7.9 and 0.9 Hz, lH), 7.02 (dd, J = 7.8 and 1.0
Hz, lH), 7.12 (t, J = 7.8 Hz, lH).
Step E: Preparation of 2-tert-butyl 8-methyl 7,7-dimethyl-3,4,6,7-tetrahydro-
[1,4]diazepino[ 6, 7 ,1-hi]indole-2,8(1H)-dicarboxylate.
To a solution of methyl l-(2-aminoethyl)-3,3-dimethylindolinecarboxylate (0.24 g, 0.966
mmol) and 37% formaldehyde in water (0.216 mL, 2.899 mmol) in methanol (6 mL) was added TFA
(0.444 mL, 5.799 mmol). The reaction was stirred at 80 °C for 1 hour. The mixture was concentrated.
The residue was dissolved in ethyl acetate. The organic phase was washed with aqueous saturated
NaHC0 , water and brine, dried with Na S0 , filtered, then concentrated to give crude methyl 7,7-
3 2 4
dimethyl-1,2,3,4,6,7-hexahydro-[1,4]diazepino[6,7,1-hi]indolecarboxylate. The crude product
obtained above was dissolved in DCM (6 mL), triethylamine (0.204 mL, 1.450 mmol) was added,
followed by di-tert-butyl dicarbonate (0.274 g, 1.256 mmol). The reaction mixture was stirred at room
temperature overnight. The reaction was concentrated. The residue was purified by silica gel column
chromatography to give the title compound (233 mg) as a colorless oil. LCMS m/z = 361.2 [M+H]\
H NMR (400 MHz, CDCh) o 1.39-1.42 (br, 15H), 3.02 (br, 2H), 3.13 (s, 2H), 3.72 (br, 2H), 3.88 (s,
3H), 4.36-4.44 (m, 2H), 6.91-7.05 (m, lH), 7.10 (d, J = 7.8 Hz, lH).
Step F: Preparation of 2-(tert-butoxycarbonyl)-7, 7-dimethyl-1,2,3,4,6,7-hexahydro-
[1,4]diazepino[ 6,7 ,1-hi]indolecarboxylic acid.
To a solution of 2-tert-butyl 8-methyl 7,7-dimethyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7, 1-
hi]indole-2,8(1H)-dicarboxylate (280 mg, 0.777 mmol) in THF (5 mL) was added IM solution of
lithium hydroxide in water (4.661 mL, 4.661 mmol). The reaction was stirred at 65 °C overnight. Three
equivalents more LiOH solution and dioxane (3 mL) were added. The reaction was heated at 85 °C for
5 hours. After the pH of the mixture was adjusted to 3-4, the mixture was extracted with ethyl acetate.
The combined organic fractions were concentrated. The residue was purified by HPLC. The fractions
were partially concentrated and extracted with ethyl acetate. The combined organic fractions were dried
over anhydrous Na S0 , filtered then concentrated to give the title compound (200 mg) as gum. LCMS
m/z = 347.2 [M+Ht.
Step G: Preparation of Compound 6.
To a solution of 2-(tert-butoxycarbonyl)-7,7-dimethyl-1,2,3,4,6,7-hexahydro
[1,4]diazepino[6,7,1-hi]indolecarboxylic acid (25 mg, 72.17 µmol), HATU (41.13 mg, 0.108 mmol)
and triethylamine (20.12 µL, 0.144 mmol) in DMF (8 mL) was added 2,2-difluoroethanamine (7.605
mg, 93.82 µmol). The reaction was stirred at room temperature overnight. The mixture was purified by
semi preparative HPLC (15-85% CH CN/H 0 with 0.1 % TFA over 30 min). The combined fractions
were neutralized with saturated aqueous NaHC0 , partially concentrated, and extracted with ethyl
acetate. The combined organics were dried then concentrated to give tert-butyl 8-((2,2-
difluoroethyl)carbamoyl)-7 ,7-dimethyl-3,4,6, 7-tetrahydro-[ 1,4]diazepino[ 6, 7, l-hi]indole-2( lH)
carboxylate, which was then dissolved in dioxane (0.5 mL). A solution of 4M HCl in dioxane (0.5 mL)
was added. The reaction mixture was stirred at room temperature for 5 h, then concentrated. The
residue was purified by semi preparative HPLC (5-60% CH CN/H 0 with 0.1 % TFA). The combined
fractions were lyophilized to give the title compound as TFA salt (20 mg, 65 .5 % ). LCMS m/z = 310.4
[M+H]\ H NMR (400 MHz, CD 0D) o ppm 1.38 (s, 6H), 3.20 (s, 2H), 3.22-3.26 (m, 2H), 3.50-3.54
(m, 2H), 3.65-3.75 (m, 2H), 4.31 (s, 2H), 6.00 (tt, J = 56.0 and 3.9 Hz, lH), 6.80 (d, J = 7.8 Hz, lH),
7.10 (d, J = 7.8 Hz, lH).
Example 1.4: Preparation of N-(2,2-difluoroethyl)-2,3,4,6-tetrahydro-lH-
spiro[[l,4]diazepino[ 6, 7 ,1-hi]indole-7 ,1 '-cyclobutane ]carboxamide ( Compound 7)
Step A: Preparation of tert-butyl 2-chloronitrobenzoate
To a suspension of 2-chloronitrobenzoic acid (1.278 g, 6.340 mmol) in toluene (12 mL)
under nitrogen was added 1,1-di-tert-butoxy-N,N-dimethylmethanamine (4.223 ml, 15.85 mmol). The
reaction was heated at 80°C overnight. The mixture was cooled to room temperature and concentrated
in vacuo. The residue was purified by silica gel column chromatography with 20% ethyl
acetate/hexanes to give the title compound (1.312 g, 80.3 % ) as yellow oil. LCMS m/z = 258.2
[M+H]\ H NMR (400 MHz, CDCh) o ppm 1.61 (s, 9H), 7.44 (t, J = 7.9 Hz, lH), 7.80 (dd, J = 7.7 and
1.6 Hz, lH), 7.83 (dd, J = 8.0 and 1.7 Hz, lH).
Step B: Preparation of diethyl 2-(2-(tert-butoxycarbonyl)nitrophenyl)malonate
To a solution of diethyl malonate (3.601 ml, 23.72 mmol) in DMSO (5 mL) was added a IM
solution of KOtBu in THF (23.72 ml, 23.72 mmol) under nitrogen at room temperature. After 20 min,
tert-butyl 2-chloronitrobenzoate (1.528 g, 5.930 mmol) in DMSO (5 mL) was added. The reaction
mixture was heated at 90 °C overnight, cooled down, poured into ice-water and extracted with ethyl
acetate. The combined organics were concentrated. The residue was purified by silica gel column
chromatography with 20% ethyl acetate/hexanes to give the title compound (1.17 g, 51.7 % ) as oil.
Exact mass calculated for C H N0 : 381.1, found LCMS m/z = 382.2 [M+H]\ H NMR (400 MHz,
18 23 8
CDCh) o ppm 1.26 (t, J = 7.2 Hz, 2x3H), 1.58 (s, 9H), 4.15-4.30 (m, 4H), 5.88 (s, lH), 7.54 (t, J = 8.0
Hz, lH), 8.08 (dd, J = 7.8 and 1.4 Hz, lH), 8.13 (dd, J = 8.1 and 1.4 Hz, lH).
Step C: Preparation of tert-butyl 2-(2-ethoxyoxoethyl)nitrobenzoate
To a solution of diethyl 2-(2-(tert-butoxycarbonyl)nitrophenyl)malonate (400 mg, 1.049
mmol) in DMSO (8 mL) was added lithium chloride (88.93 mg, 2.098 mmol) and water (18.89 uL,
1.049 mmol). The reaction mixture was stirred at 140 °C for 3h, then 80 °C overnight. After added ice
water, the mixture was extracted with ethyl acetate. The combined organics were concentrated. The
residue was purified by silica gel column chromatography with 25% ethyl acetate/hexanes to give the
title compound (226 mg, 69.7 %). LCMS m/z = 310.4 [M+H]\ H NMR (400 MHz, CDCh) o ppm
1.26 (t, J = 7.1 Hz, 3H), 1.58 (s, 9H), 4.17 (q, J = 7.1 Hz, 2H), 4.25 (s, 2H), 7.48 (t, J = 8.0 Hz, lH),
8.00 (dd, J = 8.1 and 1.4 Hz, lH), 8.04 (dd, J = 7.8 and 1.4 Hz, lH).
Step D: Preparation of tert-butyl 2-(1-(ethoxycarbonyl)cyclobutyl)nitrobenzoate
To a suspension of sodium hydride (0.207 g, 5.173 mmol) in DMF (2 mL) was added tert-butyl
2-(2-ethoxyoxoethyl)nitrobenzoate (400 mg, 1.293 mmol) in DMF (4 mL) in an ice-water bath
under N2. The reaction mixture was stirred for 10 min, then 1,3-diiodopropane (0.179 ml, 1.552 mmol)
was added. The reaction mixture was stirred at room temperature for 5 h, saturated aqueous NH Cl was
added, extracted with ethyl acetate. The combined organics were concentrated, the residue was purified
by silica gel column chromatography with 20% ethyl acetate/hexanes to give (190 mg, 42.1 % ) as
oil. LCMS m/z = 350.4 [M+H]\ H NMR (400 MHz, CDCh) o ppm 1.25 (t, J = 7.1 Hz, 3H), 1.55 (s,
9H), 1.70-1.80 (m, lH), 2.26-2.48 (m, 3H), 2.74-2.86 (m, 2H), 4.22-4.32 (m, 2H), 7.38 (t, J = 7.9 Hz,
lH), 7.76-7.81 (m, 2H).
Step E: Preparation of tert-butyl 2' -oxospiro[ cyclobutane-1,3' -indoline ]-4' -carboxylate
To a solution oftert-butyl 2-(1-(ethoxycarbonyl)cyclobutyl)nitrobenzoate (190 mg, 0.544
mmol) in ethanol (8 mL) was added 10% palladium on carbon (0.116 g, 0.109 mmol). The reaction
mixture was degassed and charged with hydrogen with a balloon, then stirred at room temperature
overnight. The mixture was filtered. The filtrate was concentrated. The residue was purified by silica
gel column chromatography to give the title compound (77 mg, 51.8 %). LCMS m/z = 274.2 [M+H]\
H NMR (400 MHz, CDC1 ) o ppm 1.67 (s, 9H), 2.25-2.35 (m, lH), 2.40-2.55 (m, 3H), 3.02-3.10 (m,
2H), 7.06 (dd, J = 7.7 and 1.1 Hz, lH), 7.24 (t, J = 7.8 Hz, lH), 7.50 (dd, J = 8.0 and 1.1 Hz, lH), 9.23
(s, lH).
Step F: Preparation of tert-butyl spiro[cyclobutane-1,3'-indoline]-4'-carboxylate
To a solution oftert-butyl 2'-oxospiro[cyclobutane-1,3'-indoline]-4'-carboxylate (77 mg, 0.282
mmol) in THF (3 mL) was added a 2M solution ofborane dimethylsulfide in THF (0.704 ml, 1.409
mmol). The reaction was heated at reflux for 2 h. The mixture was cooled down in an ice-water bath.
Methanol (1 mL) was added dropwise. The reaction was heated at reflux for 1 h. The mixture was
concentrated, the residue was purified by silica gel column chromatography with 20% ethyl
acetate/hexanes (prewashed the column with 0.1 % Et N in hexanes) to give the title compound (36 mg,
49.3 %) as oil. LCMS m/z = 260.4 [M+H]\ H NMR (400 MHz, CDCh) o ppm 1.64 (s, 9H), 1.97-2.07
(m, 4H), 2.88-2.98 (m, 2H), 3.69 (s, 2H), 6.73-6.76 (m, lH), 7.03-7.06 (m, 2H).
Step G: Preparation of 1 '-(2-aminoethyl)spiro[ cyclobutane-1,3 '-indoline ]-4' -carboxylic
acid
A mixture of tert-butyl spiro[cyclobutane-1,3'-indoline]-4'-carboxylate (44 mg, 0.170 mmol)
and 2-bromoethanamine hydrobromide (41.71 mg, 0.204 mmol) was heated at 115 °C overnight. The
mixture was dissolved in methanol and purified by semi preparative HPLC (5-60% CH CN/H 0 with
0.1 % TFA over 30 min). The combined fractions were lyophilized to give the title compound as TFA
salt (22 mg, 36.0 %). LCMS m/z = 247.2 [M+Ht.
Step H: Preparation of 2-(tert-butoxycarbonyl)-2,3,4,6-tetrahydro-lH-
spiro[[l,4]diazepino[ 6, 7 ,1-hi]indole-7 ,1 '-cyclobutane ]carboxylic acid
To a solution of 1'-(2-aminoethyl)spiro[cyclobutane-1,3'-indoline]-4'-carboxylic acid (22 mg,
61.06 µmol) in methanol (1.5 mL) was added 37% formaldehyde in water (9.091 uL, 0.122 mmol)
followed by TFA (9.351 uL, 0.122 mmol). The reaction mixture was heated at 80 °C for 1 hand
concentrated. The residue was dissolved in THF (1.5 mL), added saturated aqueous NaHC0 (1 mL)
solution, followed by di-tert-butyl dicarbonate (17 .32 mg, 79.37 µmol). The reaction was stirred at
room temperature for 4 h. The mixture was diluted with water, adjusted to pH 4 with aqueous 5% citric
acid, and extracted with ethyl acetate. The combined organics were dried over anhydrous Na S0 ,
filtered then concentrated to give the crude acid, which was used for the next step without further
purification. LCMS m/z = 359.4 [M+Ht.
Step I: Preparation of N-(2,2-difluoroethyl)-2,3,4,6-tetrahydro-1H
spiro[[l,4]diazepino[ 6, 7 ,1-hi]indole-7 ,1 '-cyclobutane ]carboxamide
To a solution of 2-(tert-butoxycarbonyl)-2,3,4,6-tetrahydro-1H-spiro[[l,4]diazepino[6,7, 1-
hi]indole-7, 1 '-cyclobutane]carboxylic acid (10 mg, 27.90 µmol), HATU (15.90 mg, 41.85 µmol) and
triethylamine (7.777 uL, 55.80 µmol) in DMF (1 mL) was added 2,2-difluoroethanamine (2.9 mg,
36.27 µmol). The reaction was stirred at room temperature for 5 h. The mixture was purified by semi
prep HPLC (10-85% CH CN/H 0 with 0.1 % TFA over 30 min). The combined fractions were
lyophilized to give tert-butyl 8-((2,2-difluoroethyl)carbamoyl)-3,4-dihydro-1H
spiro[[l,4]diazepino[6,7, 1-hi]indole-7, 1 '-cyclobutane]-2(6H)-carboxylate, which was dissolved in
dioxane (0.5 mL). A solution of 4M HCl in dioxane (0.5 mL) was added. The reaction mixture was
stirred at room temperature for 4 h and concentrated. The residue was purified by semi preparative
HPLC (5-60% CH CN/H 0 with 0.1 % TFA over 30 min). The combined fractions were lyophilized to
give the title compound as TFA salt (8 mg, 65.9 %). LCMS m/z = 322.4 [M+H]\ H NMR (400 MHz,
CD 0D) o ppm 1.92-2.05 (m, 4H), 2.73-2.80 (m, 2H), 3.22-3.26 (m, 2H), 3.50-3.55 (m, 2H), 3.59 (s,
2H), 3.71-3.82 (m, 2H), 4.29 (s, 2H), 6.05 (tt, J = 56.1 and 3.9 Hz, lH), 6.83 (d, J = 7.8 Hz, lH), 7.10
(d, J = 7.8 Hz, lH).
Example 1.5: Preparation of (S)-N-(2,2-difluoroethyl)ethyl-1,2,3,4,6,7-hexahydro
[1,4]diazepino[6,7 ,1-hi]indolecarboxamide (Compound 4) and (R)-N-(2,2-difluoroethyl)
ethyl-1,2,3,4,6, 7-hexahydro-[1,4]diazepino[ 6,7 ,1-hi]indolecarboxamide ( Compound 5).
A) Preparation of N-(2,2-difluoroethyl)ethyl-1,2,3,4,6, 7-hexahydro-[1,4]diazepino[ 6, 7 ,1-
hi]indolecarboxamide.
Step A: Preparation of methyl 3-acetyl-lH-indolecarboxylate.
To a solution of methyl lH-indolecarboxylate (1 g, 5.708 mmol) in DCM (20 mL) was
added IM solution of diethylaluminum chloride (8.562 mL, 8.562 mmol) in an ice-water bath under
nitrogen. After 30 minutes, acetyl chloride (0.812 mL, 11.42 mmol) was added dropwise. The reaction
was stirred for 2 hours in an ice-water bath. The reaction was quenched with water, then added
saturated NaHC0 solution to adjust pH to 7. The mixture was extracted with ethyl acetate. The
combined organic fractions were concentrated. The residue was purified by silica gel column
chromatography to give the title compound (1.18 g) as an off-white solid. LCMS m/z = 218.2 [M+H]\
H NMR (400 MHz, CDCh) o 2.46 (s, 3H), 3.99 (s, 3H), 7.28 (dd, J = 8.2 and 7.4 Hz, lH), 7.43 (dd, J
= 7.4 and 1.0 Hz, lH), 7.46 (dd, J = 8.2 and 1.0 Hz, lH), 7.77 (d, J = 3.1 Hz, lH), 9.14 (bs, lH).
Step B: Preparation of methyl 3-ethyl-lH-indolecarboxylate.
To a solution of methyl 3-acetyl-lH-indolecarboxylate (400 mg, 1.841 mmol) in anhydrous
THF (10 mL) was added sodium borohydride (0.139 g, 3.683 mmol) under nitrogen in an ice-water
bath. Boron trifluoride diethyl etherate (0.700 mL, 5.524 mmol) was then added dropwise. The reaction
was stirred for 2 hours while warmed to room temperature. The reaction was poured into a mixture of
ice-water and 5% aqueous NaHC0 and extracted with ethyl acetate. The combined organic fractions
were concentrated. The residue was purified by silica gel column chromatography to give the title
compound (320 mg) as an oil. LCMS m/z = 204.4 [M+H]\ H NMR (400 MHz, CDCh) o 1.25 (t, J =
7.4 Hz, 3H), 2.87-2.94 (m, 2H), 3.97 (s, 3H), 7.11-7.14 (m, lH), 7.19 (t, J = 7.8 Hz, lH), 7.51 (dd, J =
8.1 and 1.0 Hz, lH), 7.60 (dd, J = 7.4 and 1.0 Hz, lH), 8.16 (bs, lH).
Step C: Preparation of methyl 3-ethylindolinecarboxylate.
To a solution of methyl 3-ethyl-lH-indolecarboxylate (320 mg, 1.575 mmol) in TFA (10
mL) in an ice-water bath was added IM solution of borane THF complex (2.677 mL, 2.677 mmol)
dropwise under nitrogen. The reaction was stirred for 30 minutes. A 20% NaOH solution was added to
neutralize the mixture. The mixture was then extracted with ethyl acetate. The combined organic
fractions were concentrated. The residue was purified by HPLC. The combined fractions were
neutralized with saturated NaHC0 , partially concentrated, and extracted with ethyl acetate. The
combined organic fractions were dried over anhydrous Na S0 , filtered, then concentrated to give the
title compound (270 mg) as a yellow oil. LCMS m/z = 206.2 [M+H]\ H NMR (400 MHz, CDCh) o
0.96 (t, J = 7.4 Hz, 3H), 1.50-1.70 (m, 2H), 3.42 (dd, J = 8.7 and 1.7 Hz, lH), 3.60 (t, J = 8.6 Hz, lH),
3.68-3.75 (m, lH), 3.88 (s, 3H), 6.77 (dd, J = 7.8 and 1.0 Hz, lH), 7.07 (t, J = 7.8 Hz, lH), 7.33 (dd, J
= 7.8 and 1.0 Hz, lH).
Step D: Preparation of methyl 1-(2-aminoethyl)ethylindolinecarboxylate.
Methyl 3-ethylindolinecarboxylate (205 mg, 0.999 mmol) and 2-bromoethanamine
hydrobromide (0.246 g, 1.199 mmol) were heated at 120 °C for 15 hours. The mixture was dissolved in
methanol and purified by HPLC to give the title compound as a TFA salt (148 mg). LCMS m/z = 249.4
[M+H]\ H NMR (400 MHz, CD 0D) o 1.00 (t, J = 7.4 Hz, 3H), 1.53-1.68 (m, 2H), 3.14-3.29 (m,
4H), 3.52 (dd, J = 8.8 and 1.8 Hz, lH), 3.57-3.65 (m, lH), 3.65-3.73 (m, lH), 3.88 (s, 3H), 6.81 (d, J =
7.5 Hz, lH), 7.17 (t, J = 7.8 Hz, lH), 7.31 (dd, J = 7.9 and 0.9 Hz, lH).
Step E: Preparation of 2-tert-butyl 8-methyl 7-ethyl-3,4,6,7-tetrahydro
[1,4]diazepino[ 6, 7 ,1-hi]indole-2,8(1H)-dicarboxylate.
To a solution of methyl 1-(2-aminoethyl)ethylindolinecarboxylate 2,2,2-trifluoroacetate
(140 mg, 0.386 mmol) and 37% formaldehyde in water (86.30 µl, 1.159 mmol) in methanol (5 mL) was
added TFA (0.148 mL, 1.932 mmol). The reaction was stirred at 80 °C for 2 hours. The mixture was
concentrated, The residue was dissolved in ethyl acetate. The organic solution was washed with
saturated NaHC0 , water and brine, dried with Na S0 , filtered, then concentrated to give crude methyl
3 2 4
7-ethyl-1,2,3,4,6,7-hexahydro-[1,4]diazepino[6,7,1-hi]indolecarboxylate. The crude product
obtained above was dissolved in DCM (5 mL). Triethylamine (81.43 µl, 0.580 mmol) was added,
followed by di-tert-butyl dicarbonate (0.110 g, 0.502 mmol). The reaction was stirred at room
temperature overnight. The mixture was concentrated. The residue was purified by silica gel column
chromatography to give the title compound (92 mg) as an oil. LCMS m/z = 361.2 [M+H]\ H NMR
(400 MHz, CDC1 ) o 0.95 (t, J = 7.4 Hz, 3H), 1.35-1.45 (br, 9H), 1.40-1.50 (m, lH), 1.54-1.64 (m, lH),
2.80-2.98 (m, lH), 3.10-3.18 (m,lH), 3.24 (t, J = 8.9 Hz, lH), 3.34-3.45 (m, 2H), 3.68-3.76 (m, lH),
3.87 (s, 3H), 3.97-4.08 (m, 2H), 4.62-4.88 (m, lH), 6.91-7.06 (m, lH), 7.36 (d, J = 8.0 Hz, lH).
Step F: Preparation of 2-(tert-butoxycarbonyl)ethyl-1,2,3,4,6,7-hexahydro-
[1,4]diazepino[ 6, 7 ,1-hi]indolecarboxylic acid.
To a solution of 2-tert-butyl 8-methyl 7-ethyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7, 1-
hi]indole-2,8(1H)-dicarboxylate (92 mg, 0.255 mmol) in dioxane (5 mL) was added IM solution of
lithium hydroxide in water (1.531 mL, 1.531 mmol). The reaction was stirred at 90 °C overnight. A 5%
citric acid solution was added to adjust the pH of the mixture to 3-4. The mixture was then extracted
with ethyl acetate. The combined organic fractions were concentrated to give the title compound (90
mg) as gum. LCMS m/z = 347.2 [M+Ht.
Step G: Preparation of N-(2,2-difluoroethyl)ethyl-1,2,3,4,6,7-hexahydro-[1,4]diazepino[ 6,7 ,1-
hi]indolecarboxamide
To the solution of 2-(tert-butoxycarbonyl)ethyl-1,2,3,4,6,7-hexahydro-[1,4]diazepino[6,7, 1-
hi]indolecarboxylic acid (50 mg, 0.144 mmol), HATU (82.27 mg, 0.216 mmol) and triethylamine
(40.23 µl, 0.289 mmol) in DMF (2 mL) was added 2,2-difluoroethanamine (17.55 mg, 0.216 mmol).
The reaction mixture was stirred at room temperature overnight. The crude was purified by semi
preparative HPLC (15-85% CH CN/H 0 with 0.1 % TFA over 30 min). The combined fractions were
lyophilized to give tert-butyl 8-((2,2-difluoroethyl)carbamoyl)ethyl-3,4,6,7-tetrahydro
[1,4]diazepino[6,7,1-hi]indole-2(1H)-carboxylate which was dissolved in dioxane (0.5 mL), 4M HCl in
dioxane (0.5 mL) was added. The reaction mixture was stirred at room temperature for 4 hr,
concentrated. The residue was purified by semi preparative HPLC (5-60% CH CN/H 0 with 0.1 % TFA
over 30 min). The combined fractions were lyophilized to give the title compound as the TFA salt (40
mg). LCMS m/z = 310.6 [M+Ht. H NMR (400 MHz, CD 0D) o 0.89 (t, J = 7.4 Hz, 3H), 1.40-1.52
(m, lH), 1.54-1.65 (m, lH), 3.09-3.18 (m, lH), 3.32-3.50 (m, 4H), 3.54-3.72 (m, 4H), 4.18 (d, J = 4.9
Hz, lH), 4.40 (d, J = 4.9 Hz, lH), 6.00 (tt, J = 56.0 and 3.9 Hz, lH), 6.98 (d, J = 7.8 Hz, lH), 7.12 (d, J
= 7.9 Hz, lH).
B) Enantiomers of N-(2,2-difluoroethyl)ethyl-1,2,3,4,6, 7-hexahydro-[ 1,4 ]diazepino[6,7, 1-hi]indole-
8-carboxamide were obtained by chiral HPLC separation using following conditions.
Column: Chiralpak IC column 250 x 20 mm (L x I.D.)
Flow: 10 mL/min
Eluent: 15 % ethanol/hexanes with 0.1 % Et N
Detector: UV 254 nm
Retention time: 1st eluting enantiomer 18.3 min, 2nd eluting enantiomer 20.5 min
After separation, both enantiomers were further purified by semi preparative HPLC (5-50%
CH CN/H 0 with 0.1 % TFA over 30 min). The combined fractions were lyophilized to give the title
compounds as TF A salt.
Example 1.6: Preparation of (S)-N-(2,2-difluoroethyl)(2,2,2-trifluoroethyl)-1,2,3,4,6,7-
hexahydro-[1,4]diazepino[6,7 ,1-hi]indolecarboxamide and (R)-N-(2,2-difluoroethyl)(2,2,2-
trifluoroethyl)-1,2,3,4,6, 7-hexahydro-[1,4]diazepino[ 6, 7 ,1-hi]indolecarboxamide ( Compounds 8
and 9).
Step A: Preparation of methyl 3-(2,2,2-trifluoroacetyl)indolinecarboxylate.
To a solution of methyl lH-indolecarboxylate (0.40 g, 2.283 mmol) in DMF (15 mL) was
added TFAA (0.317 mL, 2.283 mmol) at room temperature. The reaction was stirred at 40 °C for 2 h.
The mixture was poured into sodium bicarbonate solution (100 mL). The precipitate was filtered. The
filtrate was extracted with EtOAc. The organic extract was dried over Na S0 and concentrated. The
residue was purified by column chromatography to give the title compound (220 mg). LCMS m/z =
272.2 [M+H]\ H NMR (400 MHz, CD Ch) o 3.99 (s, 3H), 7.37 (t, J = 7.9 Hz, lH), 7.51-7.57 (m,
2H), 8.00-8.05 (m, lH), 9.50 (bs, lH).
Step B: Preparation of methyl 3-(2,2,2-trifluoroethyl)indolinecarboxylate.
To a solution of methyl 3-(2,2,2-trifluoroacetyl)-lH-indolecarboxylate (0.10 g, 0.369 mmol)
in TFA (1.412 mL, 18.44 mmol) in an ice-bath was added Triethylsilane (0.589 mL, 3.687 mmol)
dropwise under N2. The reaction was stirred at 23 °C for 15 h. The mixture was poured into saturated
NaHC0 solution and extracted with ethyl acetate. The combined organics was concentrated. The
residue was purified by silica gel column chromatography to give the title compound ( 40 mg). LCMS
mlz = 260.0 [M+H]\ H NMR (400 MHz, CD Ch) o 2.31-2.44 (m, lH), 3.56-3.65 (m, 2H), 3.91 (s,
3H), 4.03-4.12 (m, lH), 6.82 (d, J = 7.8 Hz, lH), 7.14 (t, J = 7.8 Hz, lH), 7.37-7.44 (m, lH).
Step C: Preparation of methyl 1-(2-aminoethyl)(2,2,2-trifluoroethyl)indoline
carboxylate.
A mixture of methyl 3-(2,2,2-trifluoroethyl)indolinecarboxylate (0.040 g, 0.154 mmol) and
2-bromoethanamine.HBr (34.78 mg, 0.170 mmol) was heated at 122 °C for 15 h. The mixture was
dissolved in 2M HCl and purified by HPLC to give the title compound (20 mg). LCMS m/z = 303.0
[M+H]\ H NMR (400 MHz, CD 0D) o 2.34-2.64 (m, 2H), 3.10-3.30 (m, 4H), 3.58-3.72 (m, 2H),
3.89 (s, 3H), 4.03-4.12 (m, lH), 6.88 (d, J = 7.9 Hz, lH), 7.25 (t, J = 7.9 Hz, lH), 7.40 (d, J = 7.9 Hz,
lH).
Step D: Preparation of methyl 7-(2,2,2-trifluoroethyl)-1,2,3,4,6,7-hexahydro-
[1,4]diazepino[ 6, 7 ,1-hi]indolecarboxylate.
To a solution of methyl 1-(2-aminoethyl)(2,2,2-trifluoroethyl)indoline
carboxylatetrifluoroacetic acid (60 mg, 0.144 mmol) and Formaldehyde (4.327 mg, 0.144 mmol) in
MeOH (4 mL) was added TFA (11.04 µl, 0.144 mmol). The reaction was stirred at 80 °C for 1 h. The
mixture was concentrated. The residue was purified by HPLC to give the title compound (60
mg). LCMS m/z = 315.2 [M+Ht.
Step E: Preparation of 2-tert-butyl 8-methyl 7-(2,2,2-trifluoroethyl)-3,4,6,7-tetrahydro
[1,4]diazepino[ 6, 7 ,l-hi]indole-2,S(lH)-dicarboxylate.
To a solution of methyl 7-(2,2,2-trifluoroethyl)-1,2,3,4,6,7-hexahydro-[1,4]diazepino[6,7 ,1-
hi]indolecarboxylatetrifluoroacetic acid (60 mg, 0.140 mmol), Triethylamine (78.10 µl, 0.560
mmol) in CH Ch (1.2 mL) was added a solution di-tert-butyl dicarbonate (30.57 mg, 0.140 mmol) in
CH Ch (1.2 mL). The reaction was stirred at 23 °C for 2 h. The mixture was extracted with IM NaOH.
The organic extract was concentrated. The residue was purified by column chromatography to give the
title compound (44 mg). LCMS m/z = 415.6 [M+H]\ H NMR (400 MHz, CD 0D) o 1.32-1.47 (m,
9H), 2.24-2.40 (m, 2H), 2.81-3.00 (m, lH), 3.12-3.27 (m, 2H), 3.35-3.48 (m, lH), 3.58-3.65 (m, lH),
3.90 (s, 3H), 3.97-4.13 (m, 3H), 4.63-4.93 (m, lH), 6.95-7.16 (m, lH), 7.42 (d, J = 7.9 Hz, lH).
Step F: Preparation of 2-( tert-butoxycarbonyl)(2,2,2-trifluoroethyl)-1,2,3,4,6, 7-
hexahydro-[1,4]diazepino[ 6, 7 ,1-hi]indolecarboxylic acid.
To a solution of 2-tert-butyl 8-methyl 7-(2,2,2-trifluoroethyl)-3,4,6,7-tetrahydro
[1,4]diazepino[6,7, 1-hi]indole-2,8(1H)-dicarboxylate (0.044 g, 0.106 mmol) in MeOH (0.2 mL) was
added SM sodium hydroxide ( 40.35 µL, 0.202 mmol). The reaction was stirred at 65 °C for 3 h. The
mixture was concentrated. The residue was added 4M hydrogen chloride (49.90 µL, 0.200 mmol). The
reaction was stirred for 10 min. The mixture was concentrated to give the title compound. LCMS m/z
= 401.4 [M+Ht.
Preparation of N-(2,2-difluoroethyl)(2,2,2-trifluoroethyl)-1,2,3,4,6, 7-hexahydro
[1,4]diazepino[ 6, 7 ,1-hi]indolecarboxamide.
To a solution of 2-(tert-butoxycarbonyl)(2,2,2-trifluoroethyl)-1,2,3,4,6,7-hexahydro-
[1,4]diazepino[6,7,1-hi]indolecarboxylic acid (10 mg, 19.98 µmol), 2,2-difluoroethanamine (2.703
µL, 23.98 µmol), and triethylamine (8.355 µL, 59.94 µmol) in MeCN (0.2 mL) was added HATU
(11.40 mg, 29.97 µmol). The reaction was stirred at 23 °C for 15 h. The mixture was purified by HPLC
to give tert-butyl 8-( (2,2-difluoroethyl)carbamoyl)(2,2,2-trifluoroethyl)-3,4,6,7-tetrahydro-
[ 1,4 ]diazepino[ 6, 7, 1-hi]indole-2(1H)-carboxylate as a white solid. LCMS mlz = 464.2 [M+lt.
The above solid was then dissolved in 1.25 M methanol solution of HCl (2 mL). The reaction
was stirred at room temperature for 24 h. The mixture was concentrated to give the title compound.
LCMS mlz = 364.4 [M+ 1]\ H NMR (400 MHz, CD 0D) o ppm 2.25-2.43 (m, lH), 2.47-2.62 (m,
lH), 3.12-3.22 (m, lH), 3.38-3.52 (m, 3H), 3.58-3.79 (m, 4H), 4.01-4.11 (m, lH), 4.23 (d, J = 15.0 Hz,
lH), 4.48 (d, J = 15.0 Hz, 2H), 5.83-6.16 (m, lH), 7.09 (d, J = 7.9 Hz, lH), 7.21 (d, J = 7.9 Hz, lH).
Compounds 8 and 9, the (S) and (R) enantiomers of N-(2,2-difluoroethyl)(2,2,2-
trifluoroethyl)-1,2,3,4,6,7-hexahydro-[ 1,4 ]diazepino[6,7, 1-hi]indolecarboxamide, are obtained by
separation using supercritical fluid chromatography.
Example 2 - Generation of Stable Cell Lines
Plasmid DNA coding for a receptor of interest is produced using standard molecular biology
tools. The plasmid typically contains a multi-cloning site where the coding sequence for the receptor of
interest is inserted, a promoter to drive expression of the receptor when introduced into a host cell, and
a resistance gene sequence that causes the host cell to produce a protein that confers antibiotic
resistance. A commonly used promoter is the cytomegalovirus promoter (CMV), and a commonly used
resistance gene is the neo gene that confers resistance to neomycin. The plasmid DNA is introduced
into parental cells (commonly used cell lines include CHO-Kl and HEK293) using methods such as
lipofection or electroporation. Cells are then allowed to recover in culture for 1-2 days. At this point, a
selection agent (e.g., neomycin if the expression plasmid contained the neo gene) is added to the cell
culture media at a concentration sufficient to kill any cells that did not uptake the plasmid DNA and
therefore have not become neomycin resistant.
Since transient transfection is an efficient method to introduce plasmid DNA into cells, many
cells in the culture will initially display neomycin resistance. Over the course of a few cell divisions,
expression of proteins encoded by the plasmid is typically lost and most cells will eventually be killed
by the antibiotic. However, in a small number of cells, the plasmid DNA may become randomly
integrated into the chromosomal DNA. If the plasmid DNA becomes integrated in a way that allows
continued expression of the neo gene, these cells become permanently resistant to neomycin. Typically,
after culturing the transfected cells for two weeks, most of the remaining cells are those that have
integrated the plasmid in this manner.
The resulting stable pool of cells is highly heterogeneous, and may express vastly different
levels of receptor (or no receptor at all). While these types of cell populations may provide functional
responses when stimulated with appropriate agonists to the receptor of interest, they are typically not
suitable for careful pharmacological studies in view of receptor reserve effects caused by high
expression levels.
Clonal cell lines are therefore derived from this cell population. The cells are plated in multi
well plates at a density of one cell per well. After cell plating, the plates are inspected and wells
containing more than one cell are rejected. The cells are then cultured for a period of time and those
that continue to divide in the presence of neomycin are eventually expanded into larger culture vessels
until there are sufficient cells for evaluation.
Evaluation of Cells
Numerous methods can be used to evaluate the cells. Characterization in functional assays may
reveal that some cells exaggerate the potencies and efficacies of agonists, likely indicating the presence
of a receptor reserve. The preparation of cell membranes for evaluation in radioligand binding assays
allows for quantitative determination of membrane receptor densities. Evaluation of cell surface
receptor density may also be performed by flow cytometry using antibodies to the receptor or an
epitope tag that can be engineered into the receptor, typically at the N-terminus for GPCRs. The flow
cytometry method allows one to determine if the clonal cell population expresses the receptor in a
homogenous manner (which would be expected) and quantitate relative expression levels between each
clonal cell population. However, it does not provide absolute receptor expression levels.
If the cell line is intended to be free of receptor reserve effects, receptor expression should be
low (relative to other clones evaluated) and homogeneous (if flow cytometry evaluation is possible). In
functional assays, a suitable clone will produce agonist potencies that are lower than other clones (i.e.,
higher EC values). If partial agonists are available, the absence of receptor reserve will be reflected in
low efficacies relative to full agonists, whereas cells with higher receptor expression levels will
exaggerate partial agonist efficacies. In cells expressing high receptor levels, partial agonists may no
longer display efficacies lower than full agonists.
If agents that irreversibly bind to or covalently interact with the receptor of interest are
available, treatment of cell lines that contain no receptor reserve should reduce the available receptor
density measured by radioligand binding and may reduce the magnitude of functional responses to
agonists. However, the reduction of receptor density should occur without producing reductions in
agonist potencies or partial agonist efficacies.
Example 3: Membrane Preparations for Radioligand Binding Assays.
For the compounds of Table A, the following procedure was used. HEK293 cells stably
expressing recombinant 5-HT receptors were harvested, suspended in ice-cold phosphate buffered
saline, pH 7.4 (PBS), and then centrifuged at 48,000 g for 20 min at 4 °C. The resulting cell pellet was
then re-suspended in wash buffer containing 20 mM HEPES, pH 7.4 and 0.1 mM EDTA, homogenized
on ice using a Brinkman Polytron, and centrifuged (48,000 g for 20 min at 4 °C). The pellet was then
resuspended in 20 mM HEPES, pH 7.4, homogenized on ice, and centrifuged (48,000 g for 20 min at 4
°C). Crude membrane pellets were stored at -80 °C until used for radioligand binding assays.
Example 4: Radioligand Binding Assay.
For the compounds of Table A, the following procedure was used. Radioligand binding assays
were performed using the commercially available 5-HT receptor agonist [1 I]DOI as the radioligand
and nonspecific binding was determined in the presence of unlabeled DOI at a saturating concentration
of 10 µM. Competition experiments utilized 5-HT receptor expressing HEK293 cell membranes
obtained as described in Example 3 (15-25 µg membrane protein/well) and radioligand at final assay
concentrations of 0.4 to 0.6 nM. Experiments comprised addition of 95 µL of assay buffer (20 mM
HEPES, pH 7.4, 10 mM MgCh), 50 µL of membranes, 50 µL of radioligand stock, and 5 µL of test
compound diluted in assay buffer to 96-well microtiter plates, which were then incubated for 1 h at
room temperature. Assay incubations were terminated by rapid filtration through PerkinElmer F/C
filtration plates under reduced pressure using a 96-well Packard filtration apparatus, followed by
washing three times with ice cold assay buffer. Plates were then dried at 45 °C for a minimum of 2 h.
Finally, 25 µL of BetaScint™ scintillation cocktail was added to each well and the plates were counted
in a Packard TopCount® scintillation counter. In each competition study, test compounds were dosed at
ten concentrations with triplicate determinations at each test concentration.
The observed DOI Binding Ki values for compounds of Table A at 5-HT c, 5-HT B, and 5-
HT2A receptors are listed in Table B.
Table B
DOI Binding Ki
Compound Number
2C 2A 2B
2nd eluting enantiomer in example 1.5 19.7 nM 6.58 µM 92.3 µM
1st eluting enantiomer in example 1.5
1 55.9 nM
.06 µM 92.8 µM
1st eluting enantiomer in example 1.2
2nd eluting enantiomer in example 1.2 41 nM
62.7 µM 93.8 µM
7 36.6 nM 6.75 µM 6.81 µM
Example 5: IP Accumulation Assays.
HEK293 cells expressing recombinant 5-HT receptors were added to sterile poly-D-lysine
coated 96-well microtiter plates (35,000 cells/well) and labeled with 0.6 µCi/well of [ H]inositol in
myoinositol-free DMEM for 18 h. Unincorporated [3H]inositol was removed by aspiration and replaced
with fresh myoinositol-free DMEM supplemented with LiCl (10 mM final) and pargyline (10 µM
final). Serially diluted test compounds were then added and incubation was conducted for 2 hat 37 °C.
Incubations were then terminated by lysing cells with the addition of ice-cold 0.1 M formic acid
followed by freezing at -80 °C. After thawing, total [ H]inositol phosphates were resolved from
[ H]inositol using AG1-X8 ion exchange resin (Bio-Rad) and [3H]inositol phosphates were measured
by scintillation counting using a Perkin Elmer TopCount® scintillation counter. All EC
determinations were performed using 10 different concentrations and triplicate determinations were
made at each test concentration. The observed IP Accumulation EC values for several compounds of
Table A at 5-HT receptors are listed in Table C.
Table C
IP Accumulation EC
Compound Number
2C 2A 2B
2nd eluting enantiomer in example 1.5
7.09 nM lOOµM lOOµM
1st eluting enantiomer in example 1.5
.2 µM lOOµM lOOµM
1 43.8 nM lOOµM lOOµM
1st eluting enantiomer in example 1.2
lOOµM lOOµM
2nd eluting enantiomer in example 1.2
.2 nM lOOµM lOOµM
6 195nM
7 17.7 nM 160nM lOOµM
Example 6: Effect of Compounds on Food Intake in the Male Sprague Dawley Rat.
Male Sprague Dawley rats (225-300 g) were housed three per cage in a temperature and
humidity controlled environment (12 h: 12 h light:dark cycle, lights on at 0600 h). At 1600 hon the day
before the test, rats were placed in fresh cages and food was removed. On test day, rats were placed into
individual cages with grid floors at 1000 h with no access to food. At 1130 h, rats (n = 8) were
administered either vehicle (20% hydroxypropyl-~-cyclodextrin) or test compound via oral gavage (PO,
1 mL/kg, with an amount of 2 mg/Kg or 10 mg/Kg of test compound) 30 min prior to food presentation.
Food intake was measured at 60 min after drug administration (30 min after food presentation).
As shown in Figure 1, cumulative food intake significantly decreased relative to placebo when
compound 1 was administered at 10 mg/Kg, particularly after 1 hour and after 2 hours. After 4 hours
the difference decreased; this decrease is believed to be related to metabolism of compound 1 over time.
Other uses of the disclosed methods will become apparent to those in the art based upon, inter
alia, a review of this patent document.
Claims (29)
1. A compound selected from compounds of the table below, and pharmaceutically acceptable salts, hydrates, and solvates thereof: Table Compound Chemical Name Chemical Structure N-(2,2-difluoroethyl) methyl-1,2,3,4,6,7- hexahydro- [1,4]diazepino[6,7,1- hi]indolecarboxamide (S)-N-(2,2-difluoroethyl)- 7-methyl-1,2,3,4,6,7- hexahydro- [1,4]diazepino[6,7,1- hi]indolecarboxamide (R)-N-(2,2-difluoroethyl)- 7-methyl-1,2,3,4,6,7- hexahydro- [1,4]diazepino[6,7,1- hi]indolecarboxamide Compound Chemical Name Chemical Structure (S)-N-(2,2-difluoroethyl)- 7-ethyl-1,2,3,4,6,7- hexahydro- [1,4]diazepino[6,7,1- hi]indolecarboxamide (R)-N-(2,2-difluoroethyl)- 7-ethyl-1,2,3,4,6,7- hexahydro- [1,4]diazepino[6,7,1- hi]indolecarboxamide N-(2,2-difluoroethyl)-7,7- dimethyl-1,2,3,4,6,7- hexahydro- [1,4]diazepino[6,7,1- hi]indolecarboxamide N-(2,2-difluoroethyl)- 2,3,4,6-tetrahydro-1H- spiro[[1,4]diazepino[6,7,1- hi]indole-7,1'- cyclobutane] carboxamide Compound Chemical Name Chemical Structure (S)-N-(2,2-difluoroethyl)- 7-(2,2,2-trifluoroethyl)- 1,2,3,4,6,7-hexahydro- [1,4]diazepino[6,7,1- hi]indolecarboxamide (R)-N-(2,2-difluoroethyl)- 7-(2,2,2-trifluoroethyl)- 1,2,3,4,6,7-hexahydro- [1,4]diazepino[6,7,1- hi]indolecarboxamide
2. The compound of claim 1 wherein the compound is (R)-N-(2,2-difluoroethyl)methyl- 1,2,3,4,6,7-hexahydro-[1,4]diazepino[6,7,1-hi]indolecarboxamide or a pharmaceutically acceptable salt, hydrate or solvate thereof.
3. A pharmaceutical composition comprising a compound of claim 1 or claim 2 and a pharmaceutically acceptable carrier.
4. Use of the compound of claim 1 or claim 2, or the composition of claim 3, in the manufacture of a medicament to aid in the cessation or lessening of use of a tobacco product in an individual attempting to cease or lessen use of a tobacco product.
5. Use of the compound of claim 1 or claim 2, or the composition of claim 3, in the manufacture of a medicament to control weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco.
6. Use of the compound of claim 1 or claim 2, or the composition of claim 3, in the manufacture of a medicament to treat nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine dependency, addiction and/or withdrawal.
7. Use of the compound of claim 1 or claim 2, or the composition of claim 3, in the manufacture of a medicament to reduce the likelihood of relapse use of nicotine by an individual attempting to cease nicotine use.
8. Use of the compound of claim 1 or claim 2, or the composition of claim 3, in the manufacture of a medicament to: reduce the frequency of smoking tobacco in an individual attempting to reduce frequency of smoking tobacco; aid in the cessation or lessening of use of a tobacco product in an individual attempting to cease or lessen use of a tobacco product; aid in smoking cessation and preventing associated weight gain; control weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; reduce weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; treat nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine dependency, addiction and/or withdrawal; or reduce the likelihood of relapse use of nicotine by an individual attempting to cease nicotine use, wherein the medicament is formulated to be administered according to a method comprising: selecting an individual with an initial BMI ≥ 27 kg/m ; and administering to the individual an effective amount of a compound of claim 1 or claim 2 or the composition of claim 3 for at least one year.
9. Use of the compound of claim 1 or claim 2, or the composition of claim 3, in the manufacture of a medicament to: reduce the frequency of smoking tobacco in an individual attempting to reduce frequency of smoking tobacco; aid in the cessation or lessening of use of a tobacco product in an individual attempting to cease or lessen use of a tobacco product; aid in smoking cessation and preventing associated weight gain, controlling weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; reduce weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; treat nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine dependency, addiction and/or withdrawal; or reduce the likelihood of relapse use of nicotine by an individual attempting to cease nicotine use, wherein the medicament is formulated to be administered according to a method comprising: administering a compound of claim 1 or claim 2 or a composition of claim 3 to an individual; monitoring the individual for BMI during said administration; and discontinuing said administration if the BMI of the individual becomes < 18.5 kg/m during said administration.
10. Use of the compound of claim 1 or claim 2, or the composition of claim 3, in the manufacture of a medicament to: reduce the frequency of smoking tobacco in an individual attempting to reduce frequency of smoking tobacco; aid in the cessation or lessening of use of a tobacco product in an individual attempting to cease or lessen use of a tobacco product; aid in smoking cessation and preventing associated weight gain, controlling weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; reduce weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; treat nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine dependency, addiction and/or withdrawal; or reduce the likelihood of relapse use of nicotine by an individual attempting to cease nicotine use, wherein the medicament is formulated to be administered according to a method comprising: administering a compound of claim 1 or claim 2 or the composition of claim 3 to an individual with an initial BMI 25 kg/m ; monitoring the individual for body weight during said administration; and discontinuing said administration if the body weight of the individual decreases by more than about 1% during said administration.
11. Use of the compound of claim 1 or claim 2, or the composition of claim 3, in the manufacture of a medicament to: reduce the frequency of smoking tobacco in an individual attempting to reduce frequency of smoking tobacco; aid in the cessation or lessening of use of a tobacco product in an individual attempting to cease or lessen use of a tobacco product; aid in smoking cessation and preventing associated weight gain, controlling weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; reduce weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; treat nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine dependency, addiction and/or withdrawal; or reduce the likelihood of relapse use of nicotine by an individual attempting to cease nicotine use, wherein the medicament is formulated to be administered according to a method comprising: administering a compound of claim 1 or claim 2 or the composition of claim 3 to an individual; monitoring the individual for body weight during said administration; and discontinuing said administration if the body weight of the individual decreases by more than about 1 kg during said administration.
12. The use of any one of claims 4 to 11, wherein the medicament is formulated to be administered to an individual who is also being administered a supplemental agent.
13. Use of a compound of claim 1 or claim 2 or a composition of claim 3, in the manufacture of a medicament to: reduce the frequency of smoking tobacco in an individual attempting to reduce frequency of smoking tobacco; aid in the cessation or lessening of use of a tobacco product in an individual attempting to cease or lessen use of a tobacco product; aid in smoking cessation and preventing associated weight gain; control weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; reduce weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; treat nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine dependency, addiction and/or withdrawal; or reduce the likelihood of relapse use of nicotine by an individual attempting to cease nicotine use.
14. Use of the compound of claim 1 or claim 2, or the composition of claim 3, in the manufacture of a medicament to decrease food intake in an individual in need thereof.
15. Use of the compound of claim 1 or claim 2, or the composition of claim 3, in the manufacture of a medicament to induce satiety in an individual in need thereof.
16. Use of the compound of claim 1 or claim 2, or the composition of claim 3, in the manufacture of a medicament to treat obesity in an individual in need thereof.
17. Use of the compound of claim 1 or claim 2, or the composition of claim 3, in the manufacture of a medicament to prevent obesity in an individual in need thereof.
18. Use of the compound of claim 1 or claim 2, or the composition of claim 3, in the manufacture of a medicament to manage weight in an individual in need thereof.
19. Use of the compound of claim 1 or claim 2, or the composition of claim 3, in the manufacture of a medicament to treat type 2 diabetes in an individual in need thereof.
20. Use of the compound of claim 1 or claim 2, or the composition of claim 3, in the manufacture of a medicament prevent type 2 diabetes in an individual in need thereof.
21. Use of the compound of claim 1 or claim 2, or the composition of claim 3, in the manufacture of a medicament to treat drug and/or alcohol addiction in an individual in need thereof.
22. The use of claim 21, wherein the treatment is for alcohol addiction.
23. The use of claim 21, wherein the treatment is for drug addiction.
24. Use of the compound of claim 1 or claim 2, or the composition of claim 3, in the manufacture of a medicament to treat a seizure disorder in an individual in need thereof.
25. The use of claim 24, wherein said seizure disorder is epilepsy.
26. The use of claim 24, wherein said seizure disorder is Dravet syndrome.
27. Use of the compound of claim 1 or claim 2, or the composition of claim 3, in the manufacture of a medicament to treat urinary incontinence in an individual in need thereof.
28. Use of the compound of claim 1 or claim 2 or a composition of claim 3, in the manufacture of a 5-HT2c receptor modulator for treatment of a condition in a human body
29. A process for preparing a pharmaceutical composition, comprising admixing a compound of claim 1 or claim 2 and a pharmaceutically acceptable carrier.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562153082P | 2015-04-27 | 2015-04-27 | |
US62/153,082 | 2015-04-27 | ||
PCT/US2016/029308 WO2016176177A1 (en) | 2015-04-27 | 2016-04-26 | 5-ht2c receptor agonists and compositions and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ737412A NZ737412A (en) | 2021-06-25 |
NZ737412B2 true NZ737412B2 (en) | 2021-09-28 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10392390B2 (en) | 5-HT2C receptor agonists and compositions and methods of use | |
US11608339B2 (en) | 5-HT2C receptor agonists and compositions and methods of use | |
WO2015066344A1 (en) | 5-ht2c receptor agonists and compositions and methods of use | |
US11395824B2 (en) | 5-HT2C receptor agonists and compositions and methods of use | |
JP2018519251A5 (en) | ||
TW201605856A (en) | 5-HT2c receptor agonists | |
NZ737412B2 (en) | 5-ht2c receptor agonists and compositions and methods of use | |
NZ739883B2 (en) | 5-ht2c receptor agonists and compositions and methods of use |